Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy by Cunha, Ludmylla Costa
  
Faculdade de Ciências e Tecnologia 
Departamento de Ciências Biomédicas e Medicina 
 
 
 
 
 
 
 
 
Nano and microparticles as carriers for alveolar 
macrophage targeting in pulmonary tuberculosis therapy 
 
 
 
Ludmylla Costa Cunha 
 
 
 
 
 
 
 
 
 
2018  
  
  
Faculdade de Ciências e Tecnologia 
Departamento de Ciências Biomédicas e Medicina 
 
 
 
 
 
 
 
Nano and microparticles as carriers for alveolar 
macrophage targeting in pulmonary tuberculosis therapy 
 
 
Ludmylla Costa Cunha 
 
 
 
PhD in Biomedical Sciences 
 
Thesis supervised by Prof. Ana Grenha, PhD. 
 
 
 
 
 
2018  
 
 
ii 
 
 
 
Nano and microparticles as carriers for alveolar macrophage targeting in 
pulmonary tuberculosis therapy 
 
 
 
 
Declaração de autoria de trabalho 
 
Declaro ser a autora deste trabalho, que é original e inédito. Autores e trabalhos 
consultados estão devidamente citados no texto e constam na listagem de 
referências incluída. 
 
 
_____________________________________________________ 
 
 
Copyright – Ludmylla Costa Cunha. Universidade do Algarve. Departamento de 
Ciências Biomédicas e Medicina. 
 
A Universidade do Algarve tem o direito perpétuo e sem limites geográficos de 
arquivar e publicitar este trabalho através de exemplares impressos reproduzidos 
em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha 
a ser inventado, de o divulgar através de repositórios científicos e de admitir a sua 
cópia e distribuição com objetivos educacionais ou de investigação, não comerciais, 
desde que seja dado crédito ao autor e editor. 
 
  
 
 
iii 
 
 
Acknowledgements 
 
Agradeço à professora Ana Grenha por me acolher em seu grupo de investigação 
e pela orientação no desenvolvimento deste trabalho. 
Agradeço aos professores que colaboraram diretamente com a realização desta 
pesquisa, nomeadamente prof. Ana Costa (UAlg), prof. Deborah Power (UAlg), prof. 
João Lourenço (UAlg), prof. Leonor Faleiro (UAlg), prof. Manuela Gaspar (iMed UL) 
e prof. Francesca Buttini (Universidade de Parma). 
Igualmente, agradeço aos colaboradores dos serviços técnico e administrativo, que 
com competência e prestimosidade, contribuíram direta ou indiretamente para a 
realização deste trabalho. Em especial, destaco a colaboração do Sr. Mário Freitas 
(UAlg) e Sra. Judith Anakayana (Universidade de Parma). 
Agradeço o apoio dos meus colegas de laboratório Filipa, Jorge, Susana, e João. 
E, finalmente, meu eterno agradecimento a meus pais, irmão, Vincent e amigos 
pelo carinho, incentivo e suporte emocional ao longo dessa jornada.  
Muito obrigada!  
 
Esta pesquisa foi financiada pela Fundação para a Ciência e Tecnologia, de 
Portugal (PTDC/DTP-FTO/0094/2012 and UID/BIM/04773/2013). A bolsa de 
doutoramento foi financiada pela agência brasileira de fomento à pesquisa CAPES 
– Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – por meio do 
programa Ciências sem Fronteiras (BEX 1168-13/4). 
 
          
  
 
 
iv 
 
 
 
 
 
 
 
 
 
This page was intentionally left in blank   
 
 
v 
 
 
Contents 
 
1. General Introduction 3 
1.1 Tuberculosis 3 
1.1.1 Pathogenesis of tuberculosis 5 
1.1.2 Diagnosis and treatment of tuberculosis 9 
1.2 Pulmonary drug delivery 10 
1.2.1 Challenges for pulmonary delivery 13 
1.3 Nano and microparticles as drug delivery systems for inhalation purposes 
  15 
1.4 Biopolymers for designing drug delivery systems 19 
1.4.1 Fucoidan 21 
1.4.2 Chitosan 25 
2. Motivation and objectives 31 
3. Nanoparticles 37 
3.1 Materials and methods 37 
3.1.1 Preparation and characterisation of nanoparticles by polyelectrolyte 
complexation 37 
3.1.2 Preparation and characterisation of nanoparticles by nanoprecipitation 
  38 
3.2 Results and discussion 41 
3.2.1 Production of FUC/CS nanoparticles by polyelectrolyte complexation 
    41 
3.2.2 Production of FUC and CS nanoparticles by nanoprecipitation 45 
4. Microparticles: Materials and methods 55 
4.1 Materials 55 
4.2 Preparation of microparticles by spray-drying 55 
4.2.1 Fucoidan 55 
4.2.2 Chitosan 57 
4.2.3 Preparation of fluorescently labelled microparticles 59 
4.3 Characterisation of microparticles 60 
4.3.1 Morphology 60 
4.3.2 Particle size 60 
4.3.3 Density 60 
 
 
vi 
 
 
4.3.4 Dry powder analysis using Powder X-Ray Diffraction (PXRD) 61 
4.3.5 Drug association efficiency and loading 61 
4.4 Evaluation of aerodynamic properties 62 
4.5 In vitro drug release profiles 63 
4.5.1 Fucoidan microparticles 64 
4.5.2 Chitosan microparticles 64 
4.6 In vitro biocompatibility studies 65 
4.6.1 Cell cultures 65 
4.6.2 Assessment of metabolic activity by MTT test 66 
4.6.3 Evaluation of cell membrane integrity 67 
4.7 Macrophage activation induced by microparticles 68 
4.8 Preliminary evaluation of microparticle uptake by macrophages 68 
4.9 In vitro antibacterial activity 69 
4.9.1 Culture of mycobacteria 69 
4.9.2 Determination of minimum inhibitory concentration (MIC) 69 
4.10 Preliminary in vivo studies 71 
4.10.1 Eosinophil count on blood smears 72 
4.10.2 Ouchterlony double immunodiffusion to detect serum 
immunoglobulin E (IgE). 73 
4.11 Statistical analysis 73 
5. Fucoidan microparticles: Results and discussion 77 
5.1 Preparation and characterisation of fucoidan microparticles 77 
5.1.1 Dry powder analysis using Powder X-Ray Diffraction (PXRD) 82 
5.2 Evaluation of aerodynamic properties 85 
5.3 In vitro drug release profiles 88 
5.4 In vitro biocompatibility studies 91 
5.4.1 Assessment of metabolic activity by MTT test 91 
5.4.2 Evaluation of cell membrane integrity 96 
5.5 Macrophage activation 99 
5.6 Preliminary evaluation of microparticle uptake by macrophages 102 
5.7 Determination of minimum inhibitory concentration (MIC) 103 
5.8 Preliminary in vivo studies 104 
5.9 Conclusion 106 
 
 
vii 
 
 
6. Chitosan microparticles: Results and discussion 111 
6.1 Preparation and characterisation of chitosan microparticles 111 
6.1.1 Dry powder analysis using Powder X-Ray Diffraction (PXRD) 115 
6.2 Evaluation of aerodynamic properties 117 
6.3 In vitro drug release profiles 119 
6.4 In vitro biocompatibility studies 122 
6.4.1 Assessment of metabolic activity by MTT test 122 
6.4.2 Evaluation of cell membrane integrity 127 
6.5 Macrophage activation 130 
6.6 Preliminary evaluation of microparticle uptake by macrophages 131 
6.7 Determination of minimum inhibitory concentration (MIC) 133 
6.8 Preliminary in vivo studies 133 
6.9 Conclusion 135 
7. Final considerations 139 
7.1 General discussion 139 
7.2 Prospects for future research 146 
 
 viii 
 
 
 
 
 
 
 
 
 
This page was intentionally left in blank  
 ix 
 
 
Resumo 
 
A tuberculose (TB) é uma das principais causas de morte por infeção no 
mundo, apesar de uma vacina e vários antibióticos eficazes estarem disponíveis 
para a prevenção e tratamento da patologia. O controlo global da TB está dificultado 
por vários fatores, incluindo o diagnóstico tardio e a não adesão do paciente a 
tratamentos de longo prazo, o que leva a uma alta incidência de resistência aos 
fármacos tuberculostáticos. Em geral, existem grandes desafios associados à 
terapêutica convencional, incluindo (i) resistência aos fármacos e toxicidade; (ii) 
interrupção do tramento pelo paciente, devido à terapêutica prolongada e efeitos 
secundários graves; (iii) interações medicamentosas, particularmente com 
antirretrovirais em pacientes co-infectados com TB e HIV. Assim, a gravidade da 
situação chegou a um ponto em que o desenvolvimento de novas estratégias de 
intervenção é urgentemente necessário. 
Nesse contexto, a administração pulmonar de fármacos tuberculostáticos é 
uma abordagem promissora no tratamento da TB pulmonar. A doença representa 
aproximadamente 80% do total de casos e, portanto, o pulmão tem sido explorado 
como uma via efetiva para a administração de fármacos. Essa estratégia não só 
permite direcionar instantaneamente os fármacos para o órgão afetado, como 
também pode reduzir os efeitos adversos sistémicos dos antibióticos, que são as 
principais razões para a interrupção do tratamento por parte do paciente. No 
entanto, a administração pulmonar de fármacos enfrenta algumas limitações, como 
a complexa estrutura das vias aéreas, a degradação local de fármacos e a 
eliminação mucociliar. A fim de ultrapassar algumas dessas limitações, a 
microencapsulação de fármacos aparece como uma abordagem com potencial. 
Nesse sentido, este trabalho teve como objetivo produzir micropartículas inaláveis 
que associassem eficientemente dois fármacos tuberculostáticos de primeira linha, 
isoniazida (INH) e/ou rifabutina (RFB), visando uma aplicação na terapia da TB 
pulmonar. Fucoidan (FUC) e quitosano (CS) foram os biomateriais selecionados 
para compor a matriz dos transportadores. FUC é um polissacárido composto por 
unidades de fucose, que foram relatadas como sendo especificamente 
reconhecidas por recetores de membrana de macrófagos alveolares (a célula 
hospedeira do agente patogénico da tuberculose - Mycobacterium tuberculosis). Da 
mesma forma, o CS é também um polissacárido composto por resíduos de N-
 x 
 
 
acetilglucosamina e D-glucosamina, sendo os primeiros igualmente reconhecido 
por macrófagos de acordo com descrições da literatura. Este reconhecimento pelos 
macrófagos acredita-se que potenciará a fagocitose. 
Numa primeira abordagem foram produzidas nanopartículas, tendo-se 
considerado que o desenvolvimento de uma formulação inalável à base de 
nanopartículas implicaria uma etapa posterior de microencapsulação para 
contornar as limitações relacionadas com as propriedades aerodinâmicas dos 
sistemas nanométricos e as suas dificuldades para alcançar a região alveolar. As 
nanopartículas foram obtidas por complexação de FUC com CS, tendo-se 
desenvolvido várias formulações (rácios de massa FUC/CS de 4:1 a 1:4). Os 
sistemas sem fármaco apresentaram tamanho médio de 159 – 266 nm, PdI entre 
0,21 e 0,36 e potencial zeta entre -39 mV e +12 mV, seguindo sensivelmente a 
alteração das razões de massa. A capacidade das nanopartículas de FUC/CS para 
associar fármacos tuberculostáticos foi avaliada, tendo-se iniciado estes testes pela 
incorporação de RFB, associada à razão final polímero/fármaco de 10/1 (m/m). 
Várias tentativas foram executadas sem sucesso, pelo que o trabalho prosseguiu 
com uma segunda abordagem metodológica para produção das nanopartículas. 
Aplicou-se o método de nanoprecipitação, que levou à produção de nanopartículas 
de FUC e nanopartículas de CS com tamanho médio de 500 nm e 700 nm, 
respetivamente. No entanto, as nanopartículas obtidas apresentaram uma ampla 
distribuição de tamanhos, indicada pelos valores de PdI, que variaram entre 0,55 e 
0,83. Além disso, um protocolo de nanoprecipitação ideal para obter nanopartículas 
à base de FUC ou CS que associassem de forma efetiva INH e/ou RFB não foi 
estabelecido. Tendo em conta a ausência de sucesso da produção de sistemas 
nanométricos, e considerando as restrições temporais impostas aos trabalhos de 
doutoramento, foi decidido focar o trabalho no desenvolvimento de micropartículas 
poliméricas à base de FUC ou CS. 
As micropartículas foram produzidas por um processo de atomização, 
contendo os fármacos modelo (INH e RFB) isoladamente ou de forma combinada. 
As micropartículas de FUC associaram efetivamente a INH (95%) e a RFB (81%) 
por separado. Foram igualmente produzidas com sucesso micropartículas de FUC 
carregadas com os dois fármacos tuberculostáticos simultaneamente, as quais 
registaram elevada eficácia de associação dos fármacos (97% para INH e 95% para 
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RFB). Todas as formulações de micropartículas de FUC demonstraram ter 
propriedades aerodinâmicas favoráveis para a distribuição e penetração pulmonar 
após inalação. Para as micropartículas que associaram os fármacos isoladamente, 
obteve-se um diâmetro aerodinâmico no intervalo 2,0-3,8 µm. Da mesma forma, a 
formulação que associa os dois antibióticos apresentou um diâmetro aerodinâmico 
de 3,6 – 3,9 µm. Em geral, as formulações não evidenciaram efeitos citotóxicos nas 
células do epitélio alveolar humano (A549), embora tenha sido observada uma 
ligeira toxicidade nas células THP-1 diferenciadas em macrófagos, na 
concentração mais elevada que foi testada (1 mg/mL). Contudo, considera-se que 
esta concentração seja muito mais elevada em relação àquela que seria 
efetivamente administrada in vivo. As micropartículas de FUC desenvolvidas neste 
estudo também exibiram propensão para serem capturadas por macrófagos ou 
células diferenciadas em macrófagos (células-alvo) de forma dose-dependente. 
Particularmente, as micropartículas que associam os dois fármacos conjuntamente 
exibiram uma capacidade para ativar as células-alvo e, ainda, inibiram de maneira 
eficaz o crescimento de micobactéria in vitro, sem alterarem a atividade bactericida 
dos fármacos. A administração pulmonar in vivo (ratinhos BALB/c) das 
micropartículas de FUC (sem fármacos) indicou, num ensaio preliminar, que as 
mesmas não induziram respostas alérgicas. 
As micropartículas de CS também associaram eficientemente INH (90%) e 
RFB (97%) por separado, tendo a formulação com fármacos combinados resultado 
em 93% de eficácia de associação para INH e 99% para RFB. Todas as 
formulações apresentaram propriedades adequadas para administração pulmonar, 
com diâmetro aerodinâmico entre 2,5 e 4 µm. A ausência de toxicidade foi 
observada no epitélio alveolar humano (células A549), mas, tal como observado 
para as micropartículas de FUC, a maior concentração de micropartículas testada 
(1 mg/mL) diminuiu a viabilidade de células THP-1 diferenciadas em macrófagos, 
após 24 h de exposição, uma dose considerada sobrestimada, como mencionado 
anteriormente. As micropartículas de CS evidenciaram ainda uma grande 
capacidade de internalização por macrófagos (percentagem de fagocitose até 
99,9%), de forma independente da dose, e as micropartículas contendo ambos os 
fármacos numa única formulação, induziram a ativação de macrófagos e inibiram 
eficazmente o crescimento de micobactérias in vitro. Além disso, o biomaterial (CS) 
 xii 
 
 
foi, aparentemente, bem tolerado por ratinhos BALB/c, após administração 
pulmonar das micropartículas de CS sem fármaco. No geral, os dados obtidos 
fornecem indicações positivas sobre o potencial dos sistemas propostos para uma 
aplicação na terapia inalável da tuberculose pulmonar. 
 
Keywords: atomização, fucoidan, isoniazida, macrófagos alveolares, 
micropartículas inaláveis, quitosano, rifabutina, terapia pulmonar, tuberculose. 
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Abstract 
 
Tuberculosis (TB) is a leading infectious cause of death worldwide, even 
though a vaccine and several effective antibiotics are available for its prevention 
and treatment. Global TB control is very difficult due to various factors, including late 
diagnosis and patient non-compliance to long-term treatments, which leads to a high 
incidence of extensive resistance to effective anti-TB drugs. Overall, there are 
significant challenges associated with conventional TB therapy, including (i) drug 
resistance and toxicity; (ii) patient non-compliance, given the long-term therapy and 
severe side effects; (iii) and drug-drug interactions, particularly with antiretroviral 
drugs in patients co-infected with TB and HIV. Thus, the situation has come to a 
point where the development of novel intervention strategies is urgently needed. 
In this context, the pulmonary delivery of anti-TB drugs is a promising 
approach to treat lung TB. The disease represents approximately 80% of total 
cases, and thus the lung has been explored as an effective route for the delivery of 
drugs. This strategy not only allows targeting the infected organ instantly, but it can 
also reduce the systemic adverse effects of the antibiotics, which are main reasons 
for patient non-compliance. However, pulmonary drug delivery faces some 
limitations related with the proper airway structure, local degradation of drugs, and 
mucociliary clearance. In order to overcome some of these limitations of lung 
delivery, drug microencapsulation appears as a potential approach. In this sense, 
this work aimed at producing inhalable microparticles that efficiently associate two 
anti-TB drugs, isoniazid (INH) and/or rifabutin (RFB), for an application in pulmonary 
TB therapy. Fucoidan (FUC) and chitosan (CS) were the biomaterials selected to 
compose the matrix of the carriers. FUC is a polysaccharide composed of fucose 
units that has been reported to be specifically recognised by surface receptors of 
alveolar macrophages (the host cells of Mycobacterium tuberculosis). Likewise, CS 
is a polysaccharide composed of N-acetylglucosamine and D-glucosamine 
residues, the former being also specifically recognised by macrophages, according 
to the literature. This recognition by macrophages is believed to potentiate 
phagocytosis. 
The first approach involved the production of nanoparticles and it was 
considered that subsequent microencapsulation of the nanocarriers would be 
necessary to overcome aerodynamic limitations of nanosized carriers and their 
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ability to reach the alveolar zone. Nanoparticles were spontaneously obtained by 
complexing FUC with CS, resulting from several formulations (polymeric mass ratio 
varying from 4:1 to 1:4). The produced unloaded FUC/CS nanoparticles presented 
average size range of 159 – 266 nm, PdI ranging between 0.21 and 0.36, and zeta 
potential varying from -39 mV to +12 mV, following the alteration of the mass ratios. 
The ability of FUC/CS nanoparticles to associate anti-TB drugs was assessed, and 
tests initiated with the incorporation of RFB, which was associated to obtain final 
polymer/drug mass ratio of 10/1 (w/w). Several attempts were made unsuccessfully, 
and therefore the work continued using another production method. 
Nanoprecipitation technique was then used, resulting in FUC nanoparticles and CS 
nanoparticles with mean size of 500 nm and 700 nm, respectively. However, the 
obtained nanoparticles showed little uniformity in size, indicated by PdI values, 
varying between 0.55 and 0.83. Moreover, an optimal protocol to obtain FUC- and 
CS-based nanoparticles that efficiently encapsulate INH and RFB could not be 
established. Taking into consideration the unsuccessful nanoparticle production and 
time restraints to accomplish the aims of the PhD plan, it was decided to focus the 
study on the development of polymeric microparticles. 
Microparticles were produced by spray-drying, associating the model drugs 
(INH and RFB), either separately or in combination. FUC microparticles effectively 
associated INH (95%) and RFB (81%), separately. Likewise, FUC microparticles 
loaded with the two anti-TB drugs simultaneously were also successfully produced, 
demonstrating high drug association efficiency (97% for INH and 95% for RFB). All 
FUC-based microparticles evidenced favourable aerodynamic properties for deep 
lung delivery upon inhalation. Single drug-loaded FUC microparticles showed 
aerodynamic diameter (MMAD) in the range of 2.0–3.8 µm. Likewise, the dual drug-
loaded dry powder presented aerodynamic diameter of 3.6–3.9 µm. Overall, the 
formulations evidenced no cytotoxic effects on human alveolar epithelium cells 
(A549), although mild toxicity was observed on macrophage-differentiated THP-1 
cells at the highest tested concentration (1 mg/mL). Nonetheless, this dose is 
considered overestimated compared to that effectively observed in vivo. The 
produced FUC microparticles also exhibited a propensity to be captured by 
macrophages or macrophage-like cells (target cells) in a dose-dependent manner. 
Particularly, dual drug-loaded microparticles displayed ability to activate the target 
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cells and, moreover, effectively inhibited mycobacterial growth in vitro, preserving 
the bactericidal activity of the drugs. In vivo lung administration (BALB/c mice) of 
unloaded FUC microparticles indicated, in a preliminary assay, that the carriers 
induced no allergic responses.  
CS microparticles also associated INH (90%) and RFB (97%) efficiently, in 
separate formulations, whereas dual drug-loaded formulation resulted in 93% 
association efficiency for INH and 99% for RFB. All formulations presented 
adequate properties for deep lung delivery, with aerodynamic diameters ranging 
between 2.5 and 4 µm. Absence of toxicity was observed in human alveolar 
epithelium (A549 cells) but, as observed for FUC carriers, the highest tested 
concentration of microparticles (1 mg/mL) decreased the viability of macrophage-
differentiated THP-1 cells upon 24 h exposure. This dose is however believed to be 
overestimated, as aforementioned. CS microparticles further evidenced strong 
ability to be internalised by macrophage-like cells (percentage of phagocytosis up 
to 99.9%), regardless of the dose. Yet, dual drug-loaded carriers induced 
macrophage activation and effectively inhibited the growth of mycobacteria in vitro. 
Moreover, the biomaterial (CS) was well tolerated by BALB/c mice upon pulmonary 
administration of unloadead CS microparticles. Overall, the obtained data gave 
positive indications on the potential of the proposed systems for an application as 
inhalable tuberculosis therapy.  
 
Keywords: alveolar macrophage, chitosan, fucoidan, inhalable microparticles, 
isoniazid, lung therapy, rifabutin, spray-drying, tuberculosis. 
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1. General Introduction 
 
1.1 Tuberculosis 
 
Since ancient times, tuberculosis (TB) or illnesses resembling TB have been 
described in several parts of the world from many civilisations. Although it was 
probably described for the first time in Indian scriptures, pulmonary TB is known 
since the time of Hippocrates as phthisis, which is derived from the Greek for 
“wasting away”. TB-like diseases have also been documented in ancient Chinese 
and Arabic literature and have been described under many peculiar names during 
history, such as consumption (derived from the Latin consumer) and scrofula, a rare 
manifestation form of TB that affects the lymph nodes, especially of the neck (1,2). 
The meaning of old names has undergone great alterations with time, mainly due to 
discoveries about the nature of the disease and its effects on people. The disease 
was given the name of tuberculosis in 1839 by J.L. Schonlein, derived from the Latin 
tuberculum (“a small lump”), and came into general use in the last years of the 19th 
century (3,4).  
The information concerning the actual prevalence and mortality of TB over 
the centuries is uncertain. It is difficult to obtain accurate data from written 
documents because the diagnosis was then based exclusively on signs and 
symptoms. Moreover, the expressions pulmonary consumption and phthisis were 
often used to designate a variety of unrelated diseases. Therefore, until late in the 
19th century, many lung diseases were confused with TB and it was only during 
modern times that certain types of non-pulmonary infections have been recognised 
as being caused by tubercle bacilli, and thus belonging to the class of TB (3). 
Despite all the uncertainties, TB was the greatest single cause of disease and death 
by the end of the 19th and beginning of the 20th century in Europe. The lack of 
knowledge on TB diagnosis, its nature and treatment certainly contributed to that 
fact (2,3). 
Over the last century, there has been unquestioned scientific and clinical 
progress on this matter. The understanding of basic concepts related to the 
pathogenesis, the isolation and cultivation of the aetiological agent of TB by Robert 
Koch in 1882, have all led to the development of diagnostic techniques, vaccine and 
effective chemotherapy. Today, the disease can be cured in more than 95% of 
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cases, when the correct combination of drugs is used (2,5). However, despite the 
great advances, TB remains depressingly successful as a global epidemic until 
nowadays. 
In 2017, it was estimated that 10 million people (range 9.0–11.1 million) 
developed TB worldwide, of which 5.8 million were among men, 3.2 million among 
women and 1 million among children (aged < 15 years old). People living with 
human immunodeficiency virus (HIV) accounted for 9% of all TB cases. The 
estimate is that there were 1.3 million TB deaths (range 1.2–1.4 million) in 2017, 
and an additional 0.3 million deaths resulting from TB diseases among HIV-positive 
people cases (6). 
 
 
Figure 1.1. Percentage of new and relapse pulmonary TB cases with bacteriological 
confirmation, 2016 (6).  
 
It has been 25 years since the World Health Organization (WHO) declared 
TB a public health emergency, and this rallying call has led to significant investment 
in research over the last two decades (7). Over the time, great advances have been 
made: TB mortality has fallen 47% since 1990, with nearly all the improvement 
taking place since 2000 when the Millennium Development Goals were set (8). 
Despite the remarkable achievements and efforts, and even though nearly all cases 
can be cured, TB remains one of the world’s biggest threats, ranking alongside HIV 
a leading cause of death from an infectious disease (9).  
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Global TB control is very challenging, essentially due to the emergence of 
multidrug-resistant TB and extensively drug-resistant TB, which require longer, 
more aggressive and expensive treatments. In other words, TB cases are becoming 
increasingly complex and expensive to treat and, to worsen the situation, the spectre 
of totally drug-resistant TB is now a reality (10).  
The severity of the situation requires careful consideration and efforts to 
control the disease. In this sense, perhaps one effective way to stop the disease 
spreading and progression would be to directly interrupt the infectious cycle of TB 
where it starts, exactly in the lungs. 
 
1.1.1 Pathogenesis of tuberculosis 
 
TB is a contagious infectious disease, predominantly affecting the lungs. The 
commonest causative agent of TB is Mycobacterium tuberculosis, although the 
disease can be caused by various strains of mycobacteria (4). It is a microscopic, 
rod-shaped bacterium (0.2-0.6 mm wide and 1-10 mm long), aerobic and non-motile 
bacillus with a waxy coat that enables retention of the red dye upon treatment with 
an acidic solution in acid-fast stains (4,11).  
There are nearly 60 commonly recognised species of Mycobacterium, but 
most are saprophytic inhabitants of soil (12). Apart from M. tuberculosis, other 
mycobacteria are human pathogens such as M. africanum (13), M. marinum (14), 
M. kansasii (15), M. microti (16), M. leprae (17), M. fortuitum (18), M. bovis (19), M. 
scrofulaceum (20) and members of the M. avium complex (21).  
The clinical interest in mycobacteria started with Robert Koch (1882), who 
identified, isolated and cultivated the bacilli M. tuberculosis for the first time (2). For 
clinical purposes, pathogenic mycobacteria are assigned to three main classes: i) 
Mycobacterium leprae, which causes leprosy; ii) Mycobacterium tuberculosis 
complex, which can cause TB and include M. tuberculosis, M. bovis, M. africanum, 
and M. microti; iii) Non-tuberculous mycobacteria or environmental mycobacteria, 
which are all other strains able to cause lymphadenitis, skin disease or pulmonary 
diseases resembling TB. These include M. avium complex, M. fortuitum and M. 
kansasii. The latter can cause both leprosy and TB (4).  
As referred before, TB primarily affects the lungs, establishing a condition 
known as pulmonary TB. However, it can affect any part of the human body (2), in 
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that case being called extra-pulmonary TB. Nevertheless, only patients with 
pulmonary TB transmit the infection to new hosts (7). Therefore, transmission of 
infection within and between species occurs mainly by inhalation. Although M. 
tuberculosis is the most frequent cause of human TB, M. bovis, the agent 
responsible for bovine TB, is also known to infect humans by ingestion of infected 
milk or meat products, and very rarely by inhalation of animal aerosol micro-droplets 
when humans have contact with infected animals (22).  
The infection with M. tuberculosis follows a relatively well-defined sequence 
of events. Patients with pulmonary TB have tubercle bacilli in their sputum, in a 
bacterial load that can reach 10 million bacilli/mL (4). When the individual coughs, 
sneezes or speaks, droplets of saliva containing the pathogen are emitted into the 
air (12). These droplets can be inhaled by other individuals and the infectious dose 
is estimated at a single bacterium (23). A cough can generate around 3000 of these 
droplets, as can talking for 5 minutes, and a single sneeze can produce up to 40000 
droplets (24). 
In general, the particulate in bioaerosol ranges 0.3 – 100 µm in diameter. 
However, the infectious aerosols of primary concern are those that are generated 
as droplets of respirable size (1–10 µm) and have the capability of remaining viable 
for extended periods in the indoor environment (25,26). The size distribution of 
infectious aerosols is crucial in the pathogenesis of pulmonary TB. Aerosol particles 
with an aerodynamic diameter (Daer) over 10 µm will probably be deposited on the 
upper airways and cleared away by mucociliary action, whereas those in the range 
of 1–5 µm will most likely penetrate into lower airways (27). The infection is 
established when aerosol droplets containing few or even single infectious units 
bypass the bronchial mucociliary structure to reach the alveolar region of the lungs, 
where bacilli replicate (24).  
Once in the alveoli, alveolar macrophages play an important role in the 
pathogenesis of TB. These cells are involved in phagocytosis and killing of 
mycobacteria, as well as in the initiation of adaptive T-cell immunity (28). The 
defence mechanisms of macrophages include the fusion of the phagosomes 
containing M. tuberculosis with lysosomes, originating the so-called 
phagolysosome, which has the bactericidal capacity (29). Other mycobactericidal 
mechanisms of macrophages include the lysosomal killing of M. tuberculosis 
mediated by ubiquitin-derived peptides (30) and by the generation of nitric oxide and 
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other reactive nitrogen intermediates, which have a toxic effect on the bacilli (31). 
The ubiquitination destroys tubercle bacilli by autophagy as a ubiquitin-derived 
peptide impairs the integrity of mycobacterial membrane, allowing nitric oxide to act 
more efficiently (32).  
Few microorganisms can survive inside macrophages, due to the abundance 
of acidic phagocytic vacuoles and hydrolytic enzymes. Despite that, M. tuberculosis 
has evolved mechanisms that potentiate survival and replication inside the host (33). 
Viable and virulent M. tuberculosis displays the capacity of blocking the fusion of 
phagosomes containing mycobacteria with lysosomes. Furthermore, the 
mycobacteria appear to have the ability to disrupt the normal functioning of 
phagosomes, preventing them from developing into acidic hydrolase-rich 
compartments (34,35). Therefore, antimicrobial activity may require a more 
aggressive response from the phagocyte, and thus macrophages are equipped with 
a full range of Toll-like receptors and other pattern-recognition receptors capable of 
recognising and inducing a preliminary, inflammatory response against a microbial 
presence (29). Among these pattern-recognition receptors are the complement 
receptor (the mannose receptor) and scavenger receptors, differing in the pathogen 
recognition motif. For instance, C-type lectin receptors recognise conserved 
carbohydrate structures, including mannose and galactose, found on the surface of 
many respiratory pathogens, as M. tuberculosis (36). Additionally, the mannose 
receptor, like other C-type lectin receptors, is important in the phagocytic and 
pinocytic uptake of sugar-containing molecules (37). In fact, the mannose receptor 
is reported as capable of recognising mannose, fucose, N-acetylglucosamine units 
and sulphated sugars (36). Likewise, macrophage scavenger receptors can bind to 
a wide range of negatively charged macromolecules, including carbohydrates (e.g. 
fucoidan) (38,39). 
All these receptors induce rearrangements in the actin cytoskeleton that lead 
to the internalisation of the pathogen. Phagocytosis of pathogens by macrophages 
initiates the innate immune response (40) while inducing the activation of 
macrophages (32). Activated phagocytes, then, release cytokines that limit the 
growth of ingested organisms, and recruit additional leukocytes from the peripheral 
circulation (41).  
It should be stressed that the infection with M. tuberculosis does not 
necessarily lead to active disease. In most cases, the individual is asymptomatic 
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and non-infectious owing to a successful immune response that restrains the 
pathogen, although not eliminating it (42). In these cases, a condition known as 
latent TB infection is established (43), which often extends for the lifetime of the 
individual. In this state, the host does not transmit the infection to others, but 
reactivation of the latent infection can occur in response to perturbations of the 
immune response, leading to active TB (23,42). 
Briefly, alveolar macrophages trigger an inflammatory response immediately 
after taking up M. tuberculosis. The bacilli that manage to escape the initial 
intracellular destruction can multiply and cause the apoptosis of macrophage cells 
(28). The apoptotic cells participate in host defence by inducing the activation of 
CD4 and CD8 T-cells, which migrate to the site of inflammation, i.e. the lung (32,44).  
The presence of activated T cells at the infection site attracts other cells of the 
immune system that are organised in a highly specific way to form the so-called 
granuloma or tubercle (32,45). The granuloma basically consists of a cluster of 
infected macrophages surrounded by foamy macrophages, and other defence cells, 
covered by lymphocytes in association with a fibrous cuff of collagen and 
extracellular matrix components (23). A schematic representation of the granuloma 
structure is depicted in Figure 1.2.  
 
 
Figure 1.2. Schematic representation of the granuloma structure. Adapted from (23). 
 
In some cases, with granuloma formation, most tubercle bacilli are killed and 
disease progression is halted (32). In others, the bacilli resist the hostile 
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environment of the granuloma (e.g. hypoxia, nutrient deficiency, acidic pH) and 
induce a state of bacteriostasis, allowing them to survive during extended periods 
of latency (46). In patients with latent TB, reactivation occurs when the granuloma 
wall shatters and releases thousands of viable/infectious mycobacteria into the host 
airways, a process known as caseation (23). 
The probability of developing active clinical TB (or primary infection) after 
being infected with M. tuberculosis is small. Less than 10% of infected individuals 
develop symptoms and signs of active disease over a lifetime. However, 
containment usually fails when the person is immunocompromised (primary TB 
cases) or when the immune status of the host changes (reactivation of latent TB), 
which is usually a consequence of ageing, malnutrition, treatment with 
corticosteroids, alcohol or drug abuse, co-infection with HIV or basically any 
condition that reduces the number or impairs the function of CD4 T cells, mainly 
(23,42). Not surprisingly, infection with HIV is the most potent of these risk factors, 
with the risk of people infected with HIV developing TB being more than 20-times 
greater than that of people not infected with HIV (47).   
 
1.1.2 Diagnosis and treatment of tuberculosis 
 
The definitive test for TB disease is the detection of M. tuberculosis bacilli in 
clinical specimens from symptomatic patients. Therefore, sputum microscopy and 
culture, with subsequent drug-susceptibility testing are currently recommended as 
standard methods to diagnose pulmonary TB (48).  
Although much work has been done to develop modern diagnostic tools (e.g. 
nucleic acid amplification tests), direct sputum smear microscopy remains 
necessary and it is recommended to evaluate the response of the disease to 
treatment (49). Overall, detection of TB relies heavily on direct smear microscopy, 
solid culture and chest radiography, tools that often perform poorly, and require 
infrastructure frequently unavailable in the periphery of the health system where 
patients first seek care (50). Moreover, multiple investigations may be necessary 
over a period of weeks or months before a diagnosis is made. Delay in diagnosis is 
crucial to both disease prognosis at the individual level and transmission within the 
community. Most transmissions occur between the onset of a cough and initiation 
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of treatment. Therefore, early diagnosis and immediate initiation of treatment are 
essential for an effective TB control program (51,52). 
Currently, the recommended treatment for new cases of drug-susceptible TB 
is a 6-month regimen of four first-line drugs: isoniazid (INH), rifampicin, 
pyrazinamide, and ethambutol. It involves an initial phase of a four-drug regimen for 
the first 2 months followed by a continuation phase of two drugs: INH and rifampicin 
for the next 4 months. Up to 95% of people with drug-susceptible TB reach the cure 
with this four-drug regimen (53). In cases in which rifampicin resistance is 
suspected, other rifamycin derivatives, such as rifapentine and rifabutin (RFB) may 
be used (54). Moreover, RFB is the first-line anti-TB drug recommended for patients 
who are taking medications incompatible with rifampicin, such as antiretroviral drugs 
(55). 
In summary, TB is a curable disease as long as a rapid diagnosis is 
performed, and a proper antibiotic therapy is established and followed. Although 
advances have been made in TB therapy, standard TB regimens are limited and 
cause severe side effects that include ototoxicity, hepatotoxicity and nephrotoxicity 
and hyperuricemia, especially in the treatment of drug-resistant TB (56,57). For this 
reason, new TB drugs have started to emerge from the pipeline, and combination 
regimens that include new compounds are being tested in clinical trials. However, 
the evolution of resistance will inevitably follow the introduction of new drugs, 
making it unlikely that existing agents are removed from clinical use.  
The situation has, thus, come to a point where the development of novel 
therapeutic strategies is urgently needed. In this regard, the advent of drug delivery 
systems may hold the key to the prevention and treatment of TB disease. The 
delivery of anti-TB drugs directly to the site of infection would potentially enable the 
reduction of dosing frequency, possibly shortening treatment duration, thereby 
avoiding or reducing systemic side effects and improving patient compliance (12). 
 
1.2 Pulmonary drug delivery 
 
Site-specific delivery of drugs permits delivering drugs to a patient in a very 
specific manner that allows concentrating the drugs in the site of interest while 
reducing their concentration in the remaining tissues (58). This not only improves 
the inherent efficacy of drugs, but also potentially reduces side effects. The selective 
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delivery of drugs is, therefore, very attractive and a real need, as it provides one of 
the most potent ways to improve the therapeutic effect of drugs. 
Since it is very difficult for drug molecules to reach with high efficiency the 
intended destination in the complex cellular network of an organism, the assistance 
of a drug carrier may strongly benefit the process. Drug delivery systems offer an 
intelligent approach for carrying and protecting drugs, while in many cases providing 
simultaneous modulation of their release and absorption. However, their success is 
frequently limited by short residence times at the site of absorption or action. For 
this reason, it is deemed advantageous to potentiate the intimate contact of drug 
delivery systems with the referred sites. 
In light of this, particulate carriers are one of the most used classes of drug 
delivery systems. They offer many advantages that include the possibility of tailoring 
particle sizes and surface characteristics, improvement of drug pharmacokinetics 
and pharmacodynamics, and the possibility for delivery through various routes of 
administration, including the respiratory route (59,60). As it is well demonstrated in 
Figure 1.3, the pulmonary delivery of drugs has been increasingly studied over the 
last two decades, given the advantages over traditional routes. 
 
 
Figure 1.3. Number of scientific papers published on the topic “pulmonary drug 
delivery” on ISI Web of Science (October/2018), as a function of publication years. 
 
In general, the main reasons why the lung is an attractive route for drug 
delivery are non-invasiveness, the possibility of direct delivery to the site of action 
when treating pulmonary diseases, avoidance of the first-pass metabolism, and the 
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availability of a large surface area for systemic delivery of drugs, along with highly 
vascularised epithelium (61). Besides, drug efflux transporters and metabolising 
enzymes are present in the lung at much lower levels comparing with the 
gastrointestinal tract, which is the most common route of delivery (62). Table 1.1 
summarises the most relevant advantages and limitations of drug delivery by 
inhalation. 
 
Table 1.1. The most relevant advantages and limitations of pulmonary drug delivery. 
Advantages Limitations 
Non-invasive route  Respiratory tract is structurally complex 
Avoidance of the first-pass metabolism 
and limitation of side effects 
Lung defence mechanisms 
Extensive vascularisation 
Specific aerodynamic requirements needed to 
reach each zone of respiratory tree 
Possibility of administering lower drug 
doses 
Inhalation devices and special dosage form 
are required for drug delivery 
 
Despite marked advantages of pulmonary administration, delivery of free 
drugs is not easy and their efficiency has been potentiated by means of the use of 
drug carriers, which need to be specifically designed to meet aerodynamic 
requirements (63). Nevertheless, lung drug delivery is not only affected by 
characteristics of the inhalable formulation, further having great contribution from 
biophysical and physiological factors, e.g. aerosol particle size and breathing 
manoeuvre (inspired volume, inspiratory flow, and end-inspiratory breath holding 
time). Importantly, the physical and biochemical stability of pharmaceutical 
formulations designed for aerosolisation (dry powder, suspensions or solutions) are 
preconditions for the administration of adequate and reproducible drug doses via 
the pulmonary route (64). In parallel, inhalation devices are required to be designed 
to overcome all the obstacles and potentiate the performance of formulations. 
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1.2.1 Challenges for pulmonary delivery 
 
The lung presents several defence mechanisms that comprise relevant 
limitations to drug delivery, including cough, mucociliary apparatus and airway 
anatomic barriers. Understanding the complex architecture of the respiratory tract is 
important because it is a biophysical factor affecting the deposition of particulate 
drug delivery systems in the airways (64). As depicted in Figure 1.4, there are 
several mechanisms involved in aerosol transport and deposition in the human lung, 
including inertial impaction, gravitational sedimentation and Brownian diffusion, 
which are the most prevalent (65). Inertial impaction refers to the inability of particles 
(larger than 5 µm) to adjust its course according to the sudden change in air flow 
direction at airway bifurcations (65,66). Gravitational sedimentation is the settling of 
particles under the action of gravity and occurs mainly in small airways and alveolar 
region. Deposition by Brownian diffusion results from the random motion of particles 
of size lower than 0.5 µm, as a consequence of their collisions with gas molecules. 
It increases with decreasing particle size and is the dominant mechanism of 
deposition for particles in this size range (65,67).  
 
 
Figure 1.4. Scheme describing the main mechanisms affecting aerosol transport and 
deposition in the human lung. Adapted from (68). 
 
 As a consequence of the physical forces acting on aerosol particles, their 
deposition in the lungs is highly dependent on diameter (66). The size of particles 
aimed at inhalation is conventionally defined as the Daer, which is the diameter of 
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a spherical particle with unit density that has the same settling velocity as the particle 
in consideration (69). Some equations have been proposed to be used in the 
theoretical calculation of Daer of aerosol particles. One of the most used is displayed 
below (70,71): 
 
Daer = d (   ) 
 
where d is the particle geometric diameter, ρ is the particle density, ρ0 = 1 g/cm3 
and λ is the dynamic shape factor of the particle, which is 1 in the case of spherical 
particles (72). Nevertheless, accurate determination of Daer is only possible 
experimentally, which is routinely performed using techniques based on inertial 
impaction (e.g. cascade impactors, twin-stage impinger, etc.) as indicated in the 
European Pharmacopeia (73). Although several terminologies are used to 
characterise this parameter, the mass median aerodynamic diameter (MMAD) is 
that commonly used after characterisation by cascade impaction. MMAD represents 
the median of the distribution of airborne particle mass with respect to the 
aerodynamic diameter. This is usually accompanied by the geometric standard 
deviation, which characterises the variability of the particle size distribution, referring 
to mono- or polydisperse aerosols (66,74). Additionally, the fine particle fraction 
(FPF) is defined as the percentage relative to the total quantity of drug collected in 
the impactor that has the size equal or lower than 5 µm (75). 
In other words, aerosols with larger MMADs will deposit higher in the 
respiratory tract and a polydisperse aerosol is also more likely to show greater 
deposition in the tracheobronchial region than a monodisperse aerosol of the same 
MMAD (66). The MMAD of aerosols is, therefore, critical factors in determining the 
deposition patterns within the lung, although other conditions will also affect this 
behaviour, as detailed above. Figure 1.5 represents the relationship between Daer 
and deposition of aerosol particles in the human respiratory tract. 
 
λ ρ0 
ρ     1/2 
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Figure 1.5. Relationship between aerodynamic diameter and deposition of aerosol 
particles in the human respiratory tract. Adapted from (27,76).  
 
In brief, particles greater than 5 μm in diameter will mostly impact in the upper 
airways and are rapidly removed by coughing and mucociliary processes. In turn, 
smaller particles in the size range of 1–5 μm may escape impaction in the upper 
airways and will deposit in the lower tracheobronchial and alveolar regions. On the 
other hand, particles <1 μm may not be deposited at all, since many will be removed 
from the lung on the exhaled air stream before sedimentation can occur (66,77). 
Therefore, to reach the lower respiratory tract, particularly the alveoli, and optimise 
pulmonary drug deposition, aerosols should have aerodynamic diameters <5 µm. 
(65,78). 
 
1.3 Nano and microparticles as drug delivery systems for inhalation 
purposes 
 
Nanoparticles (NP) and microparticles (MP) are the most cited of the 
particulate carriers, in most cases presenting a matrix composed of polymeric 
materials. The International Organization for Standardization (ISO) defines  
nanoparticles as particles having at least one dimension below 100 nm (79). The 
definition is, however, not consensual in the area of drug delivery and the term is 
frequently used for spherical particles with submicron size (<1000 nm) (80,81). 
Microparticles present diameters in the micrometre range (from 1 μm to 1000 μm). 
Structurally, these systems are typically divided into two categories, according to a 
classification that is now widely accepted: nanocapsules/microcapsules, when the 
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drug is mainly confined to a cavity surrounded by a polymer membrane (shell); and 
nanospheres/microspheres when the drug is dispersed within the polymeric matrix 
(82). The drug release mechanism from carriers primarily involves drug diffusion 
through the carrier material. Additional mechanisms depend on the considered drug 
carrier. For instance, the drug may be released through pores present in the carrier 
or by water penetration into the systems or by hydrolysis/erosion of polymeric matrix 
(83). 
In general, carrier systems aim to minimise drug degradation and loss, 
enhance the solubility of poorly soluble drugs, prevent adverse effects (targeted 
therapy) and increase the availability of the drug at the target site. To reach these 
goals, carriers can be designed to slowly degrade, react to stimuli or to be site-
specific. Targeted therapy generally requires lower total doses to achieve clinically 
effective results, comparing with conventional approaches (62). In this context, the 
use of polymeric systems offers potential advantages over free drug formulations or 
even other carriers (such as liposomes), considering their higher stability and the 
possibility to modulate the systems for targeted delivery (84). For instance, inhalable 
PLGA particles containing rapamycin were more effective in clearing intracellular 
mycobacteria and presented lower cytotoxicity compared to the free drug (85). 
Nonetheless, the development of polymeric drug carriers presents some limitations, 
including lower reproducibility compared to conventional formulations, higher cost 
of materials and processing, and even the environmental impact of degradation 
products (86).  
There are many methods available to prepare nano and microparticles and it 
is not uncommon that the same method can be used to prepare both types of 
particles. Obtaining one system or the other naturally depends on specific conditions 
of the process, such as the used concentrations, intensity of stirring, etc. (87). 
Methods such as polyelectrolyte complexation, ionic gelation, solvent evaporation, 
coacervation, supercritical fluids technology and spray-drying, have been frequently 
reported (88,89). Polyelectrolyte complexation is a widely used technique to obtain 
polymeric carrier systems, because it generally offers simple and mild preparation 
processes that do not involve harsh conditions. The absence of additives results in 
low toxicity and low cost. This technique is based on electrostatic interactions 
between oppositely charged polymers, which allow spontaneous formation of 
complexes (90,91). Another method commonly used is coacervation, that also 
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occurs spontaneously upon desolvation of a homogeneous polymeric solution. The 
method is based on liquid-liquid phase separation which is promoted by the addition 
of a non-solvent (e.g. ethanol) or a salt into the polymeric solution. The non-
solvent/salt reduces the solvation of the polymer, leading to the formation of 
coacervates which can be nano- or micron sized particles (92,93). Concerning the 
production of microparticles, spray-drying is one of the most reported techniques, 
as it provides several advantages over other methods. First, it offers great control 
over critical parameters of resulting microparticles, including their size, shape and 
density. It also allows the incorporation of different excipients into the formulation to 
be spray-dried, including dispersibility enhancers to improve the aerosolisation 
characteristics of the resultant powder (94). Furthermore, it is a unique single step 
method for microencapsulation of drugs in polymeric carriers (95). Briefly, the 
polymer is first dissolved in a suitable solvent and the drug is then 
dispersed/solubilised in the polymer solution under homogenisation. This dispersion 
is then atomised in a stream of hot air, leading to the formation of small droplets. 
This happens in a drying chamber where temperature is set to enable instantaneous 
solvent evaporation, leading to the formation of microparticles. In the end, these are 
separated from the hot air by means of a cyclone separator (86). This method is 
highly reproducible, relatively easy to scale up, and offers a narrow particle size 
distribution (95). Conventional spray-dryers permit producing microparticles in a 
size ranging from 1 to several μm, but more recent equipments are also reported to 
produce particles at the nanoscale (96). 
Particle size distribution is an important feature to be considered in drug 
delivery, because it may determine the in vivo distribution of nano and microparticles 
(97). In general, microparticles are unlikely to cross most biological barriers, so they 
are often delivered directly to the site of interest. On the contrary, nanoparticles of 
adequate size may cross such barriers. In this regard, the smaller the particle size, 
the better is the absorption through epithelia (98). Nevertheless, the effectiveness 
of drug delivery systems, in some cases, depends on the internalisation of the 
systems. Generally, particles enter cells by a process termed endocytosis, which 
comprises phagocytosis and pinocytosis. Phagocytosis is a means of taking up 
material up to 10 µm in diameter and this process is limited to a certain type of cells, 
such as macrophages, neutrophils and dendritic cells. Differently, pinocytosis is a 
process characteristic of all cell types in which liquid and small non-specific particles 
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are ingested, including nanosized materials in solution (99). Taking into account the 
above considerations, both nano and microparticles have potential to be internalised 
by living cells with variable efficiency depending on their size. Some researchers 
have taken advantage of this difference, for instance, to provide targeting to 
phagocytes, such as macrophages (100,101). Additionally, other characteristics like 
surface charge, lipophilicity, etc. are also described to affect internalisation of 
particulates by cells, namely macrophages (102,103).  
As stated, phagocytosis is a process highly dependent on particle size, as 
reported in several studies addressing the subject. These have revealed that 
particles possessing diameters between 1–6 μm were the most susceptible to 
phagocytosis (37,104). In this context, pulmonary drug delivery systems have been 
designed to target alveolar macrophages, the predominant phagocytic cells involved 
in lung defence (105). Targeting alveolar macrophages has the distinct advantage 
of delivering high concentrations of drugs to a cell that plays a central role in immune 
responses and progression of certain diseases, as is the case of TB (62). As a 
matter of fact, the literature describes several works devoted to the delivery of anti-
TB drugs, upon inhalation, mediated by nano (106–108) and microparticles (109–
111). The advantage of using nanoparticles for pulmonary delivery resides on the 
fact that they are sufficiently small to avoid inertial deposition in the upper airways, 
penetrating into the lung. However, in the ambit of macrophage-targeted therapy, 
nanoparticles may find difficulties in cell internalisation, given the apparent 
preference of macrophages for microparticles. For instance, the uptake of titanium 
dioxide nanoparticles (20 nm) by rat alveolar macrophages upon aerosol inhalation 
was described as unspecific and inefficient. Within 24 h after particle deposition, 
there was only about 0.1% of the deposited nanoparticles taken up by macrophages 
(112). This is coincident with reports of avoidance of macrophage clearance by 
nanoparticles of sizes < 100 nm (37,113). Once deposited, nanosized particles 
smaller than 100 nm can readily translocate across epithelia of respiratory tract 
(113). Yet, the deposition of nanoparticles in the deep lung can be also a limitation, 
as these are reported to be exhaled due to their small size and mass (114). To 
overcome this limitation, many works have been proposing the microencapsulation 
of drug-loaded nanoparticles (115–117). The approach endows nanoparticles with 
the adequate aerodynamic properties to reach the respiratory region. This has been 
typically provided by spray-drying of nanoparticles, although other methods may 
Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy  
 
 
19 
 
also apply (118). Moreover, the microencapsulation of nanoparticles can improve 
the internalisation of the nanosized systems by alveolar macrophages (116), 
considering that nanoparticles of small size can evade phagocytosis by virtue of 
their small size (119,120). Additionally, this approach can improve nanoparticles 
aerosolisation from inhaler devices, given that they often aggregate under shear 
forces (62). 
In summary, the design of inhalable nano and microparticles is a major 
contribution to enhancing drug availability and therapeutic effectiveness in the 
respiratory zone (114). Particularly, this approach appears to be a feasible strategy 
for the treatment of TB, as inhalable systems could overcome some of the problems 
that were mentioned for conventional TB therapy and enhance the therapeutic 
efficacy of anti-TB drugs. Yet, carrier systems targeted to alveolar macrophages can 
also improve bactericidal activity on intracellular pathogens, which is especially 
valuable to fight multi-drug resistant strains (121). Therefore, inhalable drug carriers 
are considered a promising approach in the treatment of respiratory infections, such 
as pulmonary TB. 
 
1.4 Biopolymers for designing drug delivery systems  
 
Drug delivery systems can be manufactured from a large variety of raw 
materials, either natural or synthetic, and by many different preparation techniques, 
as already referred. Both the raw materials and the producing techniques allow the 
preparation of an enormous variety of carriers, regarding composition, morphology, 
surface chemistry, and size distribution (122). From the wide diversity of materials 
that are available, polymers have been extensively investigated to compose the 
matrix of drug delivery systems (123). 
Polymers remain the most versatile class of materials because they can be 
synthesised (or modified) to have appropriate chemical, physical, interfacial and 
biomimetic characteristics, which permit various specific applications. Compared 
with other types of materials, such as metals and ceramics, polymers offer the 
advantage of enabling different compositions with a wide variety of structures and 
physicochemical properties (124). In general, polymers used as matrix of drug 
delivery systems can be naturally occurring, synthetic or a combination of both 
(125). For instance, polyester alone or in combination with other polymers has been 
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widely investigated for designing drug carriers (126). Poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA) and the copolymer poly(lactic-co-glycolic acid) (PLGA) are 
among the most well-known choices for drug delivery applications, including in TB 
therapy (127–130). Although PLGA represents the ‘gold standard’ of synthetic 
biodegradable polymers (exemplified by more than 500 patents), increased local 
acidity due to degradation can lead to irritation at the application site (131). Indeed, 
the primary difficulty of most synthetic materials is the general lack of 
biocompatibility. 
In this regard, polysaccharides present favourable characteristics in 
comparison with synthetic polymers used in drug delivery. These include the higher 
propensity for biocompatibility and biodegradability, and abundant renewable 
sources (132). On the other hand, natural polymers often render extraction and 
purification difficulties due to their structural complexity. Additionally, significant 
batch-to-batch variations may occur because of their ‘biopreparation’ in living 
organisms, e.g. plants, crustaceans (124).  
Anyway, polysaccharides and their derivatives are commonly used for the 
preparation of both nano and microparticles (133–136). Polysaccharides are long 
carbohydrate polymers composed of repeated monosaccharide units joined 
together by glycosidic bonds. These molecules are usually considered 
biocompatible and biodegradable in a general manner, but these characteristics 
must be contextualized with the used carrier, the dosage and the route of 
administration (137). Because of the presence of various functional groups on their 
molecular chains, polysaccharides can be chemically modified for specific 
purposes, such as tissue and cell targeting (138). Yet, most polysaccharides have 
hydrophilic groups, including hydroxyl, carboxyl and amino groups, which may affect 
the polymer charges and also interact with functional molecules, as well as with cell 
receptors (132).  
Taking into account the promising applications of polysaccharides in drug 
delivery, research in the field of polysaccharides of marine origin has considerably 
increased in the last decades (139). As well, the discovery of metabolites from 
marine resources showing biological activity has increased significantly. Among 
marine resources, seaweeds and crustaceans are valuable sources of structurally 
diverse bioactive compounds. These include sulphated polysaccharides, such as 
fucoidan (FUC), abundantly found in the cell wall of algae; and chitosan (CS), a 
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polysaccharide derived from the exoskeleton of marine crustaceans (140). It should 
be stressed that FUC and CS are the selected biomaterials for composing the matrix 
of the delivery systems developed in the present work. The literature reports 
numerous studies on the development of nanosized drug delivery carriers based on 
FUC (80,141–147) and also works that use the polysaccharide in the composition 
of micron sized carriers (148–150). Likewise, CS has been widely proposed as 
biomaterial to compose nano (151–156) and microcarriers (157–160).  
The following sections detail the most relevant characteristics of each of the 
polymers. 
 
1.4.1 Fucoidan  
 
FUC is the major sulphated polysaccharide found in marine brown algae. In 
this regard, the candidate has authored a review addressing the use of sulphated 
seaweed polysaccharides as multifunctional materials in drug delivery applications 
(161). FUC designates a family of sulphated polysaccharides extracted from brown 
seaweeds (Phaeophycophyta) and some echinoderms (sea urchin and sea 
cucumber). The term fucoidan is commonly applied to complex sulphated 
polysaccharides, often isolated from marine algae, mainly containing fucose 
residues, but also many other monosaccharides. In turn, the term sulphated fucan 
is reserved for polysaccharides with a regular structure, mostly containing sulphated 
fucose, which is often extracted from marine invertebrates such as sea cucumber 
and sea urchin. However, not all authors consider these denominations and, 
therefore, the polymer is usually indistinctly termed fucoidan or fucan, while other 
terms like fucosan may also be referred (162,163). 
 
Origin and chemical structure 
 
Brown algae (Phaeophyta), the second most abundant group of algae, 
produce a range of active components. The structure of their cell walls consists of 
an amorphous matrix of acid polysaccharides, linked to each other by proteins. 
These acid polysaccharides are mainly composed of FUC and alginic acid, which 
confer structural toughness and flexibility to seaweed (164). In recent years, these 
fucose-containing polysaccharides have been isolated from different sources, 
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including the main genera Fucus (165), Laminaria (166), Sargassum (167), 
Ascophyllum (168), and Undaria (169). Before choosing the source, it is important 
to consider that FUC can differ in structure among algal species and may even vary 
within the same species (170). It is also known that the use of different extraction 
methods may affect the bioactivity and physicochemical properties of the biopolymer 
(171). 
Although FUC has been known for over a century, its chemical structure is 
still incompletely determined, owing to its heterogeneity and irregularity. This is due 
to the fact that marine brown algae synthesise highly branched polysaccharides, 
which structures and proportion vary in dependence of the specific taxonomic 
position. For instance, it has been shown that FUC obtained from representatives 
of Chordariales and Laminariales may display different backbone structure 
compared with that isolated from algae belonging to the order Fucales 
(163,172,173). The main sugar backbone of the polysaccharide is fucose, consisting 
essentially of α-L-fucose units. These units are sulphated in some positions, having 
species-related sulphation pattern (174,175). Apart from fucose and sulphate, FUC 
may also contain additional sugar constituents, including mannose, galactose, 
glucose, xylose, uronic acids and yet acetyl groups (167,176–178). Although it is 
not a pattern, a certain similarity in the backbone structure of different FUC 
molecules has been observed, regarding the positions of inter-glycosidic linkages. 
In this context, many studies show that several representatives of the orders 
Chordariales and Laminariales contain FUC with a linear backbone composed of 
(1→3)-linked α-L-fucose residues. However, the polysaccharide isolated from algae 
belonging to the order Fucales mostly displays a backbone composed of alternating 
(1→3)- and (1→4)-linked α-L-fucose residues (175,178–180). Representative 
backbone structures of fucoidan molecules are depicted in Figure 1.6. 
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Figure 1.6. Scheme of α‐L-fucose chains observed in fucoidans isolated from several 
algae belonging to the taxonomic orders Chordariales and Laminariales (a) and 
Fucales (b); (a) The chain is only composed of repeating (1→3)-linked α-L-fucose 
residues; (b) The chain consists of alternating (1→3)- and (1→4)-linked α-L-fucose 
residues. R represents the positions of potential attachment of carbohydrate. 
 
In general, FUC polysaccharides may be branched, presenting a variety of 
substituting groups and side chain compositions, as aforementioned. The reported 
structural data for FUC isolated from different brown seaweed species clearly 
indicates that there is no consistent basic structure of this polymer. The investment 
observed in recent years in research dedicated to obtaining highly purified fractions 
of the polysaccharide is expected to permit a better understanding of FUC structures 
(166,181,182). 
 
Physicochemical properties and biological activity 
 
The physicochemical and biological properties of algal polysaccharides, 
including FUC, are strongly correlated to their chemical composition (183). In 
seaweeds, this is the result of many factors such as harvesting region, season and 
the specific algal species (184). For instance, the natural sulphation grade of FUC 
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may range between 4% and 8%, depending on the site and season of collection of 
the algae (185).  
In general, FUC molecular weight may vary from 10 (186) to approximately 
2000 kDa (187). It is very soluble in water, producing non-viscous solutions, and its 
solubility is related to the level of branching, depending on the content of sulphate 
groups (188). Moreover, there is little evidence about gelling and film-forming 
properties of FUC (189). In fact, gelation of FUC was not observed up to 25% 
concentration (190).  
The functional properties of FUC have rendered the polymer potential 
applications in pharmaceutical and biomedical-related fields (164,191). The 
biopolymer and its oligosaccharides have been extensively studied regarding the 
evidence of diverse biological activities. These include antitumor effect (192), anti-
inflammatory (193) and antiviral activities. For instance, it has been shown that FUC 
has an antiviral effect against herpes simplex virus type 1, and human 
cytomegalovirus (194). As well, the anti-metastasis and immunomodulatory effect 
of the polymer have been demonstrated (195,196). From all the reported biological 
activities, the potent anticoagulant property of FUC is by far the most widely 
investigated (197–199). Based on the reports, the referred physicochemical and 
biological properties are related to molecular size, type of sugar content, sulphation 
degree and molecular structure of the biopolymer.  
 
Lung biodegradability 
 
The pharmacokinetics of FUC is an important consideration to be taken for 
the purpose of the present work, particularly within the context of pulmonary 
administration. 
Although FUC has been indicated in the literature as a biomaterial for 
biomedical applications, studies regarding the in vivo distribution, degradation and 
elimination of the polymer are scarce (187). Importantly, to date, there are no reports 
regarding the metabolisation of FUC in the lung environment. It is well known that 
FUC can be enzymatically degraded (200,201). In this context, lung tissue is 
recognised as a source of endogenous β-galactosidase, an enzyme able to degrade 
FUC in marine invertebrates (200). In humans, the activity of β-galactosidase has 
been demonstrated in airway epithelial cells and in alveolar macrophages (202). 
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Nevertheless, to the best of our knowledge, there is no data about FUC degradation 
by the referred enzyme, except in marine microorganisms and invertebrates (200). 
In addition, fucose-containing macromolecules can be degraded by α-L-fucosidase, 
a lysosomal enzyme widely present in human cells, blood and body fluid (203). 
Notwithstanding this fact, no data has been reported yet on the enzymatic activity 
of human α-L-fucosidase regarding FUC degradation. In summary, the metabolism 
of the polysaccharide has been poorly studied in mammals, especially in humans 
(204), but there are indications that lung biodegradation may be possible.  
 
1.4.2 Chitosan 
 
CS is a polysaccharide derived from the deacetylation of the naturally 
occurring polymer chitin. Chitin, in turn, is a biopolymer synthesised by an enormous 
number of living organisms. It occurs in nature as ordered crystalline microfibrils 
comprising the principal structural component in the exoskeleton of arthropods (e.g. 
crustaceans) or in the cell walls of fungi and yeast (e.g. Aspergillus and Mucor). It is 
the second most abundant polysaccharide after cellulose (205,206).  
 
Origin and chemical structure 
 
CS is synthesised by (partial) deacetylation of chitin. Despite the widespread 
occurrence of chitin, up to now the main commercial sources of chitin have been 
crab and shrimp shells (206). The resulting chitin needs to be graded in terms of 
purity since residual substances can cause problems for further utilisation (206). In 
this respect, the complete removal of protein is especially important for biomedical 
applications, as a percentage of the human population is allergic to shellfish, the 
primary culprit being the protein component (207). 
Chitin can be converted to CS by enzymatic means (208,209) or chemical 
processes, the latter using either acids or alkalis. Because glycosidic bonds are very 
susceptible to acid, alkaline deacetylation is used more frequently (210). Usually, 
deacetylation of chitin is achieved by treatment with concentrated sodium hydroxide 
solution (40-50%) at 100°C or higher temperature (211). Although many 
experimental conditions can be found in the literature for chitin isolation and 
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subsequent CS production, effects on molecular weight and acetylation degree 
cannot be avoided (207). 
Structurally, CS is a copolymer composed of glucosamine and N-
acetylglucosamine. Its chemical structure thus consists of repeating alternated units 
of N-acetylglucosamine and D-glucosamine, linked by β-(1→4) glycosidic bonds, as 
depicted in Figure 1.7. The polysaccharide is available in a variety of forms that 
mainly differ in the molecular weight and degree of deacetylation (212). 
 
 
Figure 1.7. Structure of chitosan showing alternated units of N-acetylglucosamine 
and D-glucosamine, linked by β-(1→4) glycosidic bonds.  
 
Commercially, the biopolymer is available as chitosan base (low and high 
molecular weight) and as chitosan salts (213,214), which provides versatility for 
different applications of CS and its derivatives (215).  
 
Physicochemical properties and biological activity 
 
The physicochemical properties of CS are generally determined by its 
chemical structure, mainly molecular weight and deacetylation degree. The 
biopolymer has functional hydroxyl and amino groups which may vary in sequence 
and quantity (216).  
In general, the biopolymer is insoluble in water, but it is readily soluble in 
dilute acidic solutions below pH 6, as it possesses primary amino groups with pKa 
of 6.5. The protonation of the amino groups along the polymeric chain allows CS to 
dissolve in aqueous acidic solutions (212,217). Yet, solubility properties seem to 
depend on the distribution of acetyl groups (218). In the same way, the viscosity is 
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influenced by CS deacetylation degree pattern as well as pH and strength of the 
solvent. Additionally, other parameters affect the intrinsic viscosity, including 
temperature, shear rate, concentration and molecular weight of the polymer 
(219,220). The latter varies from approximately 10000 to 1 million Dalton and it also 
presents variable degrees of deacetylation, depending on the method of preparation 
(207,221,222). In addition to CS preparation, its origin (i.e. crustacean species) may 
also result in different distribution of functional groups, thus influencing other 
physicochemical properties, such as solubility and viscosity (207,223). 
Physicochemical properties of CS are of utmost importance in developing 
drug formulations (205). For instance, the degree of deacetylation and the degree 
of polymerisation, which in turn decide the molecular weight of the biopolymer, are 
two major characteristics dictating the use of CS for various applications (222). The 
interest in using CS, particularly in pharmaceutical and biotechnological fields, is 
also related with the flexibility of its molecular structure that allows chemical 
modifications. Chemical modification can improve original physicochemical 
properties (e.g solubility) and provide desired and distinctive biological functions, as 
receptor-mediated gene delivery (224), cell penetration enhancement (225) or site-
specific delivery (226), to cite a few examples. 
Moreover, CS has been shown to possess mucoadhesive properties, a 
feature that has been widely exploited in drug delivery, as mucoadhesion can 
prolong retention in the site of action or increase absorption (227). Yet, different 
bioactivities have been attributed to CS, such as antitumor (228,229), antimicrobial 
(229), anti-inflammatory (228), antioxidant (229), and hypocholesterolemic effect 
(230,231). The cationic character of CS, by virtue of the primary amino groups, 
seem to be pivotal to determine its biological activities and to confer many of its 
applications in several fields (232,233). 
 
Lung biodegradability 
 
The biodegradability of CS is far more explored than that of FUC. CS can be 
degraded in vivo by several proteases, mainly by lysozyme, in a process that 
depends on the deacetylation degree, the distribution of acetyl groups, and the 
molecular weight of the polymer (234,235). Still, very few studies on in vivo 
degradation of CS have been reported thus far (236,237), especially addressing 
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pulmonary administration. It is well known that lysozyme is highly expressed in 
submucosal glands of the human airway. Yet, surface airway epithelial cells appear 
to also express lysozyme at lower levels (238). Therefore, it can be reasonably 
assumed that CS could be enzymatically degraded in the lungs. However, further 
studies are required to confirm this assumption. 
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2. Motivation and objectives 
 
TB is a major cause of mortality worldwide, even though a vaccine and 
several effective antibiotics are available for its prevention and treatment. 
Particularly, pulmonary TB represents approximately 80% of total cases and 
therefore the lung has been explored as an effective route for the delivery of drugs 
in the ambit of TB therapy (239). Pulmonary delivery of anti-TB drugs is considered 
a promising approach because it allows targeting the infected organ instantly, thus 
possibly decreasing severe systemic side effects, such as hepatotoxicity and 
nephrotoxicity, which are main reasons for patient non-compliance. However, 
several limitations of pulmonary delivery must be considered as well, mainly related 
with airway structure and specific defense mechanisms, such as the mucociliary 
clearance (240). Overcoming these limitations demands the design of 
aerodynamically suitable carriers that can potentially reach the alveoli, where 
infected alveolar macrophages reside (host cells of Mycobacterium). Additionally, 
drug delivery systems may target and stimulate cells by surface ligands, an effect 
that can be mediated by the composition of the carriers, favouring recognition and 
phagocytosis by alveolar macrophage, for instance. 
For an active targeting approach, carriers must either have a matrix 
composed of materials that act as targeting moieties themselves or incorporate 
surface ligands with selective affinity for specific receptors. For instance, 
polysaccharides of marine origin, such as FUC and CS, have been shown to 
intensify macrophage activation, mediated by membrane receptors (241). In fact,  
the use of both FUC (242,243) and CS (107,244) has been proposed for targeted 
therapy, particularly toward macrophage cells. Apparently, the two polysaccharides 
are endowed with specific features that enable macrophage targeting. As previously 
mentioned, these phagocytic cells express a variety of surface receptors capable of 
recognising, mannose, fucose, N-acetylglucosamine units and sulphated sugars 
(40,245), moieties that compose the chemical structure of the referred polymers. 
Considering all the above, FUC and CS may be of potential use in facilitating the 
internalisation of anti-TB delivery systems and possibly stimulating macrophage 
activation.  
Due to its chemical structure, FUC has been finding some applications in the 
design of polymeric nano and microparticles, which are of the most used of drug 
Nano and microparticle as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy 
32 
 
carriers. In the ambit of drug delivery, the almost totality of FUC-based carriers relies 
on the so-called fucospheres, which are microparticles obtained by polyelectrolyte 
complexation with CS (148,150). Fucoidan has also been used in the development 
of nanoparticles. Again, polyelectrolyte complexation was the predominant 
technique and CS was used in most cases as counterion (80,120,141,147,246). 
Comparatively, CS has been the focus of research as a pharmaceutical 
excipient due to several favourable chemical and biologically features. Apart from 
applications such as wound dressing and tissue engineering, CS showed promising 
features as a supporting agent in drug delivery (247). For instance, it was found that 
CS interacts with cells, which is related to changes in the characteristics of the cell 
membrane or uptake by phagocytic cells (248), an interesting feature for targeted 
cell therapies. Over the last decades, a considerable amount of work has been 
published on CS and its potential use in the design of drug delivery carriers (155–
160), as referred in the previous chapter. 
In this sense, patients with pulmonary TB could benefit from targeted therapy, 
since most anti-TB drugs currently in use, cannot suitably reach the lung and 
alveolar macrophages via oral administration, allowing for prolonged survival of 
mycobacteria in the host (110,249). Yet, the pulmonary delivery of antibiotics would 
maximise drug delivery to the site of infection, since alveolar macrophages are 
fundamentally involved in mediating the removal of inhaled particles. This approach 
could reduce drug doses and delivery frequency, improve patient compliance and 
decrease antibiotic resistance. Furthermore, inhaled antibiotic therapy targeted to 
alveolar macrophages should increase the therapeutic effect of drugs, while limiting 
the potential for systemic side effects. Yet, this strategy would represent a major 
advance in the treatment of pulmonary TB. 
Considering the motivations mentioned above, the aim of the present work 
was to explore the potential of FUC and CS as matrix of polymeric nano and 
microparticles for the pulmonary administration of anti-TB drugs. To demonstrate 
the feasibility of the approach, INH and RFB, two first-line anti-TB drugs, were used 
as models. The working mechanism herein proposed for inhalable carriers is 
illustrated in Figure 2.1. 
 
Nano and microparticle as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy 
33 
 
 
Figure 2.1. Illustration of carrier uptake by alveolar macrophages, assuming targeted 
drug delivery mediated by the polysaccharides (fucoidan or chitosan). Drug-loaded 
carriers reach the alveoli upon dry powder aerosolisation. Next, alveolar 
macrophages, infected with M. tuberculosis, engulf the particles. The polymer is 
expected to facilitate phagocytosis, because it possesses chemical moieties that are 
recognisable by the macrophage surface receptors. 
 
In order to achieve the referred general objectives, several partial goals were 
established, which are displayed below: 
i. To develop nano and microparticles based on FUC and CS; 
ii. To microencapsulate the produced nanoparticles to provide them with 
adequate morphological and aerodynamic properties for deep lung 
deposition; 
iii. To evaluate the ability of carriers to associate anti-TB drugs, individually and 
in combination, and to characterise aerodynamic properties of the systems; 
iv. To determine the drug release profiles in media relevant for pulmonary 
delivery applications; 
v. To evaluate the cytotoxicity of the systems in human pulmonary epithelial 
(A549) and macrophage-like cells (differentiated THP-1 cells);  
vi. To assess the capacity of polymeric carriers to activate alveolar 
macrophages; 
vii. To certify the ability of alveolar macrophages to uptake the proposed 
systems;  
viii. To determine the potential antibacterial activity of the produced formulations 
against a strain of mycobacteria. 
ix. To perform preliminary in vivo study to verify signs of inflammatory and 
allergic responses, possibly induced by the carriers after inhalation. 
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As a result, it is expected to develop natural polymeric carriers which 
efficiently associate antibiotics, present adequate aerodynamic properties for 
pulmonary administration and display the ability to target alveolar macrophages. 
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3. Nanoparticles 
 
3.1 Materials and methods  
 
3.1.1 Preparation and characterisation of nanoparticles by polyelectrolyte 
complexation 
 
Nanoparticles based on FUC (Laminaria japonica, Mw 598.4 g/mol, Chemos 
GmbH, Germany) and CS (Protasan UP CL 113, FMC Biopolymers, Novamatrix, 
Norway) were prepared by polyelectrolyte complexation (FUC/CS nanoparticles; 
Figure 3.1). Firstly, stock solutions of the polymers were prepared at concentrations 
of 0.1% (w/v) by dissolving the polymers in water. Given that low molecular weight 
CS is highly insoluble in water (250), water-soluble ultrapure CS (ProtasanTM) was 
used in the process. Then, stock solutions were diluted and mixed respecting the 
required concentration of each polymer. It is worth mentioning that the initial pH of 
FUC (unadjusted pH 6.2 – 6.8) and CS solutions (unadjusted pH 3.8 – 4.1) slightly 
varied according to the polymer concentration (0.25; 0.334; 0.5; 1 mg/mL). 
Polymeric nanoparticles were spontaneously obtained by mixing the 
negatively-charged FUC and positively-charged CS under gentle magnetic stirring 
at room temperature. FUC solution (2 mL) was added dropwise to the CS solution 
(2 mL) to achieve FUC/CS mass ratios varying from 4:1 to 1:4. The concentration 
of CS was maintained at 1 mg/mL, while that of FUC solutions varied to reach the 
desired ratio. After 15 min of stirring, nanoparticles were concentrated on a 10 µL-
glycerol layer by centrifugation at 16000 xg, at 15 ºC for 30 min (Centrifuge 5804R, 
Eppendorf, Germany). The supernatants were discarded, and nanoparticles 
resuspended in 200 µL purified water. The size, polydispersity index (PdI) and zeta 
potential of the prepared nanoparticles were evaluated using a Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK). 
The loading of anti-TB drugs in the formulations was performed by following 
a protocol similar to that described above. Drug-loaded nanoparticle formulations 
were prepared with FUC/CS mass ratios between 4:1 and 1:1. The amount of 
associated drug was calculated to represent a theoretical content of 10% (w/w) of 
the amount of polymers. Considering only RFB (Mw 847.00 g/mol), the drug was 
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previously dissolved (HCl 0.01M) and then dropped into the CS solution under mild 
magnetic stirring, prior to the addition of FUC solution. After preparing the 
nanoparticles, the supernatant obtained upon centrifugation was analysed by 
spectrophotometry at 500 nm to indirectly determine the RFB content of 
nanoparticles. In other words, the drug association efficiency was calculated by the 
difference between the total amount of drug added to the nanoparticles and the 
amount of non-entrapped drug, which remained in the aqueous supernatant. 
 
 
Figure 3.1. Illustration of fucoidan/chitosan nanoparticle (FUC/CS NP) preparation by 
polyelectrolyte complexation.  
 
It is important to highlight that attempts to produce FUC/CS nanoparticles 
loaded with INH (Mw 137.14 g/mol) were made, however it was soon discovered that 
drug content could not be quantified by UV-Vis spectrophotometry. A screening of 
the matrix materials (both FUC and CS), and of the drugs revealed that FUC 
interferes with the spectrophotometric analysis of INH content at the selected 
wavelengths (268.5 nm). Taking that into consideration, it was decided to quantify 
INH content by HPLC, but until a HPLC protocol was optimised, experiments 
continued using only RFB. 
 
3.1.2 Preparation and characterisation of nanoparticles by nanoprecipitation  
 
Unloaded FUC NP and CS NP were prepared by nanoprecipitation method, 
introducing some modifications in a previously reported methodology (251). FUC 
was dissolved in ultrapure water (0.2%, w/v), while CS low molecular weight (75-
85% deacetylation degree, 116 kDa, Sigma-Aldrich, Germany), was prepared by 
solubilisation in 1% (v/v) acetic acid, to obtain concentrations of 0.2% and 0.5% 
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(w/v). Absolute ethanol was used as the non-solvent. In the case of CS 
nanoparticles, the ethanol (10 mL) was added dropwise to the polymeric solution (5 
mL), at a volume ratio of solvent/non-solvent of 1:2, under mild magnetic stirring (10 
and 30 min, 1, 3 and 6 h) (Figure 3.2a). In the case of FUC nanoparticles, the mixing 
of solvent/non-solvent was performed in the other way around, that is, the polymeric 
solution was dropped into absolute ethanol (Figure 3.2b). Two solvent/non-solvent 
volume ratios were tested for this polymer (polymeric solution/ethanol of 1:2 and 
1:5). The nanoprecipitation occurred under mild magnetic stirring (10 and 30 min) 
and the concentration of FUC solution (0.2%, w/v) was kept constant in all trials. In 
order to optimise the protocol to produce both FUC and CS-based formulations of 
nanoparticles, several approaches were tested using surfactants (Tween® 20 and 
Tween® 80), sonication (ultrasonic bath; VWR, USA), and high-speed 
homogenisation (IKA® Ultra-Turrax® T25 Digital Homogeniser, Germany). 
For both polymers, nanoparticles were concentrated on a 10 µL-glycerol layer 
by centrifugation at 16000 xg, at 15 ºC for 30 min. The supernatants were discarded, 
and nanoparticles resuspended in 1 mL of milliQ water. The particle size and PdI 
were evaluated using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK).  
Both INH and RFB were associated, separately, to CS nanoparticles (10%, 
w/w relative to the amount of polymer). The association was performed in two 
different ways (Figure 3.2): i) the drug was dissolved in the non-solvent (absolute 
ethanol), or ii) the drug was dissolved in the polymeric solution. In the latter 
approach, RFB was first solubilised in HCl 0.01M, and then added to the polymeric 
solution, a procedure unnecessary for INH, which is hydrophilic. The association of 
RFB to FUC nanoparticles was also conducted following the same protocol 
illustrated in Figure 3.2b. In turn, INH was not associated to FUC nanoparticles, at 
this stage, due to the analytical limitation that was previously explained. 
For the two polymers, nanoparticles were recovered by centrifugation as 
described above and the supernatants were used to indirectly determine the drug 
association efficiency by spectrophotometry at 268.5 nm for INH and 500 nm for 
RFB. Nanoparticles were characterised in terms of size and PdI using a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). Calibration curves were performed 
using, as medium of dissolution, the supernatant resulting from the production of 
unloaded nanoparticles using the same solvent/non-solvent volume ratios used in 
the experiments. 
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Figure 3.2. Illustration of the method to produce (a) chitosan and (b) fucoidan 
nanoparticles by nanoprecipitation. Drug was solubilised either in the non-solvent 
(absolute ethanol) or in the polymeric solution. In the latter approach, RFB required 
solubilisation in HCl 0.01M prior to the addition to the polymeric solution, to address 
its hydrophobicity. 
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3.2 Results and discussion 
 
Polysaccharides have long been showing potential in drug delivery 
applications and CS is one major material with broad application in this field (250), 
as aforementioned. Many reported NP-based formulations have, thus, relied on CS. 
The exploration of FUC abilities in this regard is much more recent but numerous 
works report its use in nanoparticle production by polyelectrolyte complexation, as 
previously referred. The ionic nature of FUC enables the formation of complexes 
with oppositely charged polyelectrolytes and CS appears, in this case prominently, 
as the most used counterion, as referred in the previous chapter 
(80,120,141,147,246). However, the production of FUC-based nanoparticles 
produced by other methods, with no use of counterions has also been reported 
(145,146,252).  
Polyelectrolyte complexation has been very useful in the design of drug 
carriers, permitting drug entrapment during complex formation. Afterwards, the drug 
is released from the complex either by ion exchange mechanism or by charge 
interaction, as well as by polymer breakdown and dissolution of the complex (91). 
Although the literature reports FUC/CS nanoparticles obtained by polyelectrolyte 
complexation, to date, there are no reports describing the encapsulation of either 
INH or RFB in such systems. Nevertheless, the entrapment of anti-TB drugs, 
including INH, in nanocomplexes of other composition has been reported (253,254).  
 
3.2.1 Production of FUC/CS nanoparticles by polyelectrolyte complexation 
 
Nanoparticles were spontaneously obtained by complexing FUC with CS, a 
process that occurred in a hydrophilic environment with mild preparation conditions, 
that is in the absence of organic solvents and high shear forces that could interfere 
with the stability of encapsulated drugs (133). By mixing FUC and CS solutions, an 
electrostatic interaction was established between the negatively charged sulphate 
groups of FUC and the positively charged amino groups of CS, leading to 
nanoparticles formation.  
Several formulations of unloaded FUC/CS nanoparticles were produced with 
polymeric mass ratio varying from 4:1 to 1:4. Considering that the mixing order of 
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polymeric solutions influences nanoparticle stability (255), all formulations were 
prepared by adding FUC solution into CS solution. The opposite approach resulted 
in macroscopic precipitation for certain polymeric mass ratios, certainly as a 
consequence of reduction or elimination of electrostatic repulsion (133). In fact, 
when dropping CS into FUC solution, that has initial pH around 6, the relative charge 
density of the protonated amino group of CS, at pH 6, is lower than or equal to the 
relative charge density of sulphated ions of anionic FUC, as previously 
demonstrated (256). Therefore, visible aggregates were formed as the system 
approached an isoelectric condition. 
The developed FUC/CS nanoparticles (unloaded) were characterised in 
terms of size, PdI, and zeta potential. The detailed results are displayed in Table 
3.1. 
 
Table 3.1. Characterisation of unloaded FUC/CS nanoparticles in terms of size, 
polydispersity index (PdI) and zeta potential (mean ± SD, n = 3). Different letters 
represent significant differences in each parameter (p<0.05). 
FUC/CS (w/w) Size (nm) PdI Zeta potential (mV) 
4:1 a 246 ± 10 0.36 ± 0.04 - 39 ± 2 a 
3:1 a 243 ± 21 0.26 ± 0.03 - 39 ± 3 a 
2:1 b 159 ± 5  0.21 ± 0.03 - 30 ± 4 a 
1:1 a 234 ± 4 0.31 ± 0.04 +18 ± 3 b 
1:2 a 226 ± 20 0.30 ± 0.05 +13 ± 1 b 
1:3 a 266 ± 5  0.35 ± 0.05 +13 ± 2 b 
1:4 b 171 ± 16 0.26 ± 0.03 +12 ± 2 b 
 
As can be observed, the tested formulations resulted in nanoparticles with 
average size range of 159 – 266 nm, PdI ranging between 0.21 and 0.36, and zeta 
potential varying from -39 mV to +12 mV, following the alteration of the mass ratios. 
The surface charge of nanoparticles resulted from the excess of one of the 
polysaccharides. Therefore, it was observed that the values of zeta potential varied, 
increasing the positive charge density as the amount of CS was raised in the 
formulation, as expected. The current results agree with previous studies that 
showed similar zeta potential variation in terms of absolute value and charge, also 
demonstrating that the excessive amount of either FUC or CS confers the final zeta 
potential (143,257). This is a relevant parameter, as the distribution of the surface 
charge on a delivery system defines its stability, considering that high surface 
Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy 
43 
 
potential reduces particle agglomeration, making the carriers stable for a longer 
period (258).  
Alterations in polymer ratios not only modify the amount of charges available, 
but also may result in nanoparticles with different mean sizes. Overall, the produced 
nanoparticles evidenced average diameters around 200 nm, which is coincident  
with other studies that tested similar FUC/CS mass ratios (147,259). However, it 
should be mentioned that FUC/CS nanoparticles with larger sizes, varying from 365 
to 900 nm, have been reported (246), corroborating other studies on the production 
of FUC/CS nanoparticles that have demonstrated an effect of polymeric mass ratios 
as well as pH on the average size of FUC/CS nanocarriers (80,120,143). Polymer 
molecular weight may also have an impact on the particle size (260). 
In the present study, differences in the size mean of unloaded FUC/CS 
nanoparticles were observed, however, it was not significant among all tested mass 
ratios, except for formulations at ratios 2:1 and 1:4. These formulations resulted in 
nanoparticles with the lowest average sizes (159 and 171 nm, respectively). Thus, 
these nanoparticles were significantly smaller (p < 0.05) than those obtained from 
formulations 4:1 (246 nm), 3:1 (243 nm), and 1:3 (266 nm), the latter being the one 
that produced nanoparticles with the highest average size. 
Considering that this work aimed at producing drug delivery nanocarriers for 
TB therapy via inhalation, the ability of FUC/CS nanoparticles to associate anti-TB 
drugs was evaluated. For this phase of the work, nanoparticle formulations were 
prepared with equal or higher amount of FUC respect to CS, as we intended to take 
benefit from the theoretical ability of FUC to target macrophages, the host cells of 
tuberculosis pathogenic bacteria. In this sense, drug-loaded nanoparticles with 
FUC/CS mass ratios between 4:1 and 1:1 were prepared. Initially, it was intended 
to incorporate the model drugs separately in order to assess the effect of each drug 
on the developed systems. However, our final interest was to develop a system able 
to carry the two drugs simultaneously, thus complying with the combined therapeutic 
regimen of TB that is recommended by WHO (261). To the best of our knowledge, 
to date, very few studies have reported the co-encapsulation of drugs in 
polysaccharide-based nanoparticles, prepared by polyelectrolyte complexation 
(262). 
Firstly, the ability of FUC/CS nanoparticles to associate RFB was assessed 
by adding the drug to obtain final polymer/drug mass ratio of 10/1 (w/w). As indicated 
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in the methodology, the amount of drug associated to nanoparticles was quantified 
indirectly by analysing the supernatants resulting from nanoparticle isolation by 
centrifugation. The analysis showed that RFB was not associated with any of the 
tested formulations. The literature displays already several works on FUC/CS 
nanoparticles prepared by the same technique described herein, which report the 
successful association of different drugs (120,255,263,264). In most cases, these 
are charged molecules, which certainly facilitates the interaction with the polymers 
and entrapment within the matrix. Nevertheless, the encapsulation of neutral 
materials has also been reported in nanoparticles with different composition but 
prepared by polyelectrolyte complexation (90).  
It is well known that the formation and stability of polyelectrolyte complexes 
depends on many factors, including the concentration of the polymers, their mixing 
order, the polymeric mass ratios, solution pH, etc. (255,265). Accordingly, drug 
entrapment is also affected by polymeric ratios or by whether the resulting complex 
is loosely or tightly assembled, a condition mostly determined by the charge density 
of the constituent materials (90). As charge density is directly affected by solution 
pH (256), this parameter was then addressed as a variable condition to promote 
drug entrapment. Initially, FUC solutions had pH 6 while the pH of CS solution was 
around 4, approximately. After mixing FUC and CS solution, the final pH was 
registered as 6.2 for the formulation FUC/CS 4:1 (w/w). In other words, as the mass 
ratio of FUC increases, the pH of the nanoparticle production medium comes close 
to the initial pH of FUC solution. 
At pH 6, FUC is likely to be fully charged given that it is a strong 
polyelectrolyte with pKa between 1 and 2.5 (266). On the other hand, at this pH, few 
CS amino groups remain protonated, owing to a pKa of 6.5 (144). With this in mind, 
nanoparticles were prepared in acidic medium, knowing that it would lead to the 
protonation of CS (267). As mentioned in the methodology section, RFB was 
solubilized with HCl 0.01M, given its hydrophobic nature, allowing RFB to be 
protonated in the acidic dissolution medium (268). Nevertheless, both ultrapure CS 
and FUC were dissolved in miliQ water. Thus, for further tests, CS solution was 
prepared using HCl 0.01M to ensure that most amino groups of CS were protonated. 
In the same way, FUC solution had the pH adjusted from 6 to 4, in order to maintain 
the nanoparticle production medium at low pH. The pH of FUC solution could not be 
lower than that, because at pH 2, the anionic sulphate groups of FUC are partially 
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uncharged, meaning that electrostatic interactions between FUC and CS are weaker 
(141). With this approach, we expected to promote drug association. 
Surprisingly, varying the pH of polymeric solutions and polysaccharide mass 
ratios did not promote drug association at all. A possible explanation may lie in the 
nature of the drugs or even in the polysaccharide couple. In this respect, a study 
with dextran sulphate/CS complexes has shown an average efficiency of insulin 
loading varying from 48.6 to 96.4%. However, the complexes barely incorporated 
hydrophilic low molecular weight drugs, since they easily escape from the matrices 
(269). Actually, drug entrapment has been reported not only to depend on the nature 
of drugs, but also on the concentration of polymeric solutions, drug/polymer ratios 
and ionic strength, among other factors (262,269). Nanocomplexes of alginate/CS 
and PGA/CS, for instance, encapsulated 5-fluorouracil and temozolomide with 
variable efficiencies (16–82%), depending on: i) CS concentration, ii) the 
polysaccharide pair, iii) polymer ratios, and iv) whether the systems contained one 
or two drugs encapsulated simultaneously (262).  
Unfortunately, the several attempts to associate RFB to FUC/CS 
nanoparticles produced by polyelectrolyte complexation did not succeed. Therefore, 
it was decided to continue the work by using another methodology to produce the 
nanoparticles.  
 
3.2.2 Production of FUC and CS nanoparticles by nanoprecipitation 
 
As the complexation of FUC and CS was not successful in producing 
nanoparticles with ability to effectively associate the selected anti-TB drugs, an 
attempt was made to produce nanoparticles by nanoprecipitation. The technique is 
defined as a process that generates dispersible colloidal systems of polymeric 
compounds in the form of nanoparticles. It is a simple method conducted in one step 
and usually does not require the more aggressive conditions involving high 
temperatures, shear forces and sonication, or even the application of surfactants 
(270). The literature reports the preparation of polymeric nanoparticles using this 
technique, which is also known as solvent displacement method (271,272). 
Nanoprecipitation was originally designed for the encapsulation of hydrophobic 
molecules, but it has also been investigated for the entrapment of hydrophilic drugs 
into the nanoparticles (270,273). Basically, the approach requires two miscible 
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phases (organic and aqueous), and the polymer is soluble in one phase (solvent), 
but not in the other (non-solvent). Ultimately, nanoparticle formation results from the 
instability created at the interface by the interfacial tension between solvent and non-
solvent. In this way, the polymer immediately precipitates, entrapping the drug 
present in the medium (273).  
 
Chitosan 
 
The initial application of this method employed hydrophobic polymers as 
matrix materials, which were dissolved in organic solvents. Consequently, water 
was usually the aqueous phase (non-solvent) used in the process (274). In the 
present study, CS was dissolved in aqueous solution of 1% (v/v) acetic acid, and 
absolute ethanol was employed as the non-solvent. Firstly, unloaded CS 
nanoparticles were produced, in order to optimise the conditions. For that reason, 
several formulations were prepared by varying polymer concentration (0.2% and 
0.5%, w/v), stirring time (10 and 30 min, 1, 3 and 6 h), and using a constant volume 
ratio of solvent/non-solvent (1:2). Ethanol was used as non-solvent. Comparing with 
other alcohols which application has been reported for the same end (e.g. propanol 
and methanol), ethanol has been shown to have milder effect on particle size (270). 
Yet, it is a chemical reagent of easy access and manipulation in the laboratory. 
It has been reported that polymer concentration and stirring time are 
determinant parameters for obtaining nanosized particles by this technique. In this 
work, it was found that the use of CS solution at 0.5% (w/v) and magnetic stirring 
time of 30 min rendered nanoparticles with an average size around 700 nm. Under 
all the other tested conditions, the mean size of the precipitated particles was in the 
micron size range.  
The present work intended to produce nanoparticles for pulmonary drug 
delivery. Although it has been reported that submicron particles can potentially 
deposit in the deep lung (275,276), some researchers claim that nanosized systems 
are mostly exhaled due to their small size and mass (114). Because of that, the 
microencapsulation of nanoparticles is a strategy that could overcome this limitation, 
as previously mentioned in the introduction (Section 1.3). Anyway, obtaining 
particles with larger diameters (between 500 – 700 nm) was preferable in the 
present work.  
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The produced unloaded CS nanoparticles displayed high PdI values (0.83 ± 
0.10), indicating diversity in particle size that can occur due to aggregation (271). In 
general, nanoparticle formation by nanoprecipitation is believed to arise from the 
nucleation of small aggregates of macromolecules with subsequent aggregation of 
these nuclei. The aggregation process occurs until the colloidal stability is reached 
(274). Usually, particle agglomeration can be prevented by using different 
approaches. For instance, stabilising agents (e.g surfactants), high-speed 
homogenisation and sonication may be applied in the process to produce smaller 
particles with narrower unimodal distribution (97,277).  
In this sense, several tools were attempted to prevent particle aggregation, 
allowing the production of CS nanoparticles with narrower size distribution. Firstly, 
4% (v/v) Tween® 20 or Tween® 80 were added into CS solution and used as 
stabilisers in the production process. The presence of surfactants during the 
precipitation process prevents nanoparticle coalescence and subsequently 
formation of aggregates (277). Therefore, it was expected that the use of surfactants 
would avoid particle aggregation, subsequently narrowing particle size distribution. 
Surprisingly, the addition of Tween® 20 resulted in micron-sized CS particles with 
PdI values around 1.0. The increase in size in the presence of surfactant has been 
previously reported and this effect can raise with higher concentrations of stabiliser 
(272). Contrarily, the inclusion of Tween® 80 significantly reduced the mean size of 
CS nanoparticles (50 – 100 nm) but did not narrow the particle size distribution as 
much as expected, with PdI values remaining between 0.8 – 1.0.  
In this manner, experiments proceeded applying sonication along with the 
use of Tween® 20. Sonication was applied for 5 min, right after the mixing of non-
solvent and CS solution, containing the surfactant. Longer periods were also tested 
(15, 30, 60 min), but the evaporation of ethanol (non-solvent) was perceived during 
the process, since the volume content in the beaker was visually reduced. The 
strategy resulted in micron-sized particles with high PdI values (0.9 –1.0).  
In the same way, high speed homogenisation (Ultra-Turrax®) was applied 
instead of sonication, combined with Tween® 20, also resulting in the production of 
particles over 1000 nm in size. Next, the described approaches were also performed 
using Tween® 80, combined with either sonication or high-speed homogenisation. 
In general, the strategies decreased the size range of CS nanoparticles under 100 
nm, a result not desirable for the intended application of the carriers. It is known that 
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nanosized particles smaller than 100 nm can readily translocate across the epithelia 
of respiratory tract (113). It should be mentioned that when only sonication was 
applied (with no surfactant), it resulted in the production of micron-sized particles 
with wide size distribution (PdI around 1.0). As well, the application of high-speed 
homogenisation in the absence of surfactants originated particles with mean 
diameter over 1000 nm.  
Although particle size distribution had not been properly controlled, attempts 
to encapsulate the model drugs were made. For this phase of the present study, 
surfactants, sonication, and high-speed homogenisation were not used at all. As 
illustrated in Figure 3.2a, each drug (INH or RFB) was dissolved either in the solvent 
(CS solution at 0.5%, w/v) or in ethanol (non-solvent), and nanoparticles were 
produced at solvent/non-solvent volume ratio of 1:2. The mixing of polymeric 
solution/ethanol was conducted under mild magnetic stirring (30 min). The 
approaches illustrated in Figure 3.2a were tested and neither of them succeeded in 
encapsulating the antibiotics. 
Despite the numerous attempts to produce CS nanoparticles by 
nanoprecipitation, the obtained results were not in line with the desirable 
nanoparticle characteristics. PdI values clearly evidenced wide size distribution of 
particles, suggesting particle agglomeration. In spite of the use of several 
approaches, the formation of aggregates was not sufficiently minimised. In most 
cases, the distribution curves indicated the presence of two different particle size 
populations. The bimodal curves mostly consisted of a fraction of submicron 
particles and a second population over 1000 nm. Nanoprecipitation often enables 
the production of small nanoparticles (100 – 300 nm) with narrow unimodal 
distribution (270), which contrasts with the results obtained herein. However, 
particles with larger diameters (400 – 800 nm) have also been reported using this 
technique (278,279). In fact, some of the tested approaches generated CS particles 
in that size range (around 700 nm), which was acceptable for the purpose of this 
work. Nevertheless, we realised that this was difficult to replicate. More importantly, 
the technique did not result in the encapsulation of the model drugs, a crucial 
element for the development of this research work. 
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Fucoidan 
 
As described for CS, several experimental approaches were performed to 
identify the most appropriate conditions to control the size and polydispersity of FUC 
nanoparticles prepared by nanoprecipitation. The production of these resulted from 
the dropwise addition of the polymeric solution into ethanol, since the opposite 
approach did not enable nanoparticle formation. Similarly to CS, FUC nanocarriers 
were initially produced without drugs.  
As described in the methodology, the concentration of FUC solution (0.2%, 
w/v) was kept constant in all trials, since the first attempts to produce unloaded FUC 
nanoparticles resulted well, at this concentration. In addition, two solvent/non-
solvent volume ratios (1:2 and 1:5) were used and revealed that this variation had 
little influence on particle size, which varied between 535 – 564 nm (1:3, v/v) and 
507 – 551 nm (1:5, v/v). This observation is coincident with that of a recent study on 
starch nanoparticles, which evaluated the effect of solvent/non-solvent volume ratio 
on the particle size (271). However, the literature displays various studies of this 
effect with variable results, reporting that the decrease in the solvent/non-solvent 
ratio can lead to a rise or a reduction in the particle size (280,281). This suggests 
strong influence of the proper polymers on this parameter. 
As described before, the nanoprecipitation procedure was conducted under 
mild magnetic stirring, which was kept for 10 min or 30 min. In this case, applying 
magnetic stirring for longer was not considered, given that it could generate micron 
sized particles, as observed for CS. In terms of average size, similar values were 
obtained after stirring FUC solution and ethanol (ratio 1:2) for 10 min (535 ± 78 nm) 
and 30 min (564 ± 123 nm). Regarding the solvent/non-solvent volume ratio of 1:5, 
the corresponding mean diameters were 507 ± 43 nm (magnetic stirring for 10 min) 
and 551 ± 101, after 30 min of stirring. Hence, the approaches resulted in unloaded 
FUC particles in the nanosized range (around 500 nm), regardless of the operated 
variations in both magnetic stirring time and solvent/non-solvent volume ratio.  
Nevertheless, the obtained unloaded FUC nanoparticles displayed little 
uniformity in size, indicated by PdI values, varying within 0.55 and 0.67. Thus, as 
described for CS, several approaches regarding the process were used to address 
this issue and obtain FUC nanoparticles with narrower size distribution. It was 
expected that the use of Tween®, sonication and/or high-speed homogenisation 
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would inhibit the aggregation of the particulate carriers. Nonetheless, the used tools 
did not improve the characteristics of the produced FUC nanoparticles, under the 
tested conditions, with PdI values remaining high in order of 0.8 – 1.0. In light of this, 
the experiments continued, using no surfactants, sonication, or ultra-turrax®, and 
the encapsulation of drug was attempted. As previously explained, the tests initiated 
with RFB, rather than INH, because the latter imposed an analytical limitation that 
hindered the determination of drug content in INH-loaded FUC nanoparticles by 
spectrophotometry. In this case, drug content would be determined by HPLC, but a 
protocol had not been optimised by then. Thus, drug encapsulation experiments 
started with RFB.  
RFB (10% w/w in relation to the polymer) was dissolved in ethanol, followed 
by the dropwise addition of 0.2% (w/v) FUC solution, resulting in none or very low 
drug entrapment (5.4 – 7%). For this reason, the experiments persisted, but the 
dissolution of RFB started to be performed in HCl 0.01M instead. In this medium 
RFB becomes protonated, which could affect positively the encapsulation. After the 
dissolution step, the drug was mixed with the polymeric solution following the same 
approach. The strategy rendered submicron FUC particles showing variable 
entrapment efficiency of RFB, ranging from zero to 46%, which indicated difficulties 
in the replicability.  
Although it has been observed in the initial assays that the volume of the non-
solvent (ethanol) did not influence particle size, different solvent/non-solvent ratios 
were tested because these could interfere with drug association efficiency (282). 
The 1:2 volume ratio resulted in drug-loaded FUC nanoparticles with mean size of 
517 ± 57 nm and PdI around 0.46. The average RFB content of these carriers was 
15 ± 20%, considering that the data set varied from zero to 37%. Regarding 
solvent/non-solvent ratio of 1:5, FUC nanoparticles (503 ± 60 nm and PdI around 
0.50) were obtained, associating approximately 25 ± 17% of RFB. In this case, the 
mean value resulted from a set of values that ranged between 8.2 to 46%. In terms 
of particle size, these results are comparable with others reported in the literature 
for the same methodology (283), which was also observed regarding drug 
association efficiency (284). Nevertheless, the amount of encapsulated drug varied 
considerably among trials. 
Nanoprecipitation is known as an easy and reproducible technique, but many 
operating parameters must be managed to ensure the production of nanoparticles 
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with the intended characteristics. These include the choice of solvent, non-solvent 
type and volume, stirring rate and time, polymer concentration, to name a few. The 
referred operating conditions definitely have a major impact on the resulting 
particulate carriers (274). 
Overall, the effect of several factors was investigated and the attempt to 
optimise the methodology was performed in order to achieve a reproducible 
formulation with uniform size. A crucial requirement of a production method is that 
it should be reproducible, which was not observed. Furthermore, the tested 
protocols did not provide proper control of particle polydispersity, which is an 
important parameter to be considered. Moreover, drug association efficiency could 
not be replicated over the experiments, which is critical to accomplish the aims of 
this research. 
 
Conclusion 
 
In summary, an optimal protocol to obtain CS- and FUC-based nanoparticles 
that efficiently encapsulate INH and RFB was not established. The literature reports 
a variety of methods to produce polymeric nanoparticles that could have been 
applied in the present work. Nonetheless, the intention to use a mild and simple 
technique to produce the nanoparticles in this work should be clear. Unfortunately, 
the attempts to optimise the methods (polyelectrolyte complexation and 
nanoprecipitation) did not succeed. All things considered, due to the limited time to 
accomplish the aims of the PhD plan, it was decided to focus the work on the 
development of microparticles, which were worked out in parallel and provided more 
satisfactory results. 
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4. Microparticles: Materials and methods 
 
4.1 Materials 
 
FUC (Laminaria japonica, Mw 598.4 g/mol) and RFB were purchased from 
Chemos GmbH (Germany). CS (low molecular weight, 75-85% deacetylation 
degree, 116 kDa), citrate buffer pH 5 (citric acid ~0.096 M, sodium hydroxide ~0.20 
M), dimethylformamide (DMF), Dulbecco’s modified Eagle’s medium (DMEM), 
lipopolysaccharide (LPS), mannitol (Man), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDAC), non-essential amino acids solution and 
penicillin/streptomycin (10,000 units/mL, 10,000 g/mL), sodium dodecyl sulphate 
(SDS), Triton X-100, trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), trypan 
blue solution (0.4%), INH, and HCl were supplied by Sigma-Aldrich (Germany). 
Thiazolyl blue tetrazolium bromide (MTT), phosphate buffer saline (PBS) tablets pH 
7.4 and Tween® 80 were supplied by Amresco (USA). Dimethyl sulfoxide (DMSO) 
was provided by VWR (France) and phorbol 12-myristate 13-acetate (PMA) was 
provided by Cayman Chemicals (USA). A lactate dehydrogenase (LDH) kit was 
obtained from Takara Bio (Japan) and L-glutamine solution (200 mM) as well as 
fetal bovine serum (FBS) from Gibco (Life Technologies, USA). RPMI 1640 and 
Ham’s F12 media were supplied by Lonza Group AG (Switzerland). Middlebrook 
7H9 (M7H9; 4.7 g/L) and OADC (oleic acid, albumin, dextrose and catalase) were 
purchased from Remel (USA). Ultrapure water (milliQ, Millipore, UK) was used 
throughout the studies and other chemicals were reagent grade. 
 
4.2 Preparation of microparticles by spray-drying 
 
4.2.1 Fucoidan 
 
Microparticles based on FUC were obtained from FUC solutions at 
concentrations of 1% or 2% (w/v), depending on the formulation. FUC solutions 
were prepared by dissolving the polymer in water under magnetic stirring (MS-3000 
Biosan, Latvia). The final volume of the polymeric solutions was 50 mL. The anti-TB 
drugs INH and RFB were associated with FUC microparticles, either individually or 
combined. In the end, five formulations were obtained, with the following 
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denominations: FUC MP (unloaded MP); FUC-Man MP (unloaded MP), FUC-
Man/INH (10/1) MP; FUC/RFB (10/0.5) MP; FUC/INH/RFB (10/1/0.5) MP. The 
values in parenthesis represent the polymer/drug mass ratio (w/w). Mannitol was 
used in certain formulations to improve flow properties. In those cases, FUC was 
used at 1% (w/v) and mannitol at 0.5% (w/v). The remaining formulations were 
obtained from 2% (w/v) FUC solutions and no addition of mannitol.  
FUC solutions with no drugs but with mannitol when applicable, were kept 
under magnetic stirring until complete solubilisation of the polymer and further 
spray-dried. Regarding the preparation of microparticles containing the drugs, INH 
was ground in a porcelain mortar, solubilised with water, and added dropwise to the 
polymeric solution previously prepared. The solution was stirred for 1 h and then 
spray-dried. The polymer/drug ratio was kept at 10/1 (w/w). For obtaining 
microparticles loaded with RFB, the drug was previously ground in a glass mortar, 
solubilised with 4% (v/v) absolute ethanol. Subsequently, it was added dropwise to 
the polymeric solution which was stirred for 1 h before spray-drying. Final 
concentration of RFB was such that a polymer/drug mass ratio of 10/0.5 was 
obtained. Finally, in the case of the formulations containing both drugs in 
combination, INH was ground and solubilised with water while RFB was ground and 
solubilised with 4% (v/v) ethanol prior to drug incorporation into the polymeric 
solutions. Polymeric solutions containing both drugs underwent magnetic stirring for 
1 h before spray-drying took place. Final polymer/drug ratios for this formulation was 
FUC/INH/RFB =10/1/0.5, w/w. 
Dry powder formulations were obtained by spray-drying (Büchi B-290 Mini 
Spray Dryer, Büchi Labortechnik AG, Switzerland), with the equipment operating in 
an open mode configuration, and compressed air used as fluid. Polymeric solutions 
were spray-dried on a laboratory scale spray-dryer (Figure 4.1) equipped with a 
high-performance cyclone. During the process, the solution passes through an 
atomizer that creates a spray, forming droplets. The droplets are dried when 
exposed to the hot air in a drying chamber. The drying gas is heated at a defined 
temperature (inlet temperature) and promotes the rapid evaporation of the solvent 
present in the droplets. Next, the resultant dried particles enter the cyclone, where 
they are separated from the air stream by the helicoidal motion of the air flow. 
Finally, the obtained dry powder accumulates in the powder collector.  
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Figure 4.1. Scheme of the spray-drying process. 
 
The spray flow rate was set at 473 L/h and the inlet temperature, the aspirator 
and the feed flow used to prepare each formulation are displayed in Table 4.1. Each 
formulation was prepared in triplicate (n = 3) and dry powders were stored in 
desiccators until further use. The aqueous solutions and the resulting dry powders 
loaded with drugs were protected from light in every step of manipulation and 
storage. 
 
4.2.2 Chitosan 
 
Microparticles based on CS were obtained from 2% (w/v) solutions which 
were prepared by dissolving the polymer under stirring (MS-3000 Biosan, Latvia) in 
a mixture of 1% (v/v) acetic acid and ethanol absolute (solvent ratio 10/1). The final 
volume of the polymeric solutions was 50 mL. INH and RFB were associated with 
CS microparticles, either individually or in combination. In the end, four formulations 
were prepared, with the denominations described as follows (in parenthesis is 
indicated the mass ratio between materials: CS MP; CS/INH (10/1) MP; CS/RFB 
(10/0.5) MP; and CS/INH/RFB (10/1/0.5) MP.  
CS solutions with no drugs underwent magnetic stirring until complete 
solubilisation of the polymer and were then spray-dried. Regarding the preparation 
of microparticles containing INH only, the drug was ground in a porcelain mortar, 
solubilised in acetic acid and dropped into the polymeric solution previously 
prepared. The solution was stirred for 1 h and then spray-dried. The polymer/drug 
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ratio was kept at 10/1 (w/w). For obtaining carriers loaded with RFB, the drug was 
previously ground in a glass mortar, solubilised with 10% (v/v) absolute ethanol and 
added dropwise to the CS solution, which was stirred for 1 h before spray-drying. 
The final concentration of RFB was such that a polymer/drug mass ratio of 10/0.5 
was obtained. Finally, in the case of the formulations containing both INH and RFB 
in combination, drugs were separately ground and properly solubilised, as described 
above, prior to drug incorporation into the polymeric solutions. Polymeric solutions 
containing both drugs were kept under magnetic stirring for 1 h before spray-drying. 
Final polymer/drug ratios for the referred formulation was CS/INH/RFB = 10/1/0.5, 
w/w. 
CS solutions were then spray-dried, and the obtained dry powders were 
stored, as described above. The spray-drying parameters for producing CS 
microparticles are presented in Table 4.1  
 
Table 4.1. Spray-drying parameters (inlet temperature, aspirator and feed rate) used 
to produce fucoidan- and chitosan-based microparticles and resulting outlet 
temperature. 
Microparticles 
Inlet 
Temp.(°C) 
Aspirator 
(%) 
Feed rate 
(mL/min) 
Outlet 
Temp.(°C) 
Unloaded FUC 125 ± 1 80 2.0 69 – 73 
Unloaded FUC-Man  145 ± 1 85 1.0 86 – 92 
FUC-Man/INH (10/1)  160 ± 1 90 1.0 98 – 102 
FUC/RFB (10/0.5)  145 ± 1 85 1.0 86 – 92 
FUC/INH/RFB (10/1/0.5)  145 ± 1 85 1.0 88 – 95 
Unloaded CS  160 ± 1 80 1.3 96 – 99 
CS/INH (10/1)  160 ± 1 80 1.3 98 – 102 
CS/RFB (10/0.5)  160 ± 1 80 1.3 96 – 100 
CS/INH/RFB (10/1/0.5)  160 ± 1 80 1.3 96 – 99 
 
The production yield of the spray-drying process was calculated for all 
formulations at the relationship between the solid content in the resulting powder 
(collected microparticles) and the total solid content in the feed dispersion: 
 
 
Yield (%) = (Weight of collected MP / Weight of solids (polymer+drug) in the dispersion) x 100 (1) 
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4.2.3 Preparation of fluorescently labelled microparticles  
 
Fluorescent FUC and CS microparticles (unloaded) were produced to be 
used in a single assay (macrophage capture – Section 6.5), following the same 
conditions displayed in Table 4.1  
 
Fucoidan 
 
A fluorescent label was attached to FUC by reacting 1 g of the polymer 
(commercial powder) with fluorescein sodium salt (24.4 mg dissolved in 4 mL of 
96% (v/v) ethanol), in the presence of EDAC (9.6 mg). This was dissolved in 16 mL 
of milliQ water and added to the solution to activate the fluorescein. The covalent 
attachment of the dye to the polymer was carried out by adding fluorescein into a 
2% (w/v) FUC solution. The reaction was stirred overnight, and then dialysed (2000 
Da Mw cut-off) against distilled water, ensuring light protection during the whole 
process. 
In the end, dialysates were frozen, freeze-dried (FreeZone Benchtop Freeze 
Dry System, Labconco, USA), and stored in desiccators. Finally, the resulting 
fluorescently-labelled FUC was spray-dried and the dry powder was stored, 
protected from light, for further use. 
 
Chitosan 
 
Fluorescently-labelled CS was synthesised by reacting 1 g of CS (2%, w/v, 
dissolved in acetic acid) with fluorescein sodium salt (40 mg). The dye was first 
solubilised in 15 mL of 96% (v/v) ethanol, being then added to CS solution. The 
covalent interactions of the dye with the polymer occurred in the presence of 31 mg 
(dissolved in water) of EDAC. The reaction was kept under stirring for 24 h, 
protected from light, and then dialysed against distilled water. The obtained 
dialysates were then frozen, freeze-dried and stored, as described above. 
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4.3 Characterisation of microparticles 
 
4.3.1 Morphology 
 
The morphological examination of the produced microparticles was 
conducted by field emission scanning electron microscopy (FESEM Ultra Plus, 
Zeiss, Germany). Generally, dry powders were placed onto metal plates and 5 nm 
thick iridium film was sputter-coated (model Q150T S/E/ES, Quorum Technologies, 
UK) on the samples before viewing. 
 
4.3.2  Particle size 
 
The size of microparticles was estimated as the Feret’s diameter (distance 
between two tangents on opposite sides of the particle) and was directly determined 
with an optical microscope (Microscope TR 500, VWR International, Belgium), The 
Feret’s diameter was estimated as the mean of 300 particles (n = 3). The particle 
size distribution of drug-loaded microparticles was further determined by laser light 
scattering (SprayTec, Malvern, UK). Briefly, approximately 15 mg of dry powder 
were dispersed in 15 mL of 2-propanol and sonicated for 5 min. Data analysis is 
expressed in terms of median volume diameter of 50% (Dv50) of aerosol droplets. 
Complementarily, span values were determined to provide an indication of the width 
of size distribution. Analysis was carried out in triplicate with an obscuration 
threshold of 10% (285).  
 
4.3.3 Density 
 
Real density (g/cm3) was determined by helium pycnometry (n = 3; 
Micromeritics AccuPyc 1330, Aachen, Germany). Bulk and tap densities (g/cm3) 
were determined by measuring the volume of a known weight of powder before and 
after mechanical tapping (30 taps/min, Densipro 250410, Deyman, Spain). The 
determination of tap density involved tapping the sample until a constant volume 
was achieved. Measurements were performed in triplicate in all cases. Thus, bulk 
and tap densities (g/cm3) were calculated according to the following equations: 
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Bulk density = Dry powder weight / Initial volume of powder (2) 
Tap density = Dry powder weight / Final volume of powder (3) 
 
4.3.4 Dry powder analysis using Powder X-Ray Diffraction (PXRD) 
 
The raw materials, free drugs, and microparticles were analysed by PXRD in 
a PANalitycal X’Pert Pro diffractometer, using nickel filtered CuKα radiation with a 
wavelength of 0.154 nm. An X'Celerator detector was used and the operating 
conditions were 45 kV and 35 mA. The diffractograms were obtained in reflection 
mode from 5 to 70° 2theta with a step size of 0.05 °and 1500 s per point. 
 
4.3.5 Drug association efficiency and loading 
 
In order to determine the amount of drug associated with each formulation, 
an established amount of drug-loaded microparticle was solubilised with 10 mL of 
HCl 0.1M, under magnetic stirring for 20 min. After complete dissolution, samples 
were filtered (0.45 µm syringe filter) before quantification. 
Particularly, to quantify the content of INH and RFB associated with CS 
microparticles, the formulations CS/INH (15 mg) and CS/RFB (30 mg) were 
solubilised and analysed by UV-Vis spectrophotometry (Pharmaspec UV-1700, 
Shimadazu, Japan). Measurements were performed at a wavelength of 268.5 nm 
and 500 nm to quantify INH and RFB, respectively. In order to determine the drug 
association efficiency of CS/INH/RFB (10/1/0.5) microparticles, the dry powder (30 
mg) was properly dissolved and samples were spectrophotometrically analysed at 
both 268.5 nm and 500 nm. The analysis at 500 nm provided a direct measure of 
the RFB amount present in the CS microparticles associating the drugs in 
combination. In turn, the measurement performed at 268.5 nm required a 1:10 
dilution and represents the sum of INH and RFB contents. Next, the amount of INH 
was calculated by subtracting the absorbance obtained at 500 nm (RFB) from that 
acquired at 268.5 nm (RFB + INH). In general, the drug content of CS microparticles 
was determined after establishing calibration curves, which were performed in an 
adequate media (counting on any effect from the polymer). A screening of the matrix 
material (CS) revealed no interference of this polymer at the selected wavelengths.  
Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy  
62 
 
Differently, the polymeric matrix based on FUC presented some interference 
at the wavelength 268.5 nm. Therefore, the drug content of FUC formulations was 
determined by high-performance liquid chromatography (HPLC – Agilent 1100 
series, Germany). A LiChrospher® 100 RP-18 (4.6 µm) column of 4 mm i.d. x 250 
mm length with security guard cartridge was used. The analysis conditions were 
established as follows: 20 µL injection volumes, and flow rate of 1.0 mL/min. 
Detection was performed by a diode array detector set at a wavelength of 275 nm. 
The chromatographic analysis was achieved by using a gradient system, in which 
the mobile phase consisted of phosphate buffer 20 mM pH = 7 (A) and acetonitrile 
(B). The elution was conducted with a gradient starting with A/B = 95:5 kept for 5 
min, followed by 3 min step gradient, until a 30:70 A/B ratio was reached, which was 
then kept for 19 min.  
Overall, to determine the drug content of FUC microparticles, 20 mg of dry 
powder were accordingly solubilised (HCl 0.1M) and aliquots (20 µL) were analysed 
by HPLC. Under the conditions previously described, INH and RFB were eluted at 
5.0 and 20 min, respectively. Calibration curves (10 – 400 mg/mL) were obtained 
using INH and RFB analytical standard dissolved in HCl 0.1M.  
In the end, drug association efficiency (AE) and microparticle loading capacity 
(LC) were estimated (n = 3) by the following equations (286,287): 
 
AE (%) = (Real drug content / Theoretical drug content) x 100 (4) 
LC (%) = (Real amount of drug / Weight of MP) x 100 (5) 
 
4.4 Evaluation of aerodynamic properties 
 
The evaluation of aerosolisation properties of the produced dry powders was 
performed upon assessment in the Andersen cascade impactor (ACI, Copley 
Scientific Ltd., UK). The in vitro aerosol performance was determined by filling 
HPMC size 3 capsules (Quali-V-I, Qualicaps, Spain) with 30 mg of powder. The 
content of three capsules was discharged in each aerodynamic test using an RS01 
dry powder inhaler (Plastiape Spa, Italy). The ACI was operated at 60L/min, a flow 
rate that corresponds to a pressure drop of 4 kPa over the device. The system was 
activated for 4 seconds, a duration consistent with 4L of air drawn through the 
inhaler. The apparatus was assembled using the appropriate adaptor kit for the 60 
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L/min air flow test, thus establishing the cut-offs of the stages from -1 to 6 as 
following: 8.60, 6.50, 4.40, 3.20, 1.90, 1.20, 055, 0.26 µm.  
In order to prevent particle bounce, the collection plates were previously 
coated with 0.1% (v/v) Span® 85 in cyclohexane solution. Moreover, a glass fibre 
filter (Whatman, UK) was placed in the filter (F) part of the equipment to collect 
particles with a diameter lower than that of stage 6 cut-off. The powder was 
recovered from the apparatus with a water/acetonitrile mixture (50/50, v/v), samples 
were sonicated for 5 min, filtered (0.45 µm, RC, Sartorius, US) and analysed. The 
drug mass deposited in the impactor was determined by HPLC (Agilent 1200 series, 
Germany), following the analytical protocol described above (Section 4.3.5). Three 
samples were analysed, and mean value as well as standard deviation calculated. 
The mass of drug deposited inside the impactor and the inhaler allows the 
calculation of a number of different deposition parameters. The metered dose (MD) 
is the mass of drug recovered and quantified by HPLC and is calculated by summing 
the drug recovered from the inhaler (device and capsule) and the impactor 
(induction port, pre-separator, stages -1 to 6 and filter). The emitted dose (ED) was 
considered as the amount of drug leaving the device and reaching the impactor. The 
mass median aerodynamic diameter (MMAD) was determined by plotting the 
cumulative percentage of mass against ACI cut-off diameters on a probability scale 
versus aerodynamic diameter of the stage on a logarithmic scale. Fine particle dose 
(FPD) was defined as the mass of drug particles with size <5µm (calculated from 
log-probability plots), and the fine particle fraction (FPF) was calculated as the 
percentage ratio between FPD and ED. 
 
4.5 In vitro drug release profiles 
 
The release profiles of INH and RFB from the produced microparticles were 
determined in phosphate buffered saline (PBS, pH 7.4, VWR, USA) and in citrate 
buffer (pH 5), both containing 1% (v/v) Tween® 80. The former represents the local 
pH of the lung, while the latter simulates the pH found in macrophage cells. In 
addition, Tween® 80 not only represents the lung surfactant present in the lung lining 
fluid, but also facilitates the solubilisation of RFB, which is barely soluble in the 
referred buffers.  
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4.5.1 Fucoidan microparticles 
 
Twenty mililigramas of drug-loaded FUC microparticles were suspended in a 
test tube containing 10 mL of release medium, which was kept under mild shaking 
(100 rpm; Orbital Shaker OS 10, Biosan, Latvia) at 37 ºC (Dry line; VWR, USA). To 
determine the drug release over time, test samples were withdrawn (1 mL) at pre-
established time intervals (5, 10, 15, 30 min), centrifuged (16000 xg, 15 min; 
Heraeus Fresco 17 Centrifuge, ThermoScientific, USA), and filtered (0.45 µm 
syringe filter). The drug content was determined in the supernatant by HPLC, using 
the protocol described in section 4.3.5. Calibration curves were obtained dissolving 
the drug analytical standards in the corresponding release medium. 
 
4.5.2 Chitosan microparticles 
 
Specifically, 15 mg of CS/INH (10/1) microparticles were incubated with 
release media (10 mL) and samples (1 mL) were collected, diluted (1:10) and 
spectrophotometrically measured at 268.5 nm to determine INH content. Similarly, 
aliquots (1 mL) obtained from the incubation of 30 mg of CS/RFB (10/0.5) 
microparticles with the release media (10 mL) were analysed at 500 nm. For 
analysing carriers containing the two drugs in combination, 15 mg of CS/INH/RFB 
(10/1/0.5) microparticles were accordingly incubated and the collected samples (1 
mL) were measured at a wavelength of 500 nm to determine RFB content. Next, a 
1:10 dilution was performed, and a further measurement was made at 268.5 nm in 
order to determine the drug content representing the sum of INH and RFB. At last, 
the amount of INH was obtained by subtracting the absorbance value at 500 nm 
from that of 268.5 nm.  
Overall, tested samples were withdrawn at specific time intervals (15, 30, 45, 
60, 120 min), centrifuged (16000 g, 15 min) and the supernatant filtered (0.45 μm 
syringe filter) before analysis. Adequate calibration curves were established by 
dissolving drug standards in the media, resulting from the incubation of unloaded 
CS microparticles with the referred medium (under the same conditions described 
above), followed by centrifugation (4000 rpm, 20 min; Centrifuge MPW 223e, 
Poland) and filtration (0.45 µm syringe filter). 
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Each drug release experiment was performed in triplicate. The percentage 
(%) of drug released over time was determined based on the following equation: 
 
Drug release (%) = (Quantified drug at each time point/ Initial drug content) x 100 (6) 
 
4.6 In vitro biocompatibility studies 
 
4.6.1 Cell cultures 
 
Cell lines representing the human alveolar epithelium (A549) and rat alveolar 
macrophages (NR8383) were purchased from the American Type Culture Collection 
(ATCC, UK) and used between passages 25–36 (A549) and 9–18 (NR8383). 
Particularly, A549 cells were maintained in DMEM, supplemented with 10% (v/v) 
FBS, 1% (v/v) L-glutamine solution 200 mM, 1% (v/v) non-essential amino acids and 
1% (v/v) penicillin/streptomycin. For the assays, the adherent A549 cells were 
harvested using trypsin-EDTA solution. In turn, the semi-adherent NR8383 cells 
were grown in Ham’s F12 containing 15% (v/v) FBS, 1% (v/v) L-glutamine and 1% 
(v/v) penicillin/streptomycin. After incubation, the non-adherent fraction of NR8383 
cells was removed, adherent cells were scraped and used to perform the assays.  
THP-1 human monocytic cells were obtained from the Leibniz-Institut DSMZ 
(Braunschweig, Germany) and used between passages 10–17. This cell line was 
cultured in suspension at a density of 0.2 – 0.8 x 106 cells/mL in RPMI 1640 medium, 
supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine and 1% (v/v) 
penicillin/streptomycin. THP-1 cells were differentiated to acquire the macrophage 
phenotype by treatment with phorbol 12-myristate 13-acetate (PMA, 50nM; 0.2 x 
106 cells/mL, 48 h exposure) before performing the experiments.  
A549 and NR8383 cell lines were grown using 75 cm2 flasks for adherent 
cells whereas THP-1 cells were cultured in flasks for cells in suspension (75 cm2). 
In general, cell cultures occurred in a humidified 5% CO2 / 95% atmospheric air 
incubator at 37 ºC (HerAcell 150, Heraeus, Germany).  
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4.6.2 Assessment of metabolic activity by MTT test 
 
The cytotoxic effect of microparticles was assessed on both A549 and 
macrophage-differentiated THP-1 cells using the tetrazolium reduction assay, 
known as the MTT test. The experiment is based on the ability of the compound (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) to be enzymatically 
reduced by viable cells. The reaction induces a change in the colour of the reagent 
from yellow to purple. To perform the assay, A549 cells (1.0 x 104 cells/well) and 
macrophage-differentiated THP-1 cells (0.35 x 106 cells/well) were separately 
seeded onto 96-well plates (Orange Scientific, Belgium). Each well was filled with 
100 µL of the respective cell culture medium (CCM) and the cells were allowed to 
attach for 24 h (37 ˚C and 5% CO2 atmosphere). After this time, the cells were 
exposed to solutions of the polymers (FUC and CS as raw materials), unloaded and 
drug-loaded microparticles, for 3 and 24 h. The test solutions were previously 
prepared by dissolving the samples with the specific CCM (37 °C) without FBS at 
the concentrations of 0.1, 0.5 and 1.0 mg/mL. INH and RFB were also tested as free 
drugs at concentrations equivalent to their theoretical loading in the microparticles, 
i.e. respecting the polymer/drug mass ratio of 10/1 in the case of INH (0.01; 0.05 
and 0.1 mg/mL) and 10/0.5 for RFB (0.005; 0.025 and 0.05 mg/mL). CCM and SDS 
(2%, w/v) were used as positive and negative controls of cell viability, respectively.  
After the exposure time, 30 µL of MTT solution (0.5 mg/mL in PBS, pH 7.4) 
were added to each well and allowed to incubate for a period of 2 h at 37 ˚C. 
Thereafter, formazan crystals, formed during tetrazolium metabolisation, were 
solubilised with 50 µL of DMSO (A549 cells) or 70 µL of 10% (w/v) SDS in a 1:1 
mixture of DMF:water (THP-1 cells). Finally, absorbance was determined by 
spectrophotometry (Infinite M200, Tecan, Austria) at 540 nm and corrected for 
background absorbance at 640 nm (288). Cell viability of treated cells was 
expressed as a percentage of that observed for the positive control. The assay was 
performed at least three times, with six replicates at each concentration of test 
solutions, including controls. Relative cell viability was calculated as follows: 
 
Cell viability (%) = (A – S) / (CM – S) x 100 (7) 
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where A is the absorbance obtained for each of the concentration of test solutions, 
CM is the absorbance observed for untreated cells (incubated with cell culture 
medium only) and S is the absorbance obtained for negative control of cell viability. 
 
4.6.3 Evaluation of cell membrane integrity 
 
The integrity of cell membrane was assessed on both cell lines (A549 and 
macrophage-differentiated THP-1 cells) by the quantification of lactate 
dehydrogenase (LDH) released upon exposure to the proposed formulations. 
Leakage of enzymes such as LDH is a well-known marker of cytotoxicity. The 
cytotoxicity of the produced microparticles was evaluated in parallel with the MTT 
assay described above. For the assay, A549 cells (1.0 x 104 cells/well) and 
macrophage-differentiated THP-1 cells (0.35 x 106 cells/well) tested in the MTT 
assay for 24 h with the formulations used at the highest concentrations (i.e.1 mg/mL) 
were assessed. After the exposure time, aliquots (100 µL) of cell supernatants were 
placed into eppendorfs and centrifuged (16000 xg, 5 min). The supernatant (75 μL) 
obtained upon centrifugation was transferred to a new 96-well plate and processed 
using a commercial LDH kit (Takara Bio, Japan). The absorbance was measured by 
spectrophotometry (Infinite M200, Tecan, Austria) at a wavelength of 490 nm 
(background correction at 690 nm). Cells incubated with CCM only were considered 
the negative control; those treated with Triton X-100 (10%, v/v) were used as the 
positive control, the latter being assumed as 100% of LDH release. Thus, 
measurements were performed in triplicate and the percentage of released LDH 
was determined based on the following formula: 
 
Released LDH (%) = (Abs value / Abs T) x 100 (8) 
 
where Abs represents the absorbance obtained for the LDH release by the cells 
exposed to the test samples and Abs T is the absorbance obtained for cells treated 
with Triton X-100 (positive control).  
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4.7 Macrophage activation induced by microparticles 
 
In order to evaluate the capability of microparticles to activate macrophage-
like cells, differentiated THP-1 cells (0.35 x 106 cells/well) were incubated with dual 
drug-loaded microparticles, as well as with the polymers (commercial powders) at a 
concentration of 1 mg/mL. After a period of exposure of 24 h, cell-free supernatants 
were collected and cytokine content in the samples was measured using 
Quantikine® HS ELISA kits (R&D Systems, USA). TNF-α and IL-8 levels were 
quantified as the most relevant pro-inflammatory cytokines. The amount of each 
cytokine was expressed in pg/mL based on reference standard curves. The level of 
cytokines obtained from LPS- and CCM-treated cells was used as control. The 
absorbance of samples was determined at 450 nm in a microplate reader (Infinite 
M200; Tecan, Austria) and corrected for background absorbance at 540 nm. 
 
4.8 Preliminary evaluation of microparticle uptake by macrophages 
 
The uptake of the produced microcarriers by macrophage-like cells was 
evaluated by flow cytometry (FacScalibur cell analyser, BD Biosciences, Belgium), 
which required the exposure of cells to fluorescently-labelled particles (production 
detailed in section 4.2.3).  
The assay was performed using macrophage-differentiated THP-1 and rat 
alveolar macrophage (NR8383) cells. For the assay, phorbol-differentiated THP-1 
(0.35 x 106 cells/mL) and NR8383 (0.2 x 106 cells/mL) cells were seeded (5 mL/well) 
into 35 mm-Petri dishes containing 5 mL of the respective complete medium. Cells 
were incubated for 24 h to ensure the adhesion of 50 – 75% of the original 
population. Next, fluorescent microparticles (50 and 200 µg/cm2) were aerosolised 
onto the macrophage layer using a Dry Powder Insufflator™ (Model DP-4, Penn-
Century™, USA). Cells that were not submitted to the contact with fluorescent 
microparticles were considered as negative control. The phagocytic process 
occurred upon incubation for 2 h at 37 ºC and was stopped by the addition of a cold 
solution of PBS.3% FBS (5 mL, two applications). Then, cells were scraped, re-
suspended in 3 mL of PBS.3% and centrifuged (1500 rpm, 2 min, room temperature, 
centrifuge MPW-223e, MedInstruments, Poland). The centrifuged cells were 
washed with PBS.3% (5 mL) thrice and, finally, re-suspended in 1 mL buffer for flow 
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cytometric analysis (BD Biosciences FACSCalibur, Belgium). For this purpose, side 
scatters light was used to distinguish the viable cell population, whereas FSC-H and 
SSC-H channels were applied to measure size and granularity of cells, respectively. 
A total of 10000 events was counted within a gated region and the data were 
presented as mean fluorescence (FL) intensity. The number of cells associated with 
fluorescence was considered the definition for uptake. The assay was replicated at 
least three times for each dose. 
 
4.9 In vitro antibacterial activity  
 
4.9.1 Culture of mycobacteria 
 
The therapeutic efficacy of microparticles was evaluated in vitro against 
Mycobacterium bovis BCG (DSMZ 43990). This was provided, as a gift, by Centro 
de Estudos de Doenças Crónicas da Faculdade de Ciências Médicas da 
Universidade Nova de Lisboa (CEDOC/FCM-UNL). The stocks of mycobacteria 
were preserved and stored in -80ºC ultra-low temperature freezers (U725 Innova 
New Brunswick Scientific, USA). Mycobacteria were cultivated in M7H9 broth, 
supplemented with 10% (v/v) OADC and 0.05% (v/v) of Tween® 80. Mycobacteria 
were handled inside a laminar flow hood (Bio48 Faster, Italy), respecting the 
guidance and safety requirements to prevent contamination. That includes 
autoclave sterilisation (Uniclave88, Portugal) of infectious materials.  
 
4.9.2 Determination of minimum inhibitory concentration (MIC) 
 
The lowest concentration of free antibiotics required to inhibit mycobacteria 
growth was determined by the MTT assay (289). Firstly, stock solutions of INH (1 
mg/mL) and RFB (1 mg/mL) were prepared by dissolving the drugs in the M7H9 
supplemented medium. It is important to mention that RFB was previously 
solubilised in ethanol and only thereafter diluted with M7H9 broth. Stock solutions 
were filtered (0.22 μm sterile syringe filter) and mixed at concentrations proportional 
to the drug mass ratio contained in the microparticles. The microparticle 
formulations undergoing this assay were those containing the combination of drugs 
(FUC/INH/RFB and CS/INH/RFB = 10/1/0.5, w/w). Therefore, drug solutions were 
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mixed respecting these ratios. The susceptibility of M. bovis strain was then 
evaluated by incubating mycobacteria with a drug solution combining INH-RFB, 
followed by serial dilutions.  
Similarly, the growth inhibition of mycobacteria promoted by the produced 
dual drug-loaded microparticles was also assessed. Dry powder was dissolved with 
broth (1 mg/mL) and then diluted, based on the calculations to meet the desired 
drug concentrations. Generally, 96-well flat-bottom microplates (Orange Scientific, 
Belgium) were filled with test samples, according to the scheme displayed in Figure 
4.2. Three bacterial suspensions were prepared, and the assays were conducted 
after achieving an optical density value (ODnm) of approximately 0.2, measured by 
spectrophotometry (600 nm, Infinite M200, Tecan, Austria). For the experiment, 
solutions (180 µL) of free drugs or microparticles were added into the wells (column 
4), making continuously serial two-fold dilutions with M7H9 supplemented broth 
(columns 5 – 11). Next, 20 µL of bacterial suspension were added into the respective 
well, completing the final volume of 200 μL per well. Wells (column 2) filled with only 
M7H9 supplemented medium (200 µL) were used as negative controls. Similarly, 
bacterial suspensions (20 µL) were introduced in wells (column 3) containing M7H9 
medium (180 µL) in the absence of free drugs/microparticles, which were assumed 
as positive controls. Bacterial growth of each suspension 1, 2 and 3 was evaluated 
in B-C, D-E, and F-G rows, respectively. Assays were performed in triplicate. 
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Figure 4.2. Scheme of the 96-well microplate showing columns 4-11 filled with 
solutions of free drugs or microparticles serially diluted with M7H9 broth, containing 
mycobacteria in triplicate: lines B-C (suspension 1), lines D-E (suspension 2) and 
lines F-G (suspension 3). Contents of column 2 (only M7H9 medium) and column 3 
(bacterial suspensions in broth) were considered negative and positive control, 
respectively.  
 
The outside lane of wells (a frame-like) was filled with sterile distilled water to 
avoid the evaporation of microplate content. The plates were covered with the lid, 
sealed with parafilm, and incubated at 37 °C (Binder, USA) for 7 days. After the 
incubation time, 30 μL of MTT sterile solution were added to each well, followed by 
1 h of incubation at 37 °C. Then, 50 μL of DMSO were added into the wells, resulting 
in a colour change from yellow to dark gold, proportional to the growth rate of 
mycobacteria. The absorbance was measured by spectrophotometry (Infinite M200, 
Tecan, Austria) at 540 nm. 
 
4.10 Preliminary in vivo studies  
 
Male BALB/c mice were obtained from the Gulbenkian Institute of Science 
(Oeiras, Portugal). The animals were maintained under standard pathogen-free 
conditions and were fed commercial chow and given free access to acidified drinking 
water. The experimental procedures were approved by the local ethical committees 
of the Faculty of Pharmacy and of the Institute of Molecular Medicine in accordance 
with the European Union Directive (201/637EU) and Portuguese laws (DR 
113/2013, 2880/2015 and 260/2016.  
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Animals (aged 6 – 8 weeks) weighing 18 – 31 g received unloaded FUC or 
CS microparticles via pulmonary administration, using the method described by 
Gaspar et. al. (290). Briefly, the dry powder was administered by using a simple 
apparatus based on a 15-mL conical centrifuge tube in which the dry powder was 
inserted. A small hole was made at the bottom of the tube allowing the powder 
delivery to the mouse. A manual pump connected to the upper part of the tube 
allowed the production of a turbulent air stream for fluidising the powder. Each 
mouse was restrained in a 50-mL conical tube which had a small hole made at the 
bottom. The lower part of the tube was connected to the 15-mL tube through a baby 
bottle teat. Dry powder (60 mg) were inserted in the device and each mouse (four 
mice per group) received unloaded microparticles by inhalation upon 2 min, once a 
day, for two weeks. A control group of mice received no treatment.  
On the first day of treatment, before powder inhalation, blood samples (100 
– 200 µL) were collected from the tail vein into tubes with no anticoagulant. 
Following centrifugation, serum aliquots (30 – 50 µL) were prepared and stored at -
30 °C. After 2-weeks of treatment, mice were anaesthetised with isoflurane, samples 
of blood were collected from the retinal blood vessels and a few drops of peripheral 
blood were used to prepare blood smears (three slides per mouse). Moreover, the 
remaining blood samples were then centrifuged to separate the serum, which were 
stored at -30°C for further analysis to detect serum immunoglobulin E (IgE). 
 
4.10.1 Eosinophil count on blood smears 
 
Slides with blood smears were stained by Wright–Giemsa staining method 
(291). A total of 100 leucocytes were counted in each blood smear with the use of 
a light microscope (Microscope TR 500, VWR International, Belgium). Twelve slides 
(blood smears) were included in the count, considering three slides per mouse in 
each of the group (n=4).  
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4.10.2 Ouchterlony double immunodiffusion to detect serum immunoglobulin 
E (IgE). 
 
Ouchterlony double immunodiffusion technique was performed to determine 
if IgE was present in sera from mice treated with unloaded FUC and CS 
microparticles (292). To obtain positive control samples, C57BL/6J mice (Charles 
River, France) were sensitised to OVA (0.1 mg/mL in PBS). The intraperitoneal 
injection of OVA (200 µL) was performed twice with an interval of 2 weeks between 
administrations. Polyclonal IgE antiserum (Nordic Immunology, Netherlands) was 
used as the primary antisera to detect IgE in the serum samples. The antisera was 
diluted (1:2) with Tris-base (Nzytech, Portugal). A pool of mouse serum (8 µL) was 
prepared by combining the sera collected from the OVA-sensitised animals. 
Likewise, equal volumes of serum collected from the treated mice of each group 
were combined to prepare a pool (8 µL).  
For the Ouchterlony assay, agar gel/phosphate saline buffer 1.5% (w/v) was 
poured to a depth of 3 mm onto glass slides (25 x 75 mm) that were coated with 
dried 1% (w/v) agar gel/water. Wells were made using a template and gel punch; 
the agar plugs were removed from wells using  a water vacuum pump. The assay 
format consisted of a central well surrounded by three equidistant wells.  
The antisera solution (8 µL) was placed in the central well and the peripheral 
wells were filled with the pools of treated mouse sera and the positive control (8 µL). 
Slides were set on a horizontal surface and incubated in a moist chamber at 4°C for 
two days. Afterwards, they were washed with PBS buffer several times and stained 
with Coomassie Brilliant Blue G 250 (Serva, Germany). The slides were destained 
in 10% methanol (v/v) / 10% acetic acid (v/v) for 5 min and then washed with distilled 
water. Results were scored based on the observation of a visible line of precipitation.  
 
4.11 Statistical analysis 
 
Statistical significance was determined with student t-test and one-way 
analysis of variance (ANOVA) with the pairwise multiple comparison procedures 
(Holm-Sidak method), which were performed to compare two or multiple groups. 
Analysis was run using the Sigmaplot software (version 12.5, Systat Software Inc., 
UK). and differences were considered significant at a p-value of less than 0.05. 
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5. Fucoidan microparticles: Results and discussion 
 
5.1 Preparation and characterisation of fucoidan microparticles 
 
The rationale of selecting FUC as matrix material of inhalable microparticles, 
aimed at tuberculosis therapy, relies on its chemical composition, which includes 
moieties that enable macrophage targeting. For this reason, FUC-based 
microparticles reported herein were produced with a higher amount of polymer, 
comparing with drugs, to provide the means for polymer interaction with 
macrophages, and therefore to favour microparticle uptake (36). Moreover, drug 
concentrations were selected to produce microparticles that, when used in in vivo 
studies, permit a reduction of the dose administered by inhalation in comparison 
with oral delivery.  
FUC microparticles associating each drug separately were successfully 
obtained by spray-drying and were recovered with yields of 74% – 78% (Table 5.1). 
As well, spray-dried FUC microparticles loaded with a combination of the two first-
line anti-TB drugs (INH and RFB) were produced with high yield (81%) indicating 
the effectiveness of the technique. The use of the high-performance cyclone instead 
of the conventional cyclone separator certainly contributed to the high yields, an 
effect that was previously reported (72) and further observed in other works of our 
research group (293).  
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Table 5.1. Spray-drying yield, drug association efficiency, loading capacity, Feret´s diameter, median volume particle size (Dv50) and 
density values of fucoidan (FUC)-based microparticles (mean ± SD, n = 3). INH: isoniazid; Man: mannitol; RFB: rifabutin. 
Microparticles 
Production 
yield (%) 
Association 
efficiency (%) 
Loading 
capacity (%) 
Feret´s 
diameter (µm) 
Dv50 (µm) Span 
Density (g/cm3) 
Real Bulk Tap 
Unloaded FUC 85 ± 1 – – 1.62 ± 0.80 –  1.78 ± 0.01 0.45 ± 0.06 0.77 ± 0.19 
Unloaded FUC-Man 79 ± 1 – – 1.60 ± 0.93 –  1.66 ± 0.01 0.26 ± 0.04 0.51 ± 0.07 
FUC-Man/INH (10/1) 74 ± 6 95 ± 1 8.6 ± 0.4 1.90 ± 0.98 3.97 ± 0.11 1.76 ± 0.05 1.51 ± 0.01 0.22 ± 0.02 0.43 ± 0.04 
FUC/RFB (10/0.5) 78 ± 5 81 ± 3 3.9 ± 0.3 1.40 ± 0.70 2.51 ± 0.02 1.99 ± 0.05 1.77 ± 0.01 0.17 ± 0.01 0.33 ± 0.02 
FUC/INH/RFB 
(10/1/0.5) 
81 ± 2 
97 ± 4 (INH) 
95 ± 4 (RFB) 
8.5 ± 0.4 (INH) 
4.1 ± 0.2 (RFB) 
1.43 ± 0.75 2.77 ± 0.03 2.91 ± 0.07 1.74 ± 0.01 0.17 ± 0.01 0.35 ± 0.02 
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Considering the carriers loaded with one antibiotic, drug association 
efficiencies were 81% for RFB and 95% for INH, resulting in loading capacities of 
3.9% (RFB) and 8.6% (INH) (Table 5.1), values close to the theoretical drug 
loadings (9.1% for INH and 4.8% for RFB). When combined in the same formulation 
(FUC/INH/RFB MP), drugs were also efficiently associated to microparticles, with 
INH registering 97% and RFB 95% of association efficiency. In this case, loading 
capacities reached 8.5% (INH) and 4.1% (RFB), again close to the theoretical 
values. In all formulations, the selected theoretical drug loadings are similar to those 
reported in other works (294). The fact that both drugs were associated with similar 
efficiencies demonstrates that the process was independent of their aqueous 
solubility (125 mg/mL for INH and 0.19 mg/mL for RFB) (135,295). In general, the 
obtained values of drug association are considered high, which is tipical of spray-
dried microparticles, as the method is frequently reported to lead to high association 
of drugs (296). Furthermore, the approach of associating anti-TB drugs in a single 
formulation meets the recommendations of the WHO regarding the need to establish 
a combined therapy for TB (261). It is worth mentioning that INH is present in a 
higher amount than RFB, because the latter is a more potent drug (297), and also 
has a more toxic profile, as will be demonstrated later on in Section 5.7 (Chapter 5).  
In general, particles presented a spherical or approximately spherical shape, 
although with distinct surface features. The morphological analysis performed with 
electronic microscopy revealed that the unloaded microparticles exhibited a slightly 
convoluted shape but smooth surface (Figure 5.1a). However, the incorporation of 
drugs in the microparticles produced important modifications on their morphology, 
which became more irregular and acquired corrugated surfaces (Figure 5.1b,c), 
particularly the two formulations containing RFB. This morphology is possibly the 
result of uneven shrinkage forces occurring during the drying of droplets, depending 
on the feed composition and process conditions (95). In these cases, the presence 
of RFB may have contributed to the morphological alterations perceived on the 
produced microparticles, as the observed surface irregularities have been reported 
for other spray-dried microparticles loaded with this drug (239). The irregular surface 
can also be thought as a result of the drying process, in which the removal of ethanol 
from the microparticles’ surface occurs faster than water evaporation. The higher 
volatility of ethanol induces the formation of a primary shell that collapses as the 
water content in the core evaporates (298). 
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Figure 5.1. Scanning electron microphotographs of fucoidan (FUC)-based 
microparticles: (a) unloaded FUC microparticles, (b) FUC/RFB = 10/0.5 (w/w) 
microparticles; (c) FUC/INH/RFB = 10/1/0.5 (w/w) microparticles; (d) unloaded FUC-
Man microparticles; (e) FUC-Man/INH = 10/1 (w/w) microparticles. INH: isoniazid, 
Man: mannitol, RFB: rifabutin. 
 
As previously mentioned in the methodology, Man (0.5%, w/v) was 
incorporated in the formulation associating only INH, as producing microparticles 
only with FUC and INH, led to large aggregates clearly observed in the collecting 
Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy 
81 
 
vessel. Their formation could not be avoided by simple optimisation of spray-drying 
parameters. The incorporation of Man produced significant and visible changes in 
microparticle morphology. As depicted in Figure 5.1d, Man has apparently deposited 
over microparticles surfaces as crystals of different forms (acicular, hexagonal, etc.), 
which is also observed in Figure 5.1e, depicting FUC-Man microparticle further 
associating INH. The formation of the referred crystals is possibly related to the 
outlet temperature of the spray-drying process, as the appearance of small crystals 
is favoured by the rapid drying of the droplets due to high temperatures (299). 
Further associating INH did not induce morphological alterations comparing with 
FUC-Man microparticle (Figure 5.1d). 
Drug-loaded microparticles were found to have Feret’s diameter ranging from 
1.40 to 1.90 µm, as displayed in Table 5.1. No significant differences in microparticle 
size were noticed after drug incorporation (around 1.6 µm for unloaded FUC 
microparticles), which was expected considering the relatively low theoretical 
loading. Additionally, the particle size distribution of drug-loaded formulations was 
further measured as volume diameter by laser light scattering and showed median 
diameters (Dv50) varying between 2.51 and 3.97 µm (Table 5.1). In addition, span 
values ranged from 1.8 to 2.9 µm. The particle size distribution reflects the 
productive efficiency of spray-drying to provide dry powders with favourable 
aerodynamic properties for inhalation purposes (300). In this sense, the obtained 
results indicate that the produced microparticles present a suitable size for 
pulmonary deposition (301). To the best of our knowledge, no study to date has 
reported the production of inhalable microparticles based only on FUC with potential 
application in pulmonary TB therapy. Moreover, this is the first study describing the 
use of spray-drying to produce respirable FUC-based microparticles loaded with one 
or two first-line anti-TB drugs.  
Real, bulk and tap densities were determined (Table 5.1), considering that 
the density of particles is an important factor for successful application in inhalation 
because it strongly influences the sedimentation and dispersion properties of 
inhalable dry powders (66). Real densities of spray-dried powders ranged from 1.51 
to 1.78 g/cm3, high values that could suggest that particles have a matrix dense 
core. Because of the method of determination, bulk densities had decreased values, 
varying between 0.17 and 0.45 g/cm3, while tap densities were in the range of 0.33 
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– 0.77 g/cm3. These results are similar to others reported for spray-dried 
microparticles (302,303). In this case, the dry powders with the lowest apparent 
particle density are those containing RFB. Generally, low tap density powders are 
considered good for dispersibility, which may be the result of the airiness produced 
by the irregular and wrinkled surfaces (304), such as observed for both FUC/RFB 
and FUC/INH/RFB formulations. It is important to stress that, from an eye 
observation, the presence of RFB seemed to improve microparticle dispersibility, as 
verified in other studies with polymeric microparticles (135). In fact, experimental 
determination of aerosolisation properties has been performed to reinforce this 
observation, as is discussed later on.  
 
5.1.1 Dry powder analysis using Powder X-Ray Diffraction (PXRD) 
 
The produced dry powders were analysed by X-Ray diffraction in order to 
qualitatively determine the phases present in the samples.  Figure 5.2 presents the 
corresponding diffractograms. The presence of sharp peaks of free INH 
demonstrate its crystalline nature, which is slightly altered after its association with 
the microparticles (Figure 5.2b). This indicates a phase transition resulting from a 
new arrangement of atoms, that can lead to the appearance or disappearance of 
new diffraction peaks, according to the symmetry of the new phase (305). Spray-
drying had much stronger impact on the structure of RFB, since the drug apparently 
acquires an amorphous form after undergoing the process. Another explanation for 
such modification would be the formation of small RFB crystals during spray-drying 
in such a way that prevents their detection by the XRD equipment (Figure 5.2c). 
Nevertheless, the technique is in fact reported to modify the crystalline form of both 
drugs (306,307). This may have implications on physicochemical properties such as 
solubility, release profile, stability, and therapeutic efficacy of drugs (308). Indeed, 
amorphous state increases the aqueous solubility, which reflects on drug release 
profile, as will be further discussed in this chapter. Nonetheless, such modifications 
had no impact on drug antibacterial activity, as it will be demonstrated in section 5.7. 
Long-term stability is a matter of concern though, since amorphous materials are 
inherently unstable and tend to recrystallise upon storage (309). 
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As aforementioned, the incorporation of Man in microparticles apparently 
resulted in a deposition of crystals of different forms (acicular, hexagonal, etc.) over 
the surfaces of FUC-Man (unloaded) and FUC-Man microparticles associating INH. 
In both cases the formation of a crystalline phase was observed by XRD (Figure 
5.2a). Data suggest the existence of different polymorphs of Man in the two 
samples, although further structural testing is needed to confirm these observations. 
Fucoidan diffractogram shows that there are no reflection peaks, indicating 
that the polymer is amorphous in nature, displaying similar diffraction patterns after 
being spray-dried to produce the microparticles (Figure 5.2a). The diffractograms of 
drug-loaded FUC microparticles evidenced the absence of drug crystalline peaks, 
which indicates amorphisation or reduction of drug crystallite size (310). Drug 
amorphisation is also an evidence of the drug-polymer interaction, demonstrating 
successful incorporation into the polymeric matrix.  
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Figure 5.2. Diffractograms of (a) fucoidan (FUC) polymer, unloaded and drug-loaded 
FUC microparticles; (b) free isoniazid (INH) before and after spray-drying, (c) free 
rifabutin (RFB), before and after spray-drying. 
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5.2 Evaluation of aerodynamic properties 
 
The design of inhalable microparticles requires adequate flowability to 
promote lung deposition. In light of this, the in vitro aerosol performance was 
assessed in the ACI by using an RS01 dry powder inhaler. The obtained data are 
presented in Table 5.2. 
 
Table 5.2. Aerodynamic properties of fucoidan (FUC) microparticles loaded with 
isoniazid (INH) and/or rifabutin (RFB). Loaded amount of powder in the capsule was 
30 mg, corresponding to approximately 2.6 mg of INH and 1.4 mg of RFB, according 
to the drug content found in each formulation (n = 3, mean ± SD). FPD: fine particle 
dose; FPF: fine particle fraction; Man: mannitol; MMAD: mass median aerodynamic 
diameter. 
Microparticles 
(Polymer/drug ratio, w/w) 
Metered 
dose (mg) 
Emitted 
dose (mg) 
MMAD 
(µm) 
FPD <5 µm 
(mg) 
FPF <5µm 
(%) 
FUC-Man/INH (10/1)  2.02 ± 0.06 1.98 ± 0.05 3.78 ± 0.14 0.78 ± 0.01 39.1 ± 1.1 
FUC/RFB (10/0.5)  1.15 ± 0.01 0.97 ± 0.01 1.99 ± 0.01 0.53 ± 0.01 55.0 ± 0.1 
FUC/INH/RFB 
(10/1/0.5) 
INH 1.91 ± 0.26 1.64 ± 0.23 3.90 ± 0.01 0.82 ± 0.02 50.2 ± 2.4 
RFB 1.29 ± 0.03 1.10 ± 0.02 3.64 ± 0.32 0.53 ± 0.01 45.4 ± 1.4 
 
Regarding the formulations that associate only one antibiotic, the results 
demonstrated that 98% of the loaded INH and 84% of RFB were emitted from the 
device, indicating the suitability of FUC to be used as a matrix material in spray-
dried inhalable microparticles. The better flowability of FUC-Man/INH microparticles 
may be related to the incorporation of Man in the formulation. Man is a non-
hygroscopic sugar (311) and the visible deposition of crystals on the surface 
conferred roughness, thus avoiding microparticle aggregation. Similarly, the 
irregular surfaces observed in FUC/RFB microparticles have possibly contributed to 
the good dispersibility and flow properties of the formulation, as surface irregularities 
can reduce the contact between microparticles, thus decreasing agglomeration (78).  
With respect to the formulation containing both INH and RFB, the results 
demonstrated that more than 85% of the drugs were emitted from the device, also 
indicating good dispersibility of the produced dry powder. In the sequence of the 
previous comments, the adequate flowability is possibly a result of the wrinkled 
surfaces observed in the produced microparticles. Surface irregularities are 
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expected to reduce the interparticulate cohesive forces that lead to agglomeration, 
enhancing powder dispersibility, as well as improving the respirable fraction of the 
formulation (78,298). This aspect is crucial when a lactose carrier (or other) is not 
included in the formulation, and spray-dried microparticles are aerosolised alone 
(312). As depicted in Table 5.2, the produced powders showed FPF (≤5 µm) ranging 
within 39–55%, which represents the fraction of microparticles with potential ability 
to reach the respiratory zone. Overall, the results are in agreement with the in vitro 
respirability usually exhibited by dry powder inhaler formulations (301). Additionally, 
the use of the RS01 device may have contributed to the maximisation of the 
performance, as it is described that the spinning capsule rotation provided by this 
inhaler is more efficient in powder disaggregation compared with other capsule 
motion profiles (313,314). 
Figure 5.3 illustrates the stage-by-stage deposition profiles of INH and RFB 
in the ACI after aerosolisation of different microparticle formulations. The drug 
recovery varied between 82 and 99%, being in accordance with the values 
established by the European Pharmacopeia (75). Observing the distribution, it is 
visible that FUC-Man/INH microparticles deposited more in the upper part stages, 
while FUC/RFB microparticles were able to deposit on stages 3–4 (Figure 5.3a), 
which collect particles <3.2 µm, potentially capable to reach the deep zones of the 
lung. According to drug mass deposition on ACI stages, the MMAD of drug particles 
was estimated as 3.78 µm and 1.99 µm for FUC-Man/INH and FUC/RFB, 
respectively, which certainly justifies the previous observation.  
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Figure 5.3. In vitro aerodynamic deposition of antitubercular drugs (isoniazid – INH 
and rifabutin – RFB) in the Andersen cascade impactor. Drugs associated with 
fucoidan (FUC) microparticles (MP) either individually (a) or together in a single 
formulation (b). Values are mean ± SD, n = 3. Cps: capsule; Dev: inhaler device; IP: 
induction port; F: filter; Man: mannitol; St: stage. 
 
Differently, the dry powder associating simultaneously the two antibiotics, 
displayed uniformly drug deposition (Figure 5.3b). The similarity between the 
profiles of both drugs demonstrates that INH and RFB were equally co-deposited 
on the several stages, thus supporting the decision of developing a delivery system 
with a combination of the two drugs. Furthermore, this indicates that the drugs have 
even distribution within the microparticles. For this formulation, drug mass 
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deposition on ACI stages resulted in MMAD values of 3.6 – 3.9 µm, also suggesting 
a suitable size for deep lung deposition. In fact, particles with an aerodynamic 
diameter within the range of 1–5 µm display a greater tendency for reaching the 
respiratory zone and, if with extrafine size (<2 µm), they have more peripheral 
deposition within the area (315).  
In summary, the produced FUC-based microparticles were demonstrated to 
have adequate aerodynamic characteristics for the pulmonary delivery of anti-TB 
drugs with great propensity to reach the respiratory zone, possibly with better 
respirability being expected for microparticles associating RFB as single drug. 
Additionally, the developed microparticles also displayed particle sizes in the range 
expected to potentiate phagocytosis by alveolar macrophages (1–6 µm), the target 
cells (104). 
 
5.3 In vitro drug release profiles 
 
The in vitro release of drugs was evaluated in PBS (pH 7.4) with the addition 
of 1% (v/v) Tween® 80, resembling the lung lining fluid in terms of pH and the 
presence of surfactant (316,317). The latter also enables the dissolution of RFB, 
which is sparingly soluble in aqueous media. Considering that alveolar 
macrophages are the target cells in this study, drug release studies were also 
conducted in citrate buffer (pH 5), simulating the phagolysosomal environment 
(318). The obtained results are shown in Figure 5.4. 
Figure 5.4a comprises the release profile of INH and RFB from formulations 
containing each drug separately (thin lines). The dissolution profiles of free drugs 
are also presented (dashed lines). As can be observed, at pH 7.4, the release of 
INH and RFB from microparticles was very rapid, drugs being completely released 
after 15 min (Figure 5.4a). The rapid release of INH was expected, owing to the high 
solubility of the drug. However, the release of RFB followed a similar pattern at all 
time points and no significant differences were perceived comparing the release 
profiles of the two antibiotics. Assuming that macrophage uptake will occur in the 
sequence of the application of these microparticles, drug release studies were also 
conducted in citrate buffer (pH 5), simulating the phagolysosomal environment, as 
referred above. As depicted in Figure 5.4b, drugs were released in similar fast 
Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy 
89 
 
manner and no significant differences were observed between the two media, 
indicating that the release of drugs was not influenced by pH, in this case. 
Likewise, the two drugs were rapidly released from the microparticles 
associating INH and RFB simultaneously. In this case, INH is completely available 
after 10 min, disregard the pH of the release medium (Figure 5.4c,d). At pH 5, RFB 
released precisely at the same rate as INH (Figure 5.4d). In turn, at pH 7.4, the 
release was a little bit slower, although not to a statistically significant level (Figure 
5.4c). At pH 7.4, approximately 75% of the RFB was released within 10 min, and 
100% was released within 30 min (Figure 5.4c). The faster release in acidic medium 
is possibly a consequence of a certain protonation of the drug, which increases its 
solubility. However, no significant difference was perceived at any time point, 
demonstrating once more that the release of the two drugs from the formulation was 
not significantly influenced by pH. 
Importantly, the release of drugs from the produced microparticles did not 
show significant differences from the respective drug dissolution profiles (Figure 
5.4a-d). It should be noticed that the spray-drying process modifies the crystalline 
form of both drugs, especially RFB, as reported in the literature (306,307) and was 
also verified in the present study (section 5.1.1). As a result, the aqueous solubility 
of drugs is increased due to the conversion into amorphous form or alterations in 
the regular ordered arrangement (319).  
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Figure 5.4. Drug dissolution and in vitro release profiles of isoniazid (INH) from FUC-
Man/INH (10/1, w/w) microparticles and of rifabutin (RFB) from FUC/RFB 
microparticles (10/0.5, w/w), in (a) PBS pH 7.4-Tween® 80 and (b) citrate buffer pH 5.0-
Tween® 80, at 37 °C. Drug dissolution and in vitro release profile of INH and RFB from 
FUC/INH/RFB (10/1/0.5, w/w) microparticles in (c) PBS pH 7.4-Tween® 80 and (d) 
citrate buffer pH 5.0-Tween® 80, at 37 °C. FUC: fucoidan; Man: mannitol; mean ± SD, 
n ≥ 3. 
 
These results are in agreement with other studies reporting rapid release 
profiles of INH and RFB from spray-dried polysaccharide microparticles (135,306). 
The rapid release could be explained by two main factors: the surface irregularities, 
which increase the contact with the medium, and the high solubility of the polymeric 
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matrix. FUC is very soluble in the media, thus easily releasing the drugs. However, 
it is worth mentioning that the observations of this study do not precisely predict in 
vivo occurrences, considering that a lower amount of liquid is present in the alveoli 
compared with that involved in the assays. It is well known that the alveolar 
epithelium is covered by a thin layer (0.01–0.1 µm) of lung lining fluid, and thus 
microparticles are expected to be only partially in contact with this fluid, and not 
immersed in it (320,321). Consequently, in vivo drug release will probably occur 
more slowly, allowing microparticle internalisation by macrophage cells before 
particle dissolution and complete drug release. 
 
5.4 In vitro biocompatibility studies 
 
5.4.1 Assessment of metabolic activity by MTT test 
 
The metabolic assay MTT was performed to evaluate the effect of the 
produced microparticles on cell viability, upon 3 h and 24 h exposure. Considering 
the environment underlying tuberculosis pathogenesis, alveolar epithelial cells 
(A549) and macrophage-differentiated THP-1 cells were used. For the purpose of 
this discussion, it was considered that a material has cytotoxic potential when it 
reduces the cell viability below 70%, as designated by ISO 10993-5 (322).  
Figure 5.5 shows the results obtained for A549 cells. Overall, cell viability 
remained over 75%, except upon exposure to RFB as a free drug, at the highest 
tested concentration (0.05 mg/mL). In this case only, time- and concentration-
dependent effects were observed (p < 0.05) for RFB, decreasing cell viability below 
70%. For this drug, exposure to 0.05 mg/mL induced 69% cell viability at 3 h and 
49% at 24 h (Figure 5.5d). However, the microencapsulation of RFB seemed to 
reverse this behaviour, eliciting cell viabilities between 74 and 97% (Figure 5.5a,b) 
for RFB-loaded microparticles (single drug formulations); and 76% – 98% for 
microparticles combining the two drugs (FUC/INH/RFB formulations). This indicates 
that microencapsulation had a beneficial impact on drug toxicity, providing its 
decrease, particularly at the highest tested concentration at both time points (p < 
0.05). 
In the same way, the microencapsulation of INH seemed to have favoured 
cell tolerance to INH after 24 h exposure to all tested concentrations. Although the 
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free drug did not present any cytotoxicity (Figure 5.5c), the viability of A549 cells 
exposed to INH-loaded microparticles (single drug formulation) (Figure 5.5a,b) was 
higher than that observed for cells treated with free INH (p < 0.05). This apparent 
cytoprotective effect of microparticles was, however, not observed at 3 h. The 
formulation combining the two antibiotics showed no significant differences in 
comparison with free INH in terms of cell viabilities, considering all conditions. 
It is important to notice that the produced drug-loaded FUC microparticles 
showed different effects on the viability of A549 cells. For instance, upon 24 h 
exposure, microparticles loaded with INH only, had significantly less impact on cell 
viability than microparticles containing RFB, either alone or in combination (p < 
0.05), considering all tested doses. The stronger effect of RFB-containing 
formulations is attributed to the presence of the proper drug, which is a potent 
antibiotic (297) and may be cytotoxic, depending on the dose, as is further discussed 
in this section.  
.
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Figure 5.5. A549 cell viabilities upon (a) 3 h and (b) 24 h of exposure to fucoidan (FUC) polymer, unloaded and drug-loaded FUC 
microparticles; (c) exposure to INH as a free drug; and (d) exposure to RFB as a free drug. Cell viability was calculated as a percentage 
of positive control (untreated cells). Data represent mean ± SEM (n = 3, six replicates per experiment at each concentration). Dashed 
line indicates 70% cell viability. INH: isoniazid; Man: mannitol; MP: microparticles; RFB: rifabutin.
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Taking into consideration that FUC is herein proposed as the matrix of spray-
dried microparticles, the raw material (commercial powder) and unloaded 
microparticles were also evaluated to disclose any effect of the carrier itself. Overall, 
no cytotoxicity was observed, with cell viabilities remaining over 80% in all 
conditions (Figure 5.5a,b). Nevertheless, the literature reports opposite effects, 
describing FUC as an inhibitor of cell viability (A549 cells) in time- and dose-
dependent manner (323,324). These differences are possibly explained by varied 
FUC composition, as this is highly dependent on the source of the polymer (161). 
As such, other carrier systems based on FUC, developed for pulmonary delivery of 
antibiotics, have exhibited no toxic effect on A549 cells (120), as observed in the 
present study. Additionally, although FUC has been shown to reduce A549 cell 
viability due to its antitumor activity, the pharmacological effect of FUC varies with 
its molecular weight (325). In this work, the absence of cytotoxicity of FUC was also 
evidenced in its microparticulate form.  
Figure 5.6 exhibits the results obtained for macrophage-differentiated THP-1 
cells. These cells responded in a relatively similar manner comparing with A549 
cells, although perhaps with higher sensitivity. In fact, RFB showed again cytotoxic 
effect as a free drug, but in this case, this was observed at the concentrations of 
0.025 and 0.05 mg/mL, and at both time-points (Figure 5.6d). At 24 h, 57% and 49% 
cell viability were registered, respectively. This indicates higher susceptibility of 
macrophage-like THP-1 cells when compared to A549 cells, differing from reports 
that demonstrate higher resistance of differentiated THP-1 cells (293,326). RFB-
loaded microparticles (FUC/RFB MP) slightly decreased cell viabilities below 70% 
in all conditions, considering both time-points, except at the lowest concentration 
(0.1 mg/mL). Moreover, both concentration- and time-dependent effects were 
observed for this formulation, although with stronger contribution from the former (p 
< 0.05). Similarly, macrophage-differentiated THP-1 cells were slightly sensitive to 
the contact with microparticles of FUC/INH/RFB (10/1/0.5) after long-time exposure. 
In fact, at 24 h, cell viability decreased to 65% upon exposure to the highest dose 
of microparticles (1.0 mg/mL) (Figure 5.6a,b). Comparatively, A549 cells have 
shown 76% viability in the same conditions (p < 0.05). Concerning macrophage-like 
THP-1 cells, no significant time-dependent or dose-dependent effects were 
observed for FUC/INH/RFB = 10/1/0.5 (w,w) microparticles. 
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Figure 5.6. Macrophage-differentiated THP-1 cell viabilities upon (a) 3 h and (b) 24 h of exposure to fucoidan (FUC) polymer, unloaded 
and drug-loaded FUC microparticles; (c) exposure to INH as a free drug; and (d) exposure to RFB as a free drug. Cell viability was 
calculated as a percentage of positive control (untreated cells). Data represent mean ± SEM (n = 3, six replicates per experiment at each 
concentration). Dashed line indicates 70% cell viability. INH: isoniazid; Man: mannitol; MP: microparticles; RFB: rifabutin.
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The mild toxicity observed in THP-1 cells is clearly due to the RFB content, a 
drug that has already showed toxicity in vivo (327,328). In order to further confirm 
this, microparticles loaded with RFB, either alone or in combination, were produced 
with lower amounts of RFB to be purposely tested regarding cytotoxicity. These 
formulations are referred to as FUC/RFB (10/0.2) and FUC/INH/RFB (10/1/0.2) 
microparticles. No cytotoxicity was registered for these particles (Figure 5.6a,b), 
demonstrating that the decrease in RFB content resulted in the viability of 
differentiated THP-1 cells over 75% in all conditions. This observation confirms that 
the cytotoxic effect is due to RFB content. As well, the referred formulations showed 
no cytotoxicity on A549 cells. 
Despite THP-1 sensitivity, no cytotoxic effect was observed upon exposure 
to free INH (cell viability of 76% – 99%) and INH-loaded microparticles (cell viability 
of 73% – 98%), reinforcing the general absence of toxicity of INH in this assay 
(Figure 5.6c). In addition, unloaded FUC microparticles and the polymer itself 
(commercial powder) were also tested as control in this cell line (Figure 5.6a,b), 
resulting in cell viability above 76% in all cases, thus evidencing the absence of 
detrimental effects of the polysaccharide under the tested conditions. 
Overall, it can be considered that both A549 and macrophage-differentiated 
THP-1 cells tolerated well the exposure to FUC-based microparticles. A mild 
cytotoxic effect was registered in macrophage-like THP-1 cells when exposed to 
microparticles containing RFB, either alone or in combination, especially at the 
highest tested concentration (1.0 mg/mL), with the toxicity being attributed to the 
RFB content. However, it should be highlighted that the highest tested dose is much 
higher than the one that is expected to occur in vivo, as after the delivery, the dry 
powder will be distributed through a large surface. Therefore, the effects will 
probably be more similar to those of the lower dose (0.1 mg/mL) than to those of the 
highest dose or even that of 0.5 mg/mL. Unfortunately, it was not possible to find 
the ways that permitted weighing such a low amount of dry powder that could better 
resemble the in vivo conditions. 
 
5.4.2 Evaluation of cell membrane integrity 
 
As a complement to the MTT assay, the amount of the cytoplasmic enzyme 
LDH released upon 24 h exposure to the highest concentrations of raw material, 
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microparticles, and free drugs was also determined. The results are displayed in 
Figure 5.7. The incubation with CCM only was considered the condition inducing the 
release of a standard amount of LDH and was, thus, used for comparisons.  
The results essentially confirmed those of MTT, with free RFB having a more 
intense effect on the release of LDH. The incubation with CCM induced 21% of LDH 
release in A549 cells (Figure 5.7a) and 34% in macrophage-differentiated THP-1 
cells (Figure 5.7b). The exposure to free RFB significantly increased these values 
to 42% and 56%, respectively (p < 0.05), corroborating the observations of RFB 
cytotoxicity. Despite RFB cytotoxicity, FUC/INH/RFB microparticles generated 
similar LDH release compared with CCM in both cell lines, which reinforces the 
beneficial effect of microencapsulation regarding RFB cytotoxicity. Additionally, 
microparticles of FUC/RFB (10/0.5, w/w) induced significantly lower release of LDH 
from A549 cells, comparing with the free drug (p < 0.05), demonstrating once more 
the influence of microencapsulation on the cytotoxic effect of RFB. Despite that, the 
formulation generated greater amounts of LDH (29%) compared to control CCM (p 
< 0.05), showing a certain level of cytotoxicity.  
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Figure 5.7. Release of lactate dehydrogenase (LDH) from (a) A549 cells and (b) 
macrophage-differentiated THP-1 cells exposed to fucoidan (FUC) polymer, FUC-
based microparticles (1.0 mg/mL), free rifabutin (RFB, 0.05 mg/mL), and free isoniazid 
(INH, 0.1 mg/mL). Cell culture medium (CCM) and Triton X-100 were used as negative 
and positive controls, respectively. The released LDH was calculated based on 100% 
assumed for positive control. Data represent mean ± SEM (n = 3, six replicates per 
experiment at each concentration). * p < 0.05 compared to CCM. 
 
Curiously, free INH also induced the release of a significantly higher amount 
of LDH compared with the control CCM (29% for A549 cells and 43% for 
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macrophage-differentiated THP-1 cells, p < 0.05). This indicates a certain degree of 
toxicity of the drug that was not observed in the MTT assay. However, 
microencapsulation apparently reverted the toxicological effect (p < 0.05), as 
microparticles loaded with INH, either alone or in combination, induced LDH at 
levels close to CCM in both cell lines. For instance, INH-loaded microparticles 
(single drug formulation) elicited a significant decrease in the release of LDH (23% 
for A549 and 34% for differentiated-THP-1 cells), comparing with free INH (p < 0.05), 
corroborating the assumption that microencapsulation of drugs favours their 
toxicological profile. In microparticles associating RFB as single drug, a 
concentration-dependent effect was observed, as FUC/RFB (10/0.5, w/w) 
microparticles generated, in A549 cells, around 29% of LDH release while FUC/RFB 
(10/0.2, w/w) microparticles induced 20% release (p < 0.05). Regarding 
differentiated-THP-1 cells, the reduction of RFB content decreased the release of 
LDH from 53% to 35% (p < 0.05). 
As expected, the results of macrophage-like THP-1 cells (Figure 5.7b) 
evidenced higher sensitivity of these cells comparing with A549 cells (Figure 5.7a). 
In fact, Figure 5.7b generally shows higher values of LDH release upon exposure to 
all samples. The incubation with CCM generated 34% LDH release, which is itself 
50% higher than that observed in A549 cells. The trend of the results is however 
very similar to that found in A549 cells, with only the free drugs and FUC/RFB = 
10/0.5 (w/w) microparticles generating significantly higher LDH release comparing 
with the control CCM (p < 0.05). 
Unloaded FUC microparticles also evidenced an absence of effect on LDH 
release. The overall evaluation of in vitro cytotoxicity indicates a very acceptable 
toxicological profile of FUC-based microparticles. Nevertheless, it is considered 
beneficial to widen the toxicological studies of these microparticles to certify their 
applicability for the proposed objective.  
 
5.5 Macrophage activation 
 
As the dual drug-loaded microparticles provide better compliance with the 
combined therapy recommended for TB, this formulation was selected for the assay 
of macrophage activation. The ability of FUC/INH/RFB (10/1/0.5) microparticles to 
induce macrophage activation was then assessed by determining the amount of 
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TNF-α and IL-8 secreted by macrophage-like THP-1 cells upon contact with the 
formulation. The referred cytokines are two pro-inflammatory molecules released by 
human alveolar macrophages upon infection with M. tuberculosis (329,330). The 
synthesis of pro-inflammatory cytokines such as TNF-α and IL-8 by macrophages 
contributes to the effective control of the proliferation and dissemination of 
pathogens (331). The quantity of secreted cytokines was compared with the levels 
produced upon stimulation with LPS (positive control) and untreated cells (negative 
control).  
Figure 5.8 depicts the obtained results. The contact with drug-loaded FUC 
microparticles induced TNF-α concentrations of 1.5 × 103 pg/mL (Figure 5.8a), which 
did not differ statistically from the value registered upon LPS stimulation, although 
the nominal value was higher in that case (2.5 × 103 pg/mL). This observation is in 
agreement with a recent report showing that FUC induces TNF-α secretion from 
macrophage-differentiated THP-1 cells (332). FUC was also tested as a solution, 
which gives an indication of the effect of the polymer itself. It was shown to induce 
the production of TNF-α (1.9 × 103 pg/mL), which is not statistically different from 
the effect of microparticles. Importantly, when comparing with CCM, the induced 
TNF-α production was higher for both FUC microparticles and FUC solution (p < 
0.05).  
Similar effects were observed regarding the production of IL-8 (Figure 5.8b). 
Although in this case, LPS generated a significantly higher amount of cytokine (26 
× 103 pg/mL, p < 0.05), drug-loaded FUC microparticles also revealed an ability to 
induce its secretion, which reached 14.7 × 103 pg/mL, more than half of the amount 
corresponding to LPS. Moreover, IL-8 secretion stimulated by the produced 
microparticles and raw material were much higher than that of the control CCM (p < 
0.05). 
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Figure 5.8. TNF-α (a) and IL-8 (b) secretion by macrophage-differentiated THP-1 cells 
upon 24 h exposure to FUC/INH/RFB (10/1/0.5) microparticles (MP) and FUC as raw 
material. Cell culture medium (CCM) and lipopolysaccharide (LPS) were used as 
negative and positive controls, respectively. FUC: fucoidan; INH: isoniazid; RFB: 
rifabutin. Data represent mean ± SEM (n = 3). * p < 0.05 compared to CCM. 
 
Overall, no significant differences were observed in the production of each 
interleukin upon stimulation by dual drug-loaded microparticles and the raw material 
FUC. In this way, the results suggest that FUC is the agent responsible for the 
observed activation of macrophage-like cells. Actually, the immune modulatory 
activity of FUC has been already reported, and is mediated through the regulation 
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of immune cells, including macrophages (333,334). Although FUC has been shown 
to induce the production of TNF-α (332,335) and IL-8 (336) from macrophages and 
other immune cells (337), the polymer seems to be endowed with anti-inflammatory 
activity as well (338,339). In truth, the mechanism of action of FUC as a bioactive 
agent is yet to be unveiled, and this area worths further research. 
 
5.6 Preliminary evaluation of microparticle uptake by macrophages 
 
Taking into consideration the intended application of the developed 
microparticles, the ability of macrophage cells to internalise the carriers was deemed 
as an aspect of relevant interest and was, thus, assessed by flow cytometry. 
Macrophage-differentiated THP-1 cells and rat alveolar macrophages (NR8383) 
were exposed to two different doses of fluorescently-labelled unloaded FUC 
microparticles.  
As depicted in Figure 5.9, the percentage of THP-1 cells taking up FUC 
microparticles was around 23% (50 µg/cm2) and 87% (200 µg/cm2), demonstrating 
a dose-dependent uptake (p < 0.05). Similarly, the uptake of carriers by rat 
macrophages varied between 68 and 86% as the concentration raised from 50 to 
200 µg/cm2, also revealing a dose-dependent effect (p < 0.05). Significant 
differences (p < 0.05) were observed in the uptake ability evidenced by both cells, 
particularly at the lowest tested dose (50 µg/cm2). In this case, 23% and 68% of 
FUC microparticles were taken up by THP-1 cells and NR8383 cells, respectively. 
Therefore, the obtained results are a preliminary demonstration of the macrophage’s 
ability to uptake FUC microparticles at a considerable level, depending on the dose. 
Considering that FUC exhibits in its structure chemical motifs (sulphate groups and 
fucose units) that can be specially recognised by macrophage surface receptors 
(36), a more accurate determination of preferential macrophage phagocytosis would 
be provided by comparing the uptake of FUC microparticles with a material devoid 
of recognisable moieties. Additionally, complementing cytometry data with confocal 
microscopy images would be beneficial in corroborating the data obtained so far. 
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Figure 5.9. Uptake of fluorescently-labelled unloaded fucoidan microparticles by 
human macrophage-differentiated THP-1 cells and rat alveolar macrophages 
(NR8383 cells) upon exposure to 50 µg/cm2 and 200 µg/cm2, for a period of 2 h. 
Results are expressed as mean ± SEM (n ≥ 3). 
 
5.7 Determination of minimum inhibitory concentration (MIC) 
 
In order to measure the MIC of the produced systems, M. bovis cells were 
treated with free drugs and microparticles loaded with both INH and RFB 
(FUC/INH/RFB = 10/1/0.5, w/w). This formulation was selected since it complies 
with WHO recommendations for combined TB therapy, as previously mentioned. 
The viability of mycobacteria upon exposure to tested samples was calculated as a 
percentage of bacterial culture (control), which was considered as 100% of bacterial 
growth. 
The MIC value determined for INH as free drug was 0.125 µg/mL, which is in 
the value range reported in the literature (340,341). Comparatively, free RFB at a 
concentration of 0.004 µg/mL was sufficient to inhibit the growth of M. bovis, 
suggesting that RFB is a stronger antimycobacterial agent than INH, probably due 
to the higher lipophilicity that facilitates its internalisation through the cell membrane 
(342,343). The literature reports variable MIC values of RFB, depending on the 
strain of M. bovis and on the method of susceptibility testing (344,345). By 
combining both INH and RFB as free drugs in a single solution, the determined MIC 
values were 0.008 µg/mL (INH) and 0.004 µg/mL (RFB). It is worth noticing that the 
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MIC of INH reduced from 0.125 to 0.008 µg/mL when combined with RFB. 
Differently, either alone or in combination, RFB displayed the same MIC value 
(0.004 µg/mL). This indicates that the in vitro susceptibility of mycobacteria to INH 
is potentiated when the two anti-TB drugs were applied together.  
By exposing M. bovis to 0.08 µg/mL of FUC/INH/RFB microparticles, the 
viability of mycobacteria decreased to the minimum level, therefore being the MIC 
value of the produced systems. It is important to highlight that, at this microparticle 
concentration, the drug content, considering the respective association efficiencies, 
is approximately 0.008 µg/mL (INH) and 0.004 µg/mL (RFB). These concentrations 
correspond to the MIC values determined for the two drugs when tested in 
combination (as free drugs). Therefore, the inhibition effect on the growth of M. bovis 
was very similar when comparing dual drug-loaded FUC microparticles and the 
mixed solution of INH/RFB as free drugs. This observation indicates that the 
microencapsulation process had no effect on the antibacterial activity of the drugs. 
In summary, in vitro susceptibility of M. bovis has been observed towards drug-
loaded FUC microparticles with considerable growth inhibition, as expected. 
 
5.8 Preliminary in vivo studies 
 
Safety is a matter of utmost importance, considering the pharmaceutical 
application of the developed carriers. In vivo assays performed after product 
development should not only include the assessment of the therapeutic potential of 
formulations, as a proof-of-concept, but also address more basic knowledge, 
comprising tests of the impact of administering novel materials into the lungs. In fact, 
the area of lung delivery is in strong need of new materials that offer an alternative 
to the very narrow list of approved excipients, that is led by lactose and mannitol. 
However, new materials require safety evaluation, which comprises many aspects. 
Unlike CS, FUC is a polysaccharide that has been poorly investigated as 
biomaterial, particularly, for pulmonary delivery. In this sense, it was decided to 
perform an in vivo assessment that focused on the material used as the drug vehicle.  
To perform the assay, BALB/c mice were submitted to the contact with 
unloaded FUC microparticles by inhalation. Two parameters were considered to 
establish if immunological reactions occurred: i) eosinophilia of the peripheral blood 
smears, and ii) serum IgE detection. The characteristics of airway diseases include 
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pulmonary eosinophilia and the production of IgE (346). Eosinophils are pro-
inflammatory leukocytes with diverse functions and increasing recruitment of these 
cells into affected tissues is a basic feature of inflammatory response and allergic 
reaction (347,348). Moreover, the clinical manifestations of allergies result from the 
effects of a complex network of cells and effector molecules that include IgE, which 
plays a central role in mediating allergic disease (349). Thus, the percentage of 
eosinophils, among the white blood cells, were estimated on peripheral blood 
smears. Additionally, an Ouchterlony double immunodiffusion assay was performed 
to detect the presence of the antibody IgE in the sera of mice, since serum IgE levels 
may rise in response to inhalation of an allergen (350).  
The eosinophil count in the group treated with unloaded FUC microparticles 
was 1%, a mean value comparable with the control group (Figure 5.10). The 
obtained results suggest a non-pathological state as the values obtained for the 
treated mice fell within the haematological reference values, since the relative 
number of eosinophils varies between 0 – 5% in male BALB/c mice (351). 
 
Figure 5.10. Percentage of white blood cells counted in the blood smears. Mean 
value ± SD. 
 
This result demonstrates that the inhalation of the produced FUC 
microparticles generated no eosinophilia in the treated mice, suggesting that the 
biomaterial was well tolerated by the animals. It is important to highlight that blood 
eosinophil count is considered a biomarker of airway inflammation. Eosinophils roll 
onto the bronchial vascular endothelium, as the cells flow in the blood stream (348). 
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Thus, studies have shown that blood eosinophil measurement is associated with 
eosinophilic inflammation in the airway (348,352).Yet, considering all cell counts, no 
significant differences were perceived when comparing FUC-treated group with the 
control group (Figure 5.10). It is relevant to take into consideration the differential 
white blood cell count, since the total number of cells may increase if there is an 
inflammatory reaction, and more specifically, the relative numbers of the different 
classes of white blood cells is changed. For instance, an increase in neutrophils and 
lymphocytes is frequently observed along with eosinophilia (346).  
Complementarily to the eosinophil count, immunodiffusion tests were 
conducted to evaluate the immunological response. No reaction was detected 
between antibody-antigen. In the Ouchterlony assay, the antigen (antiserum) and 
antibody solutions diffuse away from their original wells where the test solution is 
placed and through the agar gel, toward one another, and at the point where they 
meet in the agarose, if “equivalence” occurs they form a visible line of precipitation. 
The test samples (sera of mice before and after inhalation of microparticles) did not 
precipitate in contact with antiserum IgE despite using a range of concentrations in 
the assays. The most probable justification for this observation is that a very low 
level of IgE was present in the samples. In this case, it could be said that the 
unloaded FUC microparticles did not induce IgE production, indicating the 
microparticles were well tolerated by the treated mice. Nevertheless, a suitable 
control was needed to confirm the reaction worked properly. In this study, the sera 
obtained from OVA-sensitised mice, used as positive control of IgE, did not cause 
an immunoprecipitation when used in the Ouchterlony assay, possibily due to 
protein degradation. A commercial IgE sample is in this way the best control to be 
used in the future, in order to adequately obtain clear observations. 
 
5.9 Conclusion 
 
Inhalable dry powders based on FUC and loaded with first-line anti-TB drugs 
(INH and/or RFB) were successfully produced with high drug association efficiency 
(81–97%). The produced microparticles displayed MMAD between 1.9 and 3.9 µm, 
and FPF around 39%–55%, thus evidencing suitable aerodynamic properties for 
pulmonary delivery with great potential to reach the respiratory zone. Dual drug-
loaded microparticles had no effect on the cell viability of alveolar epithelial cells 
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(A549), while a slight reduction in the viability of macrophage-differentiated THP-1 
cells (65% viable cells) was observed when exposed for 24 h to concentrations as 
high as 1.0 mg/mL. Similarly, RFB-loaded microparticles (single drug formulation) 
revealed a considerable cytotoxic effect on THP-1 at the referred concentration (1.0 
mg/mL), but this dose is considered overestimated comparing with the expected in 
vivo conditions. On the contrary, microparticles loaded with INH (single drug 
formulation) had no effect on cell viability, as indicated by metabolic assays 
performed on alveolar epithelial cells (A549) and macrophage-like cells (THP-1). 
The results of LDH assays essentially reinforced those of MTT, evidencing that RFB 
content was the major factor related to the observed cytotoxicity. The produced FUC 
microparticles were further demonstrated to be captured by macrophages and 
macrophage-like cells in a dose-dependent manner, reaching 87% of uptake. 
Moreover, they were able to induce macrophage activation by potentiating the 
secretion of cytokines, which is a clear indicator that the phagocytosis of drug-
loaded FUC microparticles may mediate the improvement of the bactericidal effect 
of macrophages. Furthermore, dual drug-loaded microparticles showed potential 
activity against a strain of mycobacteria (95% growth inhibition) and it was 
demonstrated that the bactericidal activity of drugs was maintained after spray-
drying. Finally, the preliminary in vivo study suggested that the produced 
microparticles were well tolerated by mice after pulmonary administration, since no 
blood eosinophilia was detected. 
According to the obtained data, the proposed delivery carriers associating 
one or two anti-TB drugs, are a promising tool for the inhalable treatment of 
pulmonary TB. Nevertheless, unveiling the effect of a long-term administration of 
FUC microparticles in vivo, as well as the in vivo antibacterial efficacy, are very 
relevant aspects to address in the future 
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6. Chitosan microparticles: Results and discussion 
 
6.1 Preparation and characterisation of chitosan microparticles 
 
As previously mentioned, the development of inhalable microparticles for 
treating pulmonary tuberculosis demands the design of aerodynamically suitable 
systems, able to reach the alveoli, where alveolar macrophages hosting the 
infectious bacteria reside. Particularly, further benefit may be attained if the carriers 
can be recognised and phagocytosed by alveolar macrophages. This can be 
mediated by the chemical composition of the carriers, which may favour recognition 
by macrophage surface receptors. CS was selected within this context, since it is 
composed by N-acetylglucosamine and D-glucosamine residues, the former 
described to be recognised by macrophages (353), thus possibly potentiating 
phagocytosis. In addition, the polysaccharide has been widely investigated for 
applications in the pharmaceutical field, and therefore was used as a standard for 
comparisons with the other polymer selected for this work, FUC.  
Spray-drying yielded 75–81% of dry powder, which is satisfactory and 
actually higher than other values reported for spray-dried CS microparticles 
(239,306). In this case, high yields could be attributed to the instrumentation design, 
given that the use of a high performance cyclone, instead of the manufacturer’s 
standard separator, greatly improved the powder yield (354). INH and RFB were 
efficiently associated to CS microparticles either individually or together. The 
simultaneous incorporation of the drugs in microparticle formulations represents an 
important approach towards the compliance with the combined therapeutic regimen 
of TB that is recommended by WHO (261). Table 6.1 displays, among other 
properties, the mean values of drug association efficiency of the produced CS 
microparticles along with loading capacity and production yield. INH and RFB were 
associated separately with efficiencies of 90% and 97%, respectively. When 
associated simultaneously, 93% of INH was incorporated into the formulation, while 
RFB association efficiency was as high as 99%. Surprisingly, INH and RFB 
displayed similar association efficiencies, despite the differences in the aqueous 
solubility of the two drugs, which is 125 mg/mL for INH and 0.19 mg/mL for RFB, as 
previously stated. Moreover, the incorporation of two antibiotics in a single 
formulation did not interfere with the association efficiency of each drug. As a result, 
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loading capacities of the antibiotics were found to be around 8.1% for INH and in 
the range of 4.3–4.7% for RFB, values that are close to the theoretical maximum. It 
should be noticed that the amount of INH included in the microparticles is higher 
than RFB, since the latter is a more potent antibiotic (297), and also has a more 
toxic profile, as demonstrated in Section 6.7. In addition, CS amount was maintained 
purposely high in order to favour the internalisation of microparticles by 
macrophages (353). 
These results demonstrate the efficacy of spray-drying in providing drug 
association, which was previously reported inclusive for CS-based microparticles 
associating anti-TB drugs (239,306). However, unlike the present study, the 
production of the referred microparticles required more than one production step 
and involved the use of a crosslinking agent (e.g. tripolyphosphate), which has been 
suggested to improve drug retention in the formulation (355). Several published 
articles report the production of CS microparticles loaded with one (239,306,356) or 
more anti-TB drugs (357), which were produced by spray-drying or other methods. 
However, the referred studies included dispersing agents (e.g. lactose) and other 
polysaccharides (e.g. alginate) in the process. Particularly, to the best of our 
knowledge, this is the first report that describes the preparation and evaluation of 
spray-dried CS microparticles with a combination of INH and RFB, which were 
produced in one step, with no use of other excipients, including crosslinking agents. 
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Table 6.1. Spray-drying production yield, drug association efficiency, loading capacity, Feret´s diameter, median volume particle size 
(Dv50) and density values of chitosan (CS)-based microparticles (mean ± SD, n = 3). INH: isoniazid; RFB: rifabutin. 
Microparticles 
Production 
yield (%) 
Drug 
association 
efficiency 
(%) 
Loading 
capacity (%) 
Feret´s 
diameter 
(µm) 
Dv50 (µm) Span 
Density (g/cm3) 
Real Bulk Tap 
Unloaded CS 81 ± 2 – – 1.53 ± 0.86 –  1.39 ± 0.02 0.12 ± 0.05 0.17 ± 0.01 
CS/INH (10/1) 77 ± 6 90 ± 4 8.2 ± 0.3 1.54 ± 0.87 7.8 ± 0.2 2.59 ± 0.02 1.35 ± 0.02 0.10 ± 0.01 0.18 ± 0.05 
CS/RFB (10/0.5) 76 ± 4 97 ± 4 4.7 ± 0.3 1.48 ± 0.80 9.3 ± 0.9 2.98 ± 0.07 1.37 ± 0.02 0.17 ± 0.02 0.26 ± 0.02 
CS/INH/RFB 
(10/1/0.5) 
75 ± 5 
93 ± 4 (INH) 
99 ± 5 (RFB) 
8.1 ± 0.3 (INH) 
4.3 ± 0.2 (RFB) 
1.70 ± 0.94 5.9 ± 1.7 2.68 ± 0.03 1.37 ± 0.02 0.15 ± 0.01 0.25 ± 0.02 
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It is well-known that the properties of dry powders play an important role in 
the development of inhalable formulations, as deep lung deposition depends mainly 
on characteristics like particle size, shape, and density (304). Morphological 
analysis by SEM showed that CS microparticles are generally spherical, having a 
wrinkled surface that generally becomes smoother after drug incorporation (Figure 
6.1). These morphologies correspond to previous descriptions on spray-dried CS 
microparticles (358,359). 
 
  
  
Figure 6.1. Scanning electron microphotographs of chitosan (CS)-based 
microparticles: (a) unloaded CS microparticles, (b) CS/INH = 10/1 (w/w) 
microparticles; (c) CS/RFB = 10/0.5 (w/w) microparticles; (d) CS/INH/RFB = 10/1/0.5 
(w/w) microparticles. INH: isoniazid, RFB: rifabutin. 
 
Each SEM image displays spray-dried particles with variable diameters, 
which is a common observation, as reported elsewhere (360,361). In fact, the 
volume median diameter (Dv50), estimated by laser diffraction, confirmed the 
production of microparticles with wide size distribution. Overall, the produced 
carriers presented a mean value ranging between 5.9–9.3 µm, as displayed in Table 
(c) (d) 
5 µm 5 µm 
5 µm 
5 µm 
(a) (b) 
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6.1. Likewise, span values were determined to provide an indication on the width of 
the size distribution of drug-loaded microparticles and varied from 2.6 to 3.0 µm.  
Density further influences the properties of inhalable dry powders (362). Real 
density was found to be approximately 1.40 g/cm3 in all formulations (unloaded and 
drug-loaded microparticles), as depicted in Table 6.1. Bulk density varied between 
0.10 and 0.17 g/cm3 and tap density between 0.17 and 0.26 g/cm3. The literature 
reports similar density values for spray-dried polysaccharide microparticles 
(303,363). Generally, Feret’s diameter and density did not suffer alterations after 
drug association and are similar between the different drug-loaded formulations. 
This was expected, as the amount of drugs incorporated is not high. 
 
6.1.1 Dry powder analysis using Powder X-Ray Diffraction (PXRD) 
 
As performed for FUC, a study to verify any interaction between CS and the 
drugs was conducted using XRD and results are presented in Figure 6.2. In 
accordance with a published study, chitosan diffraction peaks were perceived at 10° 
or 20° (Figure 6.2a), correlated with hydrated and anhydrous crystals, respectively 
(364). Moreover, spray-dried CS (unloaded CS microparticles) showed no sharp 
peaks, revealing the absence of crystallinity. Crystallinity degree influences the 
stability of a polymer, in which the declining crystallisation could contribute to both 
the polymer destabilisation and, consequently, the release of drugs (365).  
The analysis of free drugs was already described in Chapter 5. Briefly, it was 
observed that INH remains crystalline after spray-drying, although with peaks of 
lower intensity, while RFB assumed an amorphous form (Figure 6.2b,c). The three 
formulations of drug-loaded CS microparticles displayed similar X-ray patterns, 
despite drug compositions (Figure 6.2a). Their diffractograms evidenced broader 
peaks with low intensity, indicating almost amorphous state of formulations. These 
results are in line with other studies that demonstrated the production of amorphous 
microparticulate CS carriers (306,364). As stated in the previous chapter, drug 
amorphisation indicates its association to the CS microparticles. The amorphous 
state of microparticles may influence the dissolution behaviour of the carriers, 
leading to an enhanced bioavailability of drugs, as will be discussed later on. 
Moreover, the stability of an amorphous drug is influenced by environmental 
conditions, including humidity, temperature, and mechanical stress (366), which 
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may reduce the physical stability of carriers due to premature drug recrystallization 
from its formulation, as referred in the previous chapter. 
 
 
 
 
 
Figure 6.2. Diffractograms of (a) chitosan (CS) polymer, unloaded and drug-loaded 
CS microparticles; (b) free isoniazid (INH) before and after spray-drying, (c) free 
rifabutin (RFB), before and after spray-drying. Note to Figure 6.2: Graphics c and d 
represent the same set of data of Figure 5.2 and were reprinted in this chapter to 
facilitate reading. 
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6.2 Evaluation of aerodynamic properties 
 
The aerosolisation and deposition properties of CS microparticles were 
investigated in vitro using an ACI and the obtained data are displayed in Table 6.2. 
The percentages of drug recovery were found to vary between 86–91 (INH) and 87–
98% (RFB), complying with the recommendations of the European Pharmacopeia 
(75). Moreover, the assessment revealed high emitted doses (>90%) with respirable 
fractions (FPF ≤ 5µm) in the range of 43–63%. These results indicate adequate 
flowability of the produced microparticles, supporting the intended application of the 
systems. 
It is important to highlight the use of the RS01 inhaler, a device that disperses 
fine particles through an effective rotating capsule movement (313), which certainly 
contributed to the satisfactory aerosol performance of CS microparticles. 
 
Table 6.2. Aerodynamic properties of chitosan (CS) microparticles loaded with 
isoniazid (INH) and/or rifabutin (RFB). Loaded amount of powder in the capsule was 
30 mg, corresponding to approximately 2.8 mg of INH and 1.5 mg of RFB, according 
to the drug content found in each formulation (n = 3, mean ± SD). FPD: fine particle 
dose; FPF: fine particle fraction; MMAD: mass median aerodynamic diameter. 
Microparticles 
Metered 
dose (mg) 
Emitted 
dose (mg) 
MMAD  
(µm) 
FPD <5 µm 
(mg) 
FPF <5µm 
(%) 
CS/INH (10/1)  1.9 ± 0.1 1.9 ± 0.1 3.8 ± 0.1 1.2 ± 0.1 62.1 ± 0.2 
CS/RFB (10/0.5)  1.0 ± 0.1 1.0 ± 0.1 2.5 ± 0.1  0.6 ± 0.1 63.4 ± 0.5 
CS/INH/RFB 
(10/1/0.5) 
INH 2.2 ± 0.2 2.1 ± 0.3 4.2 ± 0.1 1.1 ± 0.2 43.6 ± 4.2 
RFB 1.0 ± 0.1 1.0 ± 0.2 4.1 ± 0.2 0.5 ± 0.1 45.2 ± 3.1 
 
The evaluation of the deposition properties of CS-based microparticles 
resulted in MMAD between 2.5 and 4.2 µm, indicating that the formulation generated 
adequate aerosol size for efficient lung penetration. Usually, particles with 
aerodynamic diameters around 1–5 µm can potentially reach the respiratory region, 
while those with less than 2 µm are prone to deposit in peripheral airways (75,315). 
In this sense, the produced drug-loaded CS microparticles display suitable 
aerodynamic diameter to reach the respiratory zone and possibly to be internalised 
by macrophages, the target cells, which are described to uptake particulate matters 
with diameter within 1–6 µm (104).  
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Drug deposition profiles on ACI stages are illustrated in Figure 6.3. 
Particularly for the formulation associating the two drugs in combination, data show 
great similarity between the profiles, evidencing co-deposition of both INH and RFB 
on the different ACI stages (Figure 6.3b). On the other hand, observing the 
distribution in Figure 6.3a, it is visible that CS/INH microparticles deposited more in 
the upper stages, in contrast with CS/RFB microparticles that accumulate on stages 
3–4, which recover particles <3.2 µm, potentially capable to reach the deep zones 
of the lung. 
These observations reinforce that spray-drying was adequate to associate 
anti-TB drugs to CS microparticles for an application in TB therapy, especially 
combining the two antibiotics in a single dry powder formulation, as the drugs are 
evenly distributed. Furthermore, the proposed systems exhibit suitable aerodynamic 
properties for deep lung delivery of anti-TB drugs. 
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Figure 6.3. In vitro aerodynamic deposition of antitubercular drugs (isoniazid – INH 
and rifabutin – RFB) in the Andersen cascade impactor. Drugs associated with 
chitosan (CS) microparticles (MP) either individually (a) or together in a single 
formulation (b). Values are mean ± SD, n = 3. Cps: capsule; Dev: inhaler device; IP: 
induction port; F: filter, St: stage. 
 
6.3 In vitro drug release profiles 
 
The in vitro determination of drug release profiles was conducted in PBS pH 
7.4, containing 1% (v/v) Tween® 80, mimicking the alveolar surfactant (316,317) and 
facilitating RFB dissolution, as referred previously. Drug release was also tested at 
pH 5.0, simulating the intracellular environment of alveolar macrophages (318).  
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As can be observed in Figure 6.4, both antibiotics are released from CS 
microparticles within two hours. The release of RFB from CS/RFB microparticles 
and the release of INH from CS/INH microparticles is very similar. At pH 7.4, there 
is an initial burst, resulting in 90% of released RFB at 30 min and total release of 
INH at the same time point (Figure 6.4a). The complete release of RFB from 
CS/RFB microparticles at pH 7.4 occurs after 60 min, a little faster than that 
observed for CS/INH/RFB formulation, from which 88% of RFB is released at the 
same period (Figure 6.4c). On the other hand, the release profiles of INH are very 
much alike regardless of the formulations. 
At pH 7.4 and at initial time points, the release of RFB was slower compared 
to INH (Figure 6.4c, p < 0.05), in the dual drug-loaded formulation. In this case, 
about 70% of RFB is released after 30 min, whereas INH is almost completely 
available in the same period. However, when testing the release in acidic medium, 
no significant difference was perceived between INH and RFB profiles at any time 
point (Figure 6.4d).  
Overall, drug release profiles exhibited similar pattern in both media, no 
significant differences being perceived, especially regarding INH. Although not 
statistically significant, RFB was released from both CS/RFB and CS/INH/RFB 
microparticles faster in pH 5.0 than at pH 7.4, certainly because of its higher 
solubility in acidic medium. In general, it is suggested that pH does not have 
significant impact on the release of the two antibiotics from CS microparticles. 
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Figure 6.4. Drug dissolution and in vitro release profiles of isoniazid (INH) from 
CS/INH (10/1, w/w) microparticles and of rifabutin (RFB) from CS/RFB microparticles 
(10/0.5, w/w), in (a) PBS pH 7.4-Tween® 80 and (b) citrate buffer pH 5.0-Tween® 80, at 
37 °C. Drug dissolution and in vitro release profile of INH and RFB from CS/INH/RFB 
(10/1/0.5, w/w) microparticles in (c) PBS pH 7.4-Tween® 80 and (d) citrate buffer pH 
5.0-Tween® 80, at 37 °C. CS: chitosan; mean ± SD, n ≥ 3. 
 
Importantly, the release of drugs from the produced microparticles showed 
different pattern compared to the respective drug dissolution profiles (Figure 6.4a-
d). For instance, the release of INH from CS/INH microparticles was initially slower 
in comparison with free INH dissolution upon 15 min in both media (Figure 6.4a,b; 
p < 0.05). Similarly, the microencapsulation markedly delayed the RFB release from 
CS/RFB formulation at initial time points in neutral and acidic media (Figure 6.4a,b; 
p < 0.05). The effect of microencapsulation on the released drug was also evident 
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for dual drug-loaded microparticles from which drugs are completely released after 
30 min (INH) and 60 min (RFB) while free drugs are completely dissolved in the 
media within 15 min. In general, polymers composing the carrier matrix play an 
important role in the modulation of drug release. Commonly, polymeric matrices that 
hydrate, forming gelatinous structures, which is the case of CS, can delay the 
diffusion of drugs through the polymeric material into the aqueous medium (367). 
However, in this case, although having a certain impact, CS microparticles did not 
extend the release of drugs for a long period. 
The rapid release observed herein has also been reported for other polymeric 
microparticles loaded with either INH or RFB proposed for pulmonary delivery 
(368,369). Nevertheless, it must be considered that the used in vitro setting does 
not represent accurately the lung physiology. In fact, the volume and thickness of 
the alveolar lung lining fluid (around 0.01–0.1 µm) is overestimated in the assay, in 
which microparticles are immersed in the release media. In this way, drug release, 
which follows microparticle dissolution, occurs rapidly, differing from in vivo 
environment wherein microparticles would be only partially in contact with the 
alveolar fluid (320,321). Thus, in vivo profiles will probably show slower release of 
drugs, as has been previously published (320). 
 
6.4 In vitro biocompatibility studies 
 
6.4.1 Assessment of metabolic activity by MTT test 
 
MTT assay was performed to evaluate the cytotoxicity of CS microparticles 
in cells of human alveolar epithelium (A549) and human macrophage-like cells 
(differentiated from THP-1 monocytes). The produced systems were tested along 
with free drugs, which were considered as controls. For the purpose of discussion, 
the occurrence of a cytotoxic effect was assumed when the material decreased cell 
viability below 70% (322). 
The exposure of A549 cells to drug-loaded CS microparticles revealed 
viabilities over 70% at all tested concentrations and at both time points under 
evaluation (3 h and 24 h), as depicted in Figure 6.5a,b. These results indicate 
absence of cytotoxicity of the produced formulations. However, despite no 
significant differences were observed in terms of dose, viabilities of A549 cells 
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decreased over time upon exposure to both CS/RFB and CS/INH/RFB formulations, 
suggesting a time-dependent effect (Figure 6.5a,b; p <0.05). In turn, macrophage-
differentiated THP-1 cells were more sensitive to the contact with formulations. In 
fact, a dose-dependent effect was perceived on these cells, as viabilities decreased 
to approximately 57–59%, when cells were exposed for 24 h to CS/RFB (10/0.5) 
and CS/INH/RFB (10/1/0.5, w/w), at the highest tested dose (1.0 mg/mL) (Figure 
6.6b). The observed toxic effect of CS microparticles on these cells is possibly an 
effect of RFB content, an antibiotic that has also shown to be toxic in vivo (327). 
Differently, the formulation associating only INH (CS/INH MP) revealed to be non-
toxic to macrophage-differentiated THP-1 cells, since viabilities remained above 
90% at all tested conditions (Figure 6.6a,b). In summary, the two formulations 
containing RFB had significantly more effect over cell viability, particularly on 
macrophage-differentiated THP-1 cells, in comparison with CS/INH formulation (p < 
0.05).  
Overall, both A549 (Figure 6.5a,b) and differentiated THP-1 cell lines (Figure 
6.6a,b) tolerated well the exposure to unloaded CS microparticles, which is in 
agreement with other studies showing low toxicity of CS-based systems tested in 
the same cell lines (370,371). Moreover, upon 24 h exposure and particularly at the 
higher concentrations, free INH had more impact over A549 cells (Figure 6.5c) and 
macrophage-like THP-1 cells (Figure 6.6c) than CS/INH microparticles (p < 0.05), 
suggesting that microencapsulation may have a beneficial effect in this regard. As 
depicted in Figures 6.5d and 6.6d, RFB as free drug was observed to induce 
cytotoxicity, decreasing cell viability to around 49% in both cell lines when tested at 
the highest concentration (24 h). As free RFB has shown a concentration-dependent 
effect (Figures 6.5d and 6.6d), microparticles with lower RFB content (polymer: drug 
ratio = 10/0.2, w/w) were purposely produced to be tested regarding cytotoxicity. By 
decreasing RFB content, the viability of A549 cells remained over 90% (Figure 
6.5a,b). Moreover, the decrease in RFB amount led to a viability of macrophage-like 
cells above 70% in all the tested conditions referred above (Figure 6.6a,b). 
Interestingly, free RFB was found to be toxic after 24 h incubation with macrophage-
differentiated THP-1 cells at 0.025 mg/mL, but the detrimental effect was not 
perceived for dry powder formulations containing RFB (Figure 6.6a,b; p < 0.05), 
reinforcing the capacity of microencapsulation to improve drug toxicological profile.  
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It is important to mention that the highest dose tested in the present study is 
considered much higher than that to be observed in vivo upon inhalation, taking into 
account the large area of the alveolar zone (372). Therefore, as was also stated in 
Chapter 5, in vivo concentrations will most likely correlate those of the lower doses 
tested, at which no cytotoxicity were perceived. In this regard, both cell lines were 
considered to tolerate well the exposure to drug-loaded CS microparticles.
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Figure 6.5. A549 cell viabilities upon (a) 3 h and (b) 24 h of exposure to chitosan (CS) polymer, unloaded and drug-loaded CS 
microparticles; (c) exposure to INH as a free drug; and (d) exposure to RFB as a free drug. Cell viability was calculated as a percentage 
of positive control (untreated cells). Data represent mean ± SEM (n = 3, six replicates per experiment at each concentration). Dashed 
line indicates 70% cell viability. INH: isoniazid; MP: microparticles; RFB: rifabutin. Note to Figure 6.5: Graphics c and d represent the 
same set of data of Figure 5.5 and were reprinted in this chapter to facilitate reading. 
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Figure 6.6. Macrophage-differentiated THP-1 cell viabilities upon (a) 3 h and (b) 24 h of exposure to chitosan (CS) polymer, unloaded 
and drug-loaded CS microparticles; (c) exposure to INH as a free drug and (d) exposure to RFB as a free drug. Cell viability was 
calculated as a percentage of positive control (untreated cells). Data represent mean ± SEM (n = 3, six replicates per experiment at each 
concentration). Dashed line indicates 70% cell viability. INH: isoniazid; MP: microparticles; RFB: rifabutin. Note to Figure 6.6: Graphics 
c and d represent the same set of data of Figure 5.6 and were reprinted in this chapter to facilitate reading. 
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6.4.2 Evaluation of cell membrane integrity 
 
Similarly to what was performed with FUC microparticles, the integrity of cell 
membrane upon exposure to CS microparticles was assessed by determining the 
level of LDH released from alveolar epithelial (A549) and macrophage-like (THP-1) 
cells. Results are presented in Figure 6.7a,b. As previously reported in Chapter 5, 
the incubation with CCM resulted in basal release of  LDH of 21% and 34%, for 
A549 and macrophage-differentiated THP-1 cells, respectively. Moreover, both INH 
and RFB as free drugs generated significantly higher release of LDH compared to 
control CCM (p < 0.05).  
The results showed that unloaded CS microparticles did not raise the release 
of the enzyme, evidencing that CS itself does not have toxic effect on any cell line 
(Figure 6.7a,b), confirming what has been reported in other works (373,374). Similar 
to the observations of the MTT assay, microparticles loaded with RFB, either alone 
or in combination exhibited cytotoxic behaviour on macrophage-differentiated THP-
1 cells upon 24 h exposure to 1 mg/mL. The two formulations containing RFB at the 
ratio polymer/RFB = 10/0.5 (w/w) released 49% (CS/INH/RFB MP) and 43% 
(CS/RFB MP) of LDH, amounts significantly greater than the 34% of CCM (p < 0.05). 
Such effect was not observed for microparticles associating the lower amount of 
RFB (polymer/RFB = 10/0.2, w/w), demonstrating that the cytotoxicity observed for 
the carriers is related to RFB content (Figure 6.7b). 
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Figure 6.7. Release of lactate dehydrogenase (LDH) from (a) A549 cells and (b) 
macrophage-differentiated THP-1 cells exposed to chitosan (CS) polymer, CS-based 
microparticles (1.0 mg/mL), free rifabutin (RFB, 0.05 mg/mL), and free isoniazid (INH, 
0.1 mg/mL). Cell culture medium (CCM) and Triton X-100 were used as negative and 
positive controls, respectively. The released LDH was calculated based on 100% 
assumed for positive control. Data represent mean ± SEM (n = 3, six replicates per 
experiment at each concentration). * p < 0.05 compared to CCM. Note to Figure 6.7: 
The set of data of free RFB, free INH, CCM and Triton is the same presented in Figure 
5.7 – Chapter 5. The data were reprinted in this figure to facilitate reading  
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Unexpectedly, a similar observation was made in A549 cells, which also 
showed increased release of LDH upon exposure to CS/INH/RFB (10/1/0.5, w/w) 
microparticles compared with CCM (Figure 6.7a; p < 0.05). This slight cytotoxicity 
was not evidenced in the MTT assay, which showed cell viability around 80%. It 
should be highlighted that, despite the increased release of LDH observed in both 
cell lines, dual drug-loaded microparticles induced lower LDH release than free RFB 
(p < 0.05) and had an effect similar to that of free INH, thus suggesting the ability of 
microencapsulation to potentially reduce drug toxicological effects, as was also 
reported for FUC microparticles in the previous chapter.  
Surprisingly, CS/INH (10/1) microparticles revealed a toxic effect on 
differentiated THP-1 cells, indicated by the release of approximately 46% of LDH 
(Figure 6.7b; p < 0.05). On the other hand, the single drug formulation displayed no 
cytotoxicity on A549 cell line, corroborating the MTT results. In addition, CS/INH 
(10/1) microparticles significantly promoted less LDH release than free INH (p < 
0.05), particularly on A549 cells (Figure 6.7a).  
Differently, free RFB and CS/RFB (10/0.5) microparticles induced LDH 
release from A549 cells at similar levels, but the former had more effect on 
differentated-THP-1 cells than the latter (p < 0.05). Additionally, the overall data 
demonstrated that the level of enzyme secreted after exposure to the produced 
microparticles is far lower than that observed for the positive control (Triton X-100). 
It is worth mentioning that the different outcomes registered in both assays 
(MTT and LDH release) have been reported in other occasions (133,375) and was 
also registered in Chapter 5, referring to FUC microparticles developed in the 
present study. This is due the fact that the two methods assess cell-particle 
interactions in different ways. Microparticles possibly interact with cytoplasmic 
membrane, promoting cell lysis, but may not immediately interfere with intracellular 
organelle functions, such as mitochondrial dehydrogenase activity (376). On the 
other hand, particles may enhance metabolic activity, despite the small number of 
viable cells, leading to an overestimation of cell viability, determined by MTT assay 
(133). Therefore, the measurement of LDH release should be taken as a 
complement to the MTT assay, but there is the need to extend the range of tests to 
rigorously characterise the safety profile of the proposed carriers. 
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6.5 Macrophage activation 
 
As described in the previous chapter for FUC microparticles, the ability of 
dual drug-loaded CS microparticles (CS/INH/RFB = 10/1/0.5, w/w) to activate 
macrophage-like cells was evaluated by determining the amount of secreted pro-
inflammatory cytokines (TNF-α and IL-8) upon the exposure.  
Macrophage-differentiated THP-1 cells were exposed to the microparticles 
for 24 h prior to cytokine quantification. As observed in Figure 6.8, dual drug-loaded 
CS microparticles induced the secretion of a considerable amount of cytokines, 614 
pg/mL for TNF-α and 10.6 x 103 pg/mL for IL-8. In both cases the values were much 
higher than those of basal secretion, considered that produced by cells incubated 
with CCM, the negative control (p < 0.05). No significant differences were found 
between TNF-α secretion promoted by loaded carriers and CS polymer (Figure 
6.8a), evidencing that the observed effect is induced by the polymer rather than by 
its particulate form. However, a significant difference was observed for IL-8, 
comparing the two samples (Figure 6.8b; p < 0.05). In that case, drug encapsulation 
apparently interfered with cell receptor signaling during immune activation, thus 
decreasing macrophage activation ability. A possible explanation for this effect is 
that, the length of the released polymeric chain and also the number of fractions of 
N-acetylglucosamine residues influences the level of immune activation and drug 
encapsulation can possibly alter this pattern (377). It is worth mentioning that N-
acetylglucosamine moieties are reported to be recognised by macrophage 
receptors (353), thus, possibly, inducing cell activation. 
Although the formulations induced cytokine production at lower levels 
compared to LPS, the overall observation is that the exposure of macrophage-like 
cells to CS microparticles resulted in cell activation demonstrated by the increased 
release of TNF-α and IL-8 in comparison with CCM. This is corroborated by other 
studies that described the ability of CS to promote the production of the referred 
cytokines by macrophage-like cells (306,378). Although the natural 
immunomodulatory properties of CS have been already demonstrated (379), the 
mechanism through which CS particles induce immune response still needs to be 
unveiled. 
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Figure 6.8. TNF-α (a) and IL-8 (b) secretion by macrophage-differentiated THP-1 cells 
upon 24 h exposure to CS/INH/RFB (10/1/0.5) microparticles (MP) and CS as raw 
material. Cell culture medium (CCM) and lipopolysaccharide (LPS) were used as 
negative and positive controls, respectively. CS: chitosan; INH: isoniazid; RFB: 
rifabutin. Data represent mean ± SEM (n = 3). * p < 0.05 compared to CCM. Note to 
Figure 6.8: The set of data of CCM and LPS is the same presented in Figure 5.8 – 
Chapter 5. The data were reprinted in this figure to facilitate reading. 
 
6.6 Preliminary evaluation of microparticle uptake by macrophages 
 
The uptake of CS microparticles was assessed in macrophage-differentiated 
THP-1 cells and rat alveolar macrophages NR8383. Cells were exposed to 
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fluorescently-labelled CS microparticles at concentrations of 50 and 200 µg/cm2, for 
2 h, and the obtained results are presented in Figure 6.9. Microparticle uptake by 
macrophage-differentiated THP-1 cells was demonstrated to be very high at both 
concentrations (94.3 ± 1.5 for 50 µg/cm2 and 98.1 ± 1.8% for 200 µg/cm2). Likewise, 
rat macrophages (NR8383 cells) internalised up to 99.9 ± 0.1, regardless of the 
dose. These preliminary results suggest high affinity of macrophages for CS 
microparticles independently of concentrations and cell type. It is well-known that 
macrophages are specialised cells, which recognise and engulf particulate matter, 
and thus the internalisation of particles was expected. Nevertheless, residues of N-
acetylglucosamine, a structural unit of CS, have been described to be preferentially 
recognised by macrophages (353). The presence of such units possibly mediated 
the phagocytic mechanism, which could explain the high affinity of cells for the 
produced microparticles. However, it is deemed adequate to consider future assays 
providing comparison with a material devoid of units recognised by macrophages. 
In this way, the favourable recognition of CS-based carriers by macrophage-like 
cells could be unequivocally established. Furthermore, obtaining confocal 
microscopy images would be beneficial to corroborate cytometry data gathered so 
far. 
 
 
Figure 6.9. Percentage of human macrophage-differentiated THP-1 cells and rat 
alveolar macrophages (NR8383 cells) phagocytosing fluorescently-labelled chitosan 
microparticles. Cells were exposed (2 h) to 50 and 200 µg/cm2 of microparticles. Data 
represent mean ± SEM (n ≥ 3). 
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6.7 Determination of minimum inhibitory concentration (MIC) 
 
The viability of M. bovis cells was verified upon exposure to dual drug-loaded 
CS microparticles and free drugs (either alone or in combination). Due to time 
constraints, only the dry powder combining the two antibiotics was tested in this 
assay (CS/INH/RFB = 10/1/0.5, w/w), as the formulation complies with WHO 
recommendations for combined TB therapy, as previously mentioned. 
MIC values were calculated in relation to control (culture of mycobacteria), 
assumed as 100% bacterial growth. As reported in Chapter 5, the MIC determined 
for the free drugs was 0.125 µg/mL for INH and 0.004 µg/mL for RFB, evidencing 
the stronger antimicrobial effect of RFB compared to INH. When in combination, 
free INH and RFB inhibited bacterial growth by 94 ± 1%, presenting MIC values of 
0.008 µg/mL and 0.004 µg/mL, respectively. In what concerns the microcarriers, a 
dose of 0.08 µg/mL of drug-loaded CS microparticles was the minimum 
concentration needed to inhibit mycobacterial growth by 96 ± 1%. At this 
concentration, microparticle drug contents are approximately 0.007 µg/mL (INH) 
and 0.004 µg/mL (RFB), considering the association efficiencies. It is worth 
mentioning that these results are in line with MIC values determined for the free 
antibiotics in combination. In other words, no differences were perceived in terms of 
inhibition effects comparing drug-loaded CS microparticles (96 ± 1%) and INH/RFB 
solution (94 ± 1%). This indicates that the microencapsulation of the drugs in 
combination did not interfere with their antibacterial activity. As well, results 
demonstrate that the proposed formulation can potentially inhibit the growth of M. 
bovis in vitro. 
 
6.8 Preliminary in vivo studies 
 
As stated in the previous chapter, in vivo assays of a drug delivery system 
comprise a wide range of experiments. This applies not only to the developed drug-
loaded carriers, but also for the biomaterial itself. Although CS has been widely 
proposed as biomaterial to be used in the pharmaceutical field, very few studies on 
in vivo toxicity upon pulmonary administration have been reported (380).  
Nano and microparticles as carriers for alveolar macrophage targeting in pulmonary tuberculosis therapy 
134 
 
As performed for FUC, blood samples collected from BALB/c mice that 
inhaled unloaded CS microparticles were analysed in order to verify the occurrence 
of eosinophilia and/or the presence of IgE in the sera of treated animals.  
Results from the blood smears revealed an eosinophil count of around 1% in 
the group of mice treated with unloaded CS microparticles, which was similar to the 
control mice (Figure 6.10), indicating a non-pathological state as the values obtained 
are within the reference range for eosinophil count in male BALB/c mice (0 – 5%), 
as discussed in the previous chapter. Therefore, the normal relative number of 
eosinophils in the sera indicates the absence of inflammatory response after 
inhalation of the produced CS microparticles. Furthermore, the overall count of white 
blood cells, which are inflammatory cells, disclosed no significant differences when 
comparing the two groups (Figure 6.10), reinforcing that the inhalable dry powder 
was well tolerated by the animals. 
 
 
Figure 6.10. Percentage of white blood cells counted in the blood smears. Mean ± SD. 
 
As discussed in Chapter 5, immunodiffusion tests (Ouchterlony technique) 
were conducted as a complementary evaluation of an allergic response, possibly 
induced by the carriers, and showed no visible precipitation reactions between 
antibody-antigen. As stated in the previous chapter, this is probably due to the fact 
that low levels of IgE were present in the sera of treated mice, suggesting the 
biomaterial did not induce allergic reaction. However, a commercial IgE sample, to 
be used as control, is needed to confirm that observation.  
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6.9 Conclusion 
 
Inhalable CS dry powders loaded with INH and RFB, either separately or in 
combination, were prepared by spray-drying, with drug association efficiency 
varying between 90% and 99%, depending on the formulation. The developed 
microparticles displayed MMAD in the range of 2.5 – 4.2 µm and FPF varying from 
43% to 63%, thus evidencing thus adequate aerodynamic properties for deep lung 
delivery. Cytotoxicity assays demonstrated good tolerability of alveolar epithelial 
cells to the produced formulations, while a slight decrease on cell viability of 
macrophage-like cells was observed at the highest tested microparticle 
concentration (1.0 mg/mL) after 24 h exposure to dry powders containing RFB. 
Nevertheless, this dose was considered as possibly overestimated comparing to 
real in vivo conditions. Furthermore, a preliminary evaluation indicated strong ability 
of CS microparticles for macrophage uptake (up to 99.9%) but complementing 
cytometry data with confocal microscopy would be beneficial in corroborating the 
data described herein. Importantly, CS-based microcarriers induced macrophage 
activation and demonstrated to preserve drug antibacterial activity against M. bovis 
in vitro. A preliminary in vivo evaluation showed no indication of allergyc reponse in 
mice that inhaled CS microparticles, suggesting that the biomaterial was well 
tolerated by the animals. In conclusion, the developed CS microparticles were 
considered to exhibit suitable properties to mediate inhalable therapy for pulmonary 
TB.  
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7. Final considerations 
 
7.1 General discussion 
 
In the present study, we proposed the use of respirable carriers composed of 
polysaccharides, namely FUC and CS, for the treatment of pulmonary TB. Natural 
polymers possess several favourable characteristics in comparison with synthetic 
polymers used in drug delivery, including higher propensity for biocompatibility and 
biodegradability, and the fact that they are abundant renewable sources (132). 
Furthermore, FUC and CS are reported to be specifically recognised by 
macrophage receptors (40,245) and have been shown to potentiate macrophage 
activation, mediated by membrane receptors (241). The induction of macrophage 
activation is beneficial, in this case, as activated macrophages control more 
efficiently the proliferation and dissemination of pathogens, such as M. tuberculosis 
(42). Thus, the use of FUC and CS as matrix of polymeric carriers allows targeted 
TB therapy, particularly toward alveolar macrophages infected with mycobacteria. 
We explored the potential of FUC and CS as matrixes of nano and 
microparticles for the pulmonary delivery of anti-TB drugs. The feasibility of the 
approach was demonstrated by using INH and RFB as model anti-TB drugs.  
 
NANOPARTICLES 
 
The production of nanoparticles initiated with a complexation between the 
two polymers, considering that they exhibit opposite electrical charge. As 
aforementioned, FUC has been used in the development of nanoparticles and 
polyelectrolyte complexation is the predominant technique, in most cases having 
CS as counterion (120,141,147,246,264,381). Nanoparticles were then produced 
by polyelectrolyte complexation between FUC and CS, but the technique did not 
allow the incorporation of drugs into the carriers. A possible explanation lies in the 
nature of the drugs, although drug entrapment is also influenced by the 
concentration of polymeric solutions, drug/polymer ratios and ionic strength among 
other factors (269).  
In light of this, nanoprecipitation was used as an alternative production 
method, resulting in the formation of polymeric nanoparticles with variable size and 
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PdI values. Several approaches were applied aiming at obtaining particles in the 
submicron range with unimodal size distribution. Importantly, CS nanoparticles were 
not able to associate any drug during the nanoprecipitation process. Differently, the 
technique allowed the encapsulation of RFB in FUC nanoparticles, registering 
association efficiencies up to 46%, although not in a reproducible manner. 
Reproducibility is crucial when developing an experimental protocol. Indeed, 
nanoprecipitation is generally known as an easy and reproducible technique, but 
many operating parameters must be managed to ensure the production of 
nanoparticles with the adequate characteristics. These include the choice of solvent, 
non-solvent type and volume, stirring rate and time, polymer concentration, etc., to 
name a few. The referred operating conditions may have a major impact on the 
resulting characteristics of the carriers (274). Although nanoprecipitation has been 
widely applied to produce polymeric nanoparticles (271,282), the knowledge about 
the self-assembly of other polymers is yet needed to elucidate a generic application 
of such an easy method to a wide range of polymers. 
In summary, two different techniques were used to produce nanoparticles 
based on FUC and CS. Both resulted in the formation of particles in the nanoscale, 
but the tested protocols did not allow drug encapsulation in a reproducible and 
efficacious manner. Therefore, due to time constraints, it was decided to direct the 
efforts to the development of microparticles. 
 
MICROPARTICLES 
 
Characterisation of microparticles 
 
Respirable microparticles based on FUC and CS were successfully produced 
by spray-drying. This was the method of choice because it offers great control over 
critical parameters of the resulting microparticles, including their size, shape and 
density. Furthermore, it is a unique single step method for microencapsulation of 
drugs in polymeric carriers (95). The yields of the process varied between 74 and 
85%, proving that spray-drying is a great choice for the production of FUC and CS 
microparticles.  
In addition, the present research demonstrated the capacity of FUC and CS 
microparticles to associate not only one, but also two first-line anti-TB drugs 
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simultaneously in a single formulation. To date, this is the first study describing the 
use of spray-drying to produce respirable FUC-based microparticles loaded with one 
or two first-line anti-TB drugs. Contrarily, the production of CS microparticle loaded 
with one anti-TB drug has been reported in the last years (239,306). However, as 
far as we know, the association of two anti-TB drugs to spray-dried CS 
microparticles is described herein for the first time. Both polysaccharides provided 
microparticles with high drug association efficiencies (> 80%). However, FUC 
microparticles provided slightly lower and more variable association efficiency (81 – 
97%) comparing with CS microparticles (90 – 99%). For each polymer, no significant 
differences were perceived in terms of the ability to associate the drugs, when 
comparing single and dual drug-loaded microparticles. In light of this, we may state 
that producing FUC and CS microparticles loaded with two anti-TB drugs is a better 
choice, since these formulations comply with the combined therapy that WHO 
recommends for TB (261). 
Microparticles based on FUC or CS were analysed regarding size, density 
and morphology because these parameters strongly influences the sedimentation 
and dispersion properties of inhalable dry powders (66). The determined real 
densities were around 1.35 – 1.78 g/cm3, suggesting that microparticles have a 
matrix dense core. As well, the particle shape may have a strong impact on carrier 
performance, and thus the developed microparticles were analysed by SEM, 
showing variable morphologies. FUC provided slightly convoluted microparticles 
with smooth surfaces that assumed a more irregular shape and acquired wrinkles, 
after the incorporation of RFB. The perceived changes were attributed to the drug 
itself, as this observation has been reported for other spray-dried microparticles 
loaded with RFB (239). Nevertheless, ethanol, used to dissolve RFB, was also 
ascribed a role in this effect. In fact, the removal of ethanol from microparticle 
surfaces occurs faster than water evaporation, inducing the formation of a primary 
shell that collapses as the water content in the core evaporates (298). In turn, the 
association of INH conferred to FUC microparticles a spherical shape with crystal 
structures, a consequence of Man deposition on particle surface. It should be 
noticed that the dual drug-loaded microparticles displayed a morphology 
comparable with those associating RFB (single drug formulation), with wrinkled 
irregular particles. Differently, CS rendered spherical microparticles, having irregular 
surface that generally becomes smoother after drug incorporation. This indicates 
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that drug association had less impact on the morphology of CS microparticles, 
comparing with FUC. As has been stated for long, the morphology of spray-dried 
particles depends on their composition along with the operating parameters (382).  
Considering the irregular shape of FUC microparticles, one could expect 
enhanced dry powder aerosolisation, endowed by reduced cohesive forces between 
particles, thus preventing agglomeration and improving respirability (78,298). 
Nevertheless, both FUC and CS-based dry powders exhibited similar in vitro 
performance when evaluating aerosolisation properties using ACI. The emitted dose 
of drug-loaded FUC microparticles (84 – 98%) is comparable to that exhibited by 
CS carriers (>90%), all being in accordance with the values established by the 
European Pharmacopeia (75). Likewise, respirable fractions (FPF ≤ 5µm) of FUC 
microparticles (39 – 55%) are close to those of CS counterparts (43 – 63%). The 
aerodynamic diameters of FUC and CS carriers are very much alike, as dual drug-
loaded microparticles and INH-loaded microparticles (single drug formulation) 
presented MMAD around 4 µm. Yet, dry powders containing RFB (single drug 
formulation) displayed MMAD of approximately 2 µm (FUC) and 2.5 µm (CS), 
anyway values not significantly different. These values are in the size range required 
for deep lung deposition of aerosols (315).  
The evaluation of drug release profiles is a matter of utmost importance when 
designing drug delivery systems. Hence, the in vitro release of drugs from the 
developed carriers was determined in media relevant for pulmonary administration 
and specific of the context of this thesis: i) in PBS (pH 7.4) with the addition of 1% 
(v/v) Tween® 80, resembling the lung lining fluid in terms of pH and the presence of 
surfactant (316,317); and in more acidic medium (citrate buffer pH 5) to simulate the 
phagolysosomal environment, assuming macrophage uptake of microparticles 
(318). Overall, both INH and RFB were rapidly released from microparticles, 
regardless of the formulation. In general, 100% drug release was observed within 
120 min. CS microparticles evidenced, however, a slightly slower profile, although 
not to a statistically significant level. This is easily explained with the gelling ability 
of CS that delays drug diffusion (367), which is not a characteristic of FUC. 
Moreover, the pH did not interfere with drug release profiles. As previously 
discussed, we expect that in vivo drug release will occur more slowly, considering 
that a lower amount of liquid is present in the alveoli compared with that involved in 
the assays. It is well known that the alveolar epithelium is covered by a thin layer 
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(0.01–0.1 µm) of lung lining fluid, and thus microparticles are expected to be only 
partially in contact with this fluid, and not immersed in it (320,321). This will certainly 
impact on drug dissolution, and thus on the release profile. 
In summary, according to the observed features, it can be inferred that both 
FUC and CS provided spray-dried microparticles suitable for pulmonary delivery 
with great potential to reach the respiratory zone and capacity to release the 
associated drugs.  
 
Assessment of biological behaviour 
 
Taking into consideration that safety and biocompatibility are important 
parameters in the design of drug delivery systems, the cytotoxicity of the proposed 
polymeric carriers was assessed in human pulmonary epithelial (A549) and 
macrophage-differentiated THP-1 cells.  
The metabolic assay MTT was performed, testing three different 
concentrations of microparticles (0.1, 0.5 and 1.0 mg/mL) at two time points (3 and 
24 h). Cells were exposed to free drugs (INH and RFB) as well, at doses equivalent 
to theoretical loadings in the microparticles: 10% (w/w) for INH (0.01; 0.05 and 0.1 
mg/mL) and 5% (w/w) for RFB (0.005; 0.025 and 0.05 mg/mL).  
Overall, cells tolerated well the contact with both polymers and unloaded 
microparticles, suggesting that the selected biomaterials are non-toxic. Similarly, 
microparticles loaded with INH (single drug formulation) had no effect on cell viability 
in both cell lines. Nonetheless, macrophage-differentiated THP-1 cells were 
sensitive, after 24 h-exposure, to dry powders (1 mg/mL) containing RFB. The 
observed toxic effect was assumed to be due to RFB content, given that the free 
drug has been reported to be toxic in vivo (327,328) and the control assays with free 
RFB demonstrated similar effect. With this in mind, microparticles with reduced 
amount of RFB (2%, w/w) were produced to be purposely tested in cytotoxicity 
assays, revealing no toxic effect under the same conditions. The obtained results, 
thus, confirmed that the cytotoxicity was due to the content of RFB, although the 
used dose was possibly overestimated comparing to real in vivo conditions. 
Such sensitivity was not observed in alveolar epithelial cells (A549) that 
showed viability over 70% in all tested conditions, considering formulations 
composed of either FUC or CS. To complement the observations of the MTT assay, 
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the release of the cytoplasmic enzyme LDH by the cells, upon exposure to 
microparticles, was determined. Essentially, the results obtained in the LDH release 
assessment were aligned with those of MTT, with only punctual differences in two 
of CS-based microparticle formulations. The different outcomes can be explained 
by the fact that the two methods assess cell-particle interactions in distinct ways. 
For instance, particles may enhance metabolic activity, despite the small number of 
viable cells, leading to an overestimation of cell viability, determined by the MTT 
assay (133). Therefore, the measurement of LDH release should be taken as a 
complement to the MTT assay, as indicated above, but there is the need to extend 
the range of tests to rigorously characterise the safety profile of the proposed 
carriers. 
Furthermore, both FUC and CS microparticles, loaded with anti-TB drugs, 
were demonstrated to preserve in vitro the drug antibacterial activity against M. 
bovis (around 95% growth inhibition), the two formulations with MIC values of 0.08 
µg/mL. These concentrations correspond to the MIC values determined for the two 
drugs when tested in combination (as free drugs). Therefore, these observations 
demonstrate that in both cases the process of microencapsulation preserved the 
bactericidal activity of drugs (evaluated in vitro against M. bovis).  
Preliminary in vivo experiments were also conducted to evaluate a possible 
allergic reaction generated by the inhalation of FUC and CS microparticles 
(unloaded) by mice. The analysis of blood smears revealed eosinophil counts 
around 1% in the group of mice treated with unloaded microparticles (FUC and CS), 
similar to control and in agreement with the haematological reference range for 
eosinophil count in male BALB/c mice (351). This demonstrates that the inhalation 
of the produced carriers generated no sign of airway inflammation, since 
eosinophilia was not perceived in the peripheral blood. Thus, it was suggested that 
both biomaterials, FUC and CS, were well tolerated by the animals. Nevertheless, 
this is a very initial step in the evaluation of biocompatibility of polymers that needs 
to be complemented with more robust assays and dedicated studies. That will be 
the necessary kick-off for the solid proposal of alternative excipients that are 
currently one of the pin-points of lung drug delivery. 
Despite presenting similar characteristics and behaviours in the more basic 
aspects of characterisation (drug loading, aerosolisation properties, 
biocompatibility), important and perhaps unexpected differences were found 
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between the two systems when performing specific biological assays regarding the 
intended application. As previously stated, the rationale of selecting FUC and CS as 
matrix of inhalable microparticles, aimed at the delivery of anti-TB drugs, relies on 
their chemical composition, including in both cases moieties that favour macrophage 
targeting.  
This suggested that microparticle uptake by the target cells would be 
favoured by the matrix composition. Additionally, there was also the possibility that 
microparticle-cell interaction resulted in macrophage activation, enabling better 
control of the infection mediated by increased cytokine production (383). The 
literature reports that macrophages recognise preferentially fucose and mannose 
moieties (384). Based on this, a more favourable behaviour of FUC microparticles 
was expected. In fact, these had stronger impact on macrophage activation, 
comparing with CS carriers. However, the induced interleukin production was 
significantly higher than the negative control (CCM) in both cases. In parallell, the 
preliminary evaluation of microparticle uptake by macrophage-like cells (human 
differentiated macrophages and rat alveolar macrophages) revealed that FUC 
microparticles were internalised in a dose-dependent manner (23 – 87% uptake). In 
contrast and quite surprisingly, CS microparticles showed very high tendency (up to 
99%) to be captured, regardless of the dose. Thus, this study has shown that 
alveolar macrophages can potentially uptake the proposed carriers and provided 
experimental evidence of the theoretical rationale of this project.  
In summary, the obtained data demonstrate that the proposed respirable 
carriers present adequate aerodynamic properties for reaching the respiratory zone. 
Their biological evaluation evidenced absence of cytotoxicity, considering the doses 
that correspond to a more realistic in vivo condition. Moreover, a preliminary 
assessment indicated no allergic reaction in mice after pulmonary administration of 
the microparticles. In addition, it was revealed that the microencapsulation process 
had no impact on the bactericidal efficacy of the anti-TB drugs. Furthermore, a 
preliminary evaluation indicated strong ability of the developed carriers to undergo 
macrophage uptake and the ability to induce macrophage activation. Considering 
all above, the developed microparticles based on FUC or CS are considered to hold 
potential as pulmonary delivery systems for the treatment of pulmonary TB. It is 
worth mentioning that the developed single drug formulations are herein proposed 
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as add-on therapy whereas dual drug-loaded microparticles properly comply with 
the combined therapy for TB treatment. 
 
7.2 Prospects for future research 
 
Considering the entire set of data, the developed polymeric microparticles 
loaded with first-line anti-TB drugs, either alone or in combination, are promising 
tools for the implementation of an inhalable therapy of pulmonary TB. However, 
several aspects must be addressed in the future to permit more conclusive findings. 
Essentially, further investigation is required to have a more realistic view of the 
safety and efficacy of the proposed carriers. The relevant aspects that must be 
addressed in the future include:  
 
i. To evaluate physical stability of the carriers; 
ii. To complement the obtained cytometry data regarding the macrophage 
uptake of microparticles with confocal microscopy; 
iii. To assess the capacity of the produced carriers to enhance macrophage 
phagocytosis mediated by the chemical groups on the polymeric structures 
of FUC and CS. This can be evaluated by comparison with a polysaccharide 
devoid of units recognised by macrophages; 
iv. To further evaluate the biocompatibility of the carriers, in vivo, in order to 
determine whether or not unloaded microparticles induce an allergic 
response. 
v. To perform in vivo evaluation of the capacity of drug-loaded carriers to reach 
alveoli by characterising the distribution of particles upon inhalation with 
imaging technique; 
vi. To evaluate the in vivo antibacterial efficacy of drug-loaded microparticles; 
vii. To unveil the in vivo effect of a long-term administration of the developed 
microparticles. 
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